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The primary objective of this dissertation is to develop two classes of Bayesian 
models for probability encoding in medical decision analysis.  The models are 
developed from the original Bayes’ Theorem and various fundamental concepts that 
underlie the development of contemporary statistics.   
The models are developed with the nature of medical evidence in mind.  This 
is because probability encoding hinges on the availability and features of evidence.  
Forming the basis of reasoning, evidence refers to any explicit warranted reference 
given in an appropriate and specific context for supporting or rejecting a hypothesis, 
claim or belief.   
 Specially designed for analysing subject-level evidences, the first class of 
models follows the framework of Generalised Linear Models (GLM).  Unlike the 
conventional GLM approach, these models require the union of the observed 
evidences (likelihood) with a carefully chosen prior of the canonical parameter(s) that 
underlie the distribution of the outcome variable.    
The second class of models may be referred to as meta-analytic methods as 
they are applied for synthesising aggregate-level evidences from reported sources.  To 
reflect the large amount of heterogeneity among the studies to be combined, the 
models incorporate some random effects in the set-up.  Inevitably, these models are 
hierarchical in nature and have to be estimated with the Gibbs sampler.   
Although these techniques are complicated so that all salient features 
underlying the decision problems are adequately captured, they are also simple 
enough for routine use in clinical practice. 
The recognition of the importance of Bayesian ideas in probability encoding 
will also bring considerable impact on how evidence-based medicine (EBM) is 
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practiced.   One must be ready to embrace more sources of prior evidences which 
have hitherto being ignored in the current EBM practice.  Through the Bayesian 
framework the synergism between subjective and objective evidences come into play, 
with the decision analyst and domain experts giving valid testimony and searching for 
relevant evidence useful for medical decision making. 
The application of the proposed Bayesian models is a small step towards the 
fuflillment of EBM’s objective of making use the most complete evidence available 
for treating patients.  It is hoped that the practical aspect of the Bayesian models and 
their related concepts will appeal to clinicians and decision analysts engaged in 
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Due to the growing public awareness, medical practice is in the middle of a profound 
transition.  Contemporary scientific medicine has entered upon a period of 
“paradigmatic instability”—that is, a period in which clinicians need to scrutinise 
their practice afresh.  Advances in medical research and technology mean that 
clinicians know more about disease than ever.  New medicines are constantly being 
developed, life support and intensive care improve all the time and patients can 
recover quickly after modern microsurgery.  Yet, clinicians still do not have all the 
answers, and many disorders cannot be cured.  Clinicians are also confronted with a 
wide range of decisions with ethical considerations, which their predecessors might 
not have encountered.   
 What is going on is that one of the most basic assumptions underlying medical 
practice is being challenged.  The assumption is not about the validity of new medical 
discoveries, but concerns the intellectual foundation of medical care or simply put, 
whatever a clinician decides is sound and desirable for his patients.  The implicit 
message of this transition in medical practice is that while many decisions are 
undoubtedly correct, some are not, and elaborate mechanisms are needed to sort out 
which are the desirable ones.   
As such, this dissertation would like to point out that the burning issue is not 
whether there are variations in medical practice and the urgency to reconcile them, but 
rather how we ensure clinicians make good decisions.  Undoubtedly, guidelines are 
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important in preventing malpractice, but one must bear in mind that medical practice 
is subject to change as scientific knowledge advances.   Therefore, the more 
fundamental issue is to develop a reliable framework upon which clinicians could 
make sound decisions in view of the continual evolution of patterns of medical care. 
In fact, this is the desired attribute that forms the basis of all medical guidelines. We 
must reckon that the quality of medical care is determined mainly by the quality of 
clinical decisions that dictate what actions are taken.  
With this in mind, the application of decision analysis is advocated. Decision 
analysis is a methodology based on a probabilistic framework that provides a logical 
and systematic structure for generating clear and consistent action for the decision-
maker [1].  From the perspective of game theory [2], a decision problem is a triple (C, 
pi, O), that consists of an option space (C) to be applied by the decision-maker, a set of 
outcomes (O) to be realised by the decision maker, and a mediation mechanism, or 
mapping function, pi: C → O, that relates choices and outcomes [3].  The decision 
maker is an entity who is capable of making an autonomous choice from a set of 
options. He also has the authority and responsibility to implement the selected 
alternative. 
While many clinicians may not appreciate the mathematical details involved, 
its framework does provide the structure and guidance for systematic thinking in 
difficult situations.  The whole spectrum of activities concerning clinician-patient 
communication is also structured to help decision makers to identify choices under 
uncertainty.  This is helpful for carrying out decision making related to their practice. 
Consciously or subconsciously, explicitly or implicitly, every decision maker might 
have applied some basic rules advocated by the discipline and it often proves useful in 
developing medical guidelines and for identifying the most desirable therapeutic 
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strategy for patients. Due to the hailstorm of uncertainties that surround medical care 
and therapeutic interventions, proper decision analysis is a reliable anchor in the sea 




1.2 Medical Decision Analysis  
In its broad sense, medical decision analysis refers to a cluster of quantitative 
techniques useful for the modelling, measurement and evaluation of medical 
evidences, processes and outcomes.  This notion is familiar to most clinical 
researchers who apply statistical methods to evaluate results generated from their 
studies.  Several methodological issues of this nature are explored extensively in the 
dissertation and they serve to provide useful inputs for medical guideline development 
and decision making.   
In addition, the narrower sense of decision analysis is also highlighted and 
implemented in various problems.  More familiar to economists, industrial engineers, 
mathematicians and policy-makers, it refers to the modelling of a decision in the form 
of a tree or an influence diagram and the process of identifying the optimal course of 
actions that maximises the decision maker’s satisfaction. It offers a structured, 
systematic and quantitative approach for evaluating decisions with alternatives, 
uncertain outcomes and competing objectives.   
Decision tree [4] and influence diagram [5] are two different ways for 
presenting the decision problems.  While the tree diagram may be a more 
conventional form of representation, influence diagram provides a more elegant and 
succinct representation when the size of the tree becomes ungainly large.  However, a 
decision tree is preferred over an influence diagram should the problem on hand is 
less complicated, as it provides a more visual approach to decision problems.  The 
comparison of decision trees and influence diagrams is documented in literature [6].  
It is also worthwhile to note that both the decision trees and influence diagrams are 
isomorphic, that is, any property built on the latter can be converted into the former, 
and vice versa.  
1. Introduction 
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One of the many notable advantages for applying decision analysis is that it is 
able to generate a number of graphical tools for model evaluation.  At each step of 
modelling a great deal of insights may be produced so that the analysis could be 
modified promptly and efficiently.  The following sequence of steps is applied for 
developing a medical decision analysis [7]: 
 
 Define the decision problem and its time horizon 
 Identify a set of candidate decision alternatives 
 List the possible clinical outcomes of each of the candidate alternatives 
 Represent the sequence of events leading to the clinical outcomes  
 Determine the probability of each chance event 
 Assign a value to each clinical outcome 
 
 
The term “decision alternative” denotes the decision maker’s range of options.   
In a decision tree or an influence diagram, the decision and the chance outcomes are 
represented by nodes.  The value of each outcome is often expressed in terms of the 
decision maker’s utility.  In the patient’s context, the utility quantifies his differing 
attitudes to risk and his relative desirability of the outcome states.  As a rational entity, 
he must be able to rank his preferences according to the outcomes of the various 
options.  The probabilities on the chance nodes, on the other hand, quantify the 
pervading uncertainties, which always create clouds of discomfort to medical decision 
makers.  A chance node is thus the point in a decision tree at which probability 
determines which outcome will occur.  In medical decision analysis, possible 
outcomes of chance nodes include disease present/absent, survive/dead, 
1. Introduction 
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improvement/deterioration in health condition, remission/relapse following a surgical 
operation, and recovery/no recovery after treatment.  A patient’s utility and the 
probabilities on the chance nodes are determined independently.   
  The normative Expected Utility Theory (EUT) [2] states that the decision 
maker chooses between uncertain outcomes by comparing their expected utility value, 
which is the weighted sum obtained by adding the utilities of outcomes multiplied by 
their respective probabilities.  The most desired decision is one that maximises the 
expected utility.  The fundamental axioms of expected utility are documented in 
references [2, 6].  It is interesting to note that while these assumptions are reasonable 
under most circumstances; many decision theorists find some of the axioms 
controversial.  These range from introspection regarding particular decision situations 
to formal psychological experiments in which human subjects make choices that are 
inconsistent with one or more of the axioms [8-12].  The behavioural paradoxes, 
however, do not necessarily invalidate the idea that one should still make decisions 
according to the EUT.  The argument all along has been that people do not seem to 
make coherent decisions without some guidance.  In constructive terms, the decision 
assessment process helps to mould the decision maker’s preferences and his 
understanding about uncertainties.  Individuals who do not think long and hard 
enough in developing their preferences and beliefs might have a tendency to make 
inconsistent judgements [6].   
In terms of the above-mentioned set-up, there is no drastic difference between 
medical decision analysis and ordinary decision analysis frequently applied in 
business, economics, engineering, military operations and public policy evaluation.  
However, extra care must be taken in the formulation phase so that the chance and 
decision variables chosen should cohere with the medical domain and reflect the 
1. Introduction 
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current state of medical knowledge.  This also helps to determine the types and 
number of alternatives and objectives for a specific decision problem.  In addition, 
elicitation of patient utilities may also pose a serious challenge to the analyst as many 
patients may not know their preferences precisely.   
The use of decision analysis in solving medical problems engages the patients 
in every single step of the process, as the primary goal is to maximise the patient’s 
well-being.  Hence, medical decision analysis should be duly recognised as an integral 
part of contemporary medical practice.  It is also fast becoming an indispensable tool 
of evidence-based medicine (EBM), a particular branch of medical practice that is 
gaining world-wide attention in recent years.  Emerged in the 1990s, EBM formalises 
the scientific principle of basing clinical practice on evidence.  Advocating the 
conscientious, explicit and judicious use of current best evidence in health care [13], 
EBM allows research findings be critically appraised and interpreted, thus increasing 
the likelihood of making better informed decisions.   . 
To facilitate discussion, the terms used throughout the dissertation must be 
properly defined.  A “clinician” is a qualified doctor who renders medical care to 
patients, either in the form of surgical operation or drug treatment or both.  Next, 
“decision maker” is referred to both clinician and patient who are an integral part of 
the decision-making process.  An “analyst” , who may be a decision analyst or 
statistician by profession, is one who provides expertise in solving specific technical 
problems at various stages of the process, including probability encoding and 
generation of patients’ utility.  An investigator is one who initiates and conducts the 
decision analysis.  Last but not least, “domain experts” are those who provide 





Utility elicitation and probability encoding are crucial to the proper formulation and 
analysis of a medical decision problem.  The objective of this dissertation is to focus 
on developing useful probability-encoding models for routine use in medical decision 
analysis. 
Central to probability encoding and the analysis of medical decision problems 
is the collection and interpretation of evidence.  However, evidence is always 
tentative and obscure in nature.  This is because medical research bears a large degree 
of uncertainties, which may not be completely eradicated even by employing the most 
sophisticated study design and analytical method.  In fact, all forms of inductive 
conclusions are provisional and are subject to change in light of new evidence.  The 
major causes of uncertainty in medical decision analysis include the following: 
 
 
 limited knowledge of the medical problem under study 
 missing information for the complete understanding of a problem  
 subjects enrolled for study are merely a sample of the larger population (sampling 
error) 
 censored medical information  
 errors due to both investigators’ limited sensory power and sensitivity of the 
medical equipment 
 varying conditions of related medical research findings 
 inadequate or inconsistent conclusions from past medical studies 
 
 
The public is often baffled with conflicting and uncertain medical evidence 
reported in news.   For example, there are mixed published evidence regarding the 
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potential benefits for breast cancer screening on mortality [14].   Even in situations 
where there is consistent evidence, uncertainties pervade.  While it is generally 
acknowledged that higher levels of physical activity are associated with decreased 
risk of coronary heart disease, hypertension, cancer and possibly longevity [15-16], 
there is a shortage of convincing evidence on what is the threshold level of desired 
physical activity.  Contrary to the common belief that prolonged vigorous physical 
exercises might exert unnecessary burden on our body, there is evidence showing that 
professional athletes might enjoy better long-term life expectancy than the general 
public [17].   
The persisting variable degree of uncertainty calls for the application of 
probabilistic thinking in medical decision analysis.  Since uncertainty cannot be 
eliminated from decision problems, it has to be accommodated and modelled with 
relevant available evidences.   
Relevant evidence is one that makes the fact requiring proof more or less 
probable.  Therefore, the probabilities we assign to our conclusion(s) depend not only 
on how much evidence we have but also how we interpret the evidence and how 
confident we are with the interpretation.  We must also revise our assigned 
probabilities when new evidence surfaces.  These are then updated on the chance 
nodes of the decision model.  Hence, the methodological issues involved in using 
evidence for medical decision making involves not only evidential collection, but also 
how we analyse the evidence and with what degree of assurance. 
Probability provides decision analysts with the scientific theories, 
mathematical concepts and computational techniques for quantifying uncertainties.  
Under uncertainty, the decision maker knows the specific outcomes associated with 
each alternative, but he does not know the probabilities to be associated with the 
1. Introduction 
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states [18].  This is often the scenario of a typical medical decision problem and it 
leads one to recognise that medical decision making is “an art of probabilities” [19].  
It is beyond the scope of this dissertation to provide a formal treatment of probability 
and its related concepts such as causality [20].  One may refer to the relevant 
references for a more rigorous treatise [21-24].   
To sum up, this dissertation aims to develop a useful and versatile framework 
for probability encoding which may be routinely applied in solving medical decision 
problems.  This calls for not only a proper understanding of probability but also the 
nature of medical evidence gathered and interpreted for decision making.  A reliable 
probability-encoding framework is one that is able to reflect the very nature of 
medical evidence, which forms the main focus of the next section.  
Considering the unique characteristics of clinical research and decision 
making, the Bayesian framework is advocated.  With the help of several specific 
models developed under the framework, routine clinical decision making may be 
carried out with much ease.  They are applied to shed light on a number of clinical 
and healthcare decision problems. However, the implications of the Bayesian 
framework are far more profound.   Capable of transforming our current notion of 
evidence, probability and decision making, the Bayesian framework will enrich the 
practice of EBM which advocates the judicious use of best evidence in health care.  
The Bayesian probability-encoding models advocated in this dissertation are 
sophisticated in nature but not beyond the scope of the less mathematically-inclined, 
especially the clinicians.  To accede to their needs, this dissertation is prepared with 
medical professionals in mind.  The specific Bayesian models advocated are designed 




1.4 Medical Evidence 
1.4.1 The Salient Nature  
Since the reliability and accuracy of probability encoding hinges on the use of 
evidence, the nature of medical evidence must be closely examined.  While the above 
discussion suggests that evidence is tentative and uncertain in nature, the following 
explains that it may be both objective and subjective.  It is a common mistake that 
evidence can only exist in an objective state.  This is partly caused by its confusion 
with other related terms such as facts, information and data. 
What is taken as a fact depends upon the extent to which observations are 
corroborative.  It is any thing capable of being received by the senses.   We may 
gather evidence about some phenomenon, but if this evidence is to any degree 
inconclusive we are not entitled to conclude that it entails factual contents of the 
problem.  Moreover, a fact is evidential only if it is applied in an appropriate context 
where inferences about the problem can be made.  It is said to be “proved” or 
“disproved” when after considering all the evidence before it, the medical community 
believes it to exist, or considers its existence so probable that any prudent clinician 
ought to act upon the supposition that it exists.  Similarly, while we might all agree 
that evidence generates information, we cannot equate the two terms.  For instance, a 
document written in an obscure language may be recognised as relevant but non-
informative for drawing inferences or decision-making.  It becomes informative only 
when some explicit meanings are attached.  Last but not least, data are quantified 
evidence intentionally gathered or established as references for verifying a hypothesis.  
These are typically clinical observations as seen, measured and recorded.  Clinicians 
sometimes speak of “hard data”.  This refers to clinical or para-clinical data that can 
be precisely defined and measured, such as blood cell count, heart rate and glucose 
1. Introduction 
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level.  By contrast, soft data are observations that are relatively difficult to define, 
measure and classify.  Typical examples include sorrow, anxiety, general well-being 
and pain experienced by patients.  The “hardening” of soft data refers to all means 
employed to improve the criteria, measurement and quantification of soft data in order 
to match that of hard data as closely as possible.   
More importantly, our observations of any kind produce only abstraction or 
representation of the phenomenon in question.  Observation is a subjective affair and 
subjects are known to differ widely in their sensory capacity and other observational 
characteristics.  This implies that the concept of evidence should not be limited to 
references that are directly observable to the subject.  Otherwise, a medical decision 
maker may have to discard a great deal of evidence that cannot be observed directly, 
such as patients’ personal assessment of fear or depression.   
Moreover, most clinicians are accustomed to believe that knowledge is only 
justified with empirical confirmation.  According to the conventional scientific 




 propose a hypothesis concerning an observed phenomenon 
 design a study to test the hypothesis 
 acquire and analyse the data from the study 
 test the results against the hypothesis  
 draw conclusions given the results  





However, this leaves open a number of metaphysical and ontological questions, 
including the source of inspiration for hypothetical development, the dependence of 
observation and analysis on the researchers’ perceptions and the epistemological path 
to gaining insightful conclusions of the study.  Clearly, scientific investigation is not a 
100% objective affair.  
Similarly, the warrantability of evidence may also be established through 
semantic clarification and logical reasoning. For example, a clinician does not need to 
conduct an experiment to prove that plunging from a high-rise building without any 
safety aid can cause death.  Moreover, empirical warrantability stems from a 
confirmatory relation to specific conditions of first-person experience, which may be 
established outside the self in the real world (observation) or through personal 
experience, if honestly reported.  
In a nutshell, it is erroneous to think that evidence can always be observed or 
measured objectively.  To be useful for decision making, the relevance of evidence 
must be established.  This requires a proper presentation of the qualitative and 
quantitative characterisation of phenomenon under study.  Moreover, one must also 
ensure that the relevant evidence is collected and analysed within the appropriate 
context. 
 
1.4.2 Expert Opinion 
Taking into account its subjective nature, evidence may then be classified as 
tangible (real or documentary) or intangible, with testimony as the most common 
form of the latter.  Simply put, evidence is the means by which the claimant tries to 
defend/prove his case and the opposition tries to cast doubt upon or disprove the 
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hypothesis.  Therefore, medical evidence should also include testimonial assertions 
and authoritative opinions (direct evidence) that are admissible and relevant.   
In this context, the so-called authorities or experts must be competent (based 
on verifiable collateral facts) and are able to elucidate their opinions. The challenges 
facing decision analysts are to assess the admissibility and relevance of these opinions 
and to quantify them so that they are evidential or informative for decision-making.  It 
is a precondition for admissibility that evidence is relevant.   
This dissertation asserts that testimony is a valid form of evidence, whereby a 
witness relates what he believes.  In providing testimony for medical decision-making, 
the expert effectively acts as a “witness” and his evidence is often presented in the 
form of “opinion”.  To facilitate discussion it is important to distinguish the expert 
from the analyst, who elicits the evidence from the former in providing solutions to 
decision making.  
 Generally, opinion refers to ideas or beliefs provided by a subject while 
interpreting a particular phenomenon.  It has been well-settled in the legal discipline 
that a view offered that is based on one’s education, training and experience is an 
“expert opinion”.  Expertise, in its broadest sense, is the accurate application of 
knowledge, beliefs and experience to certain situations.  Experts typically identify and 
understand the nature of a presented problem within their domain of knowledge and 
are able to establish its representation beyond the scope of novice.  As such, expert 
opinions may only be offered by a suitably-qualified person widely acknowledged in 
his field of practise, and with a good credential and track record.  Such evidence may 
be more appropriately termed as “opinion evidence”, in accordance with the earlier 
discussion of evidence.   
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 As such, the admissibility of expert opinion depends on two factors.  First, the 
analyst who is responsible for eliciting the opinion evidence must be satisfied with the 
witness’s status as an expert and this will, naturally, involve a consideration of his 
qualification and experience.  The burden of proof in establishing expertise lies with 
the analyst seeking to call the witness.  Second, an expert opinion must relate to an 
issue that goes beyond the competence of the analyst and must be necessary to aid the 
analyst in understanding the issue of reaching a decision of the presented evidence.  
The identified expert bears such evidential burden and he must be able to defend and 
justify his given opinions, including cross examination from his fellow specialists. 
 
1.4.3 A Revised Definition and its Implications 
Taking all these matters into consideration, “medical evidence” may mean any 
or all of the following: subjective assessment provided by patients (pain, depression, 
etc), directly observable/measurable evidence (state of emaciation, symptoms of 
disease, etc.), indirectly observable evidence (cancerous cells revealed in X-rays, 
heart murmur, etc), factual records of the patients (personal and family medical 
history, smoking and drinking habits, etc) and clinicians’ expert knowledge acquired 
through individual training, practice and peer sharing. 
Thus, the current definition that “evidence is a fact or datum which is used, or 
could be used, in making a decision or judgement in solving a problem” [25] is 
somewhat inadequate.  As such, evidence should be more appropriately defined as “an 
explicit warranted reference given in an appropriate and specific context for 
supporting or rejecting a hypothesis, claim or belief” and it encompasses any facts, 
data or information, whether weak or solid, obtained through experience, published 
results and observational and experimental research.  A reference qualifies as 
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evidence so long as it is relevant either to the understanding of the problem or to the 
clinical decisions made about the case.   
What is the implication of this revised definition of evidence?  It suggests that 
all medical evidence must be organised, analysed and interpreted with the Bayesian 
framework.  With this in mind, the Bayesian probability-encoding models are 
advocated in this dissertation.  It is capable of coping with the unique nature of 
medical evidence, including a priori beliefs and expert opinions, and thus, should be 
recognised as the most appropriate and versatile framework for medical decision 
analysis and EBM practice as a whole.  Through fulfilling the objective depicted 
earlier, this dissertation sets off to prove that the incorporation of Bayesian thinking 
into medical decision analysis is never an expensive or painful endeavour.  Hopefully 
this is a welcome addition to the literature of contemporary medical practice, 







The specific Bayesian models proposed in the dissertation are developed from either 
the original Bayes’ Theorem [26] or from the various fundamental concepts that 
underlie the development of contemporary statistics.  Considering the nature of 
evidences often encountered in medical decision analysis, two classes of probability-
encoding models are developed.  The first deals with subject-level evidence, while the 
second accommodates aggregate-level evidences reported in medical literature.  Both 
are designed for routine use in medical practice.   
The models developed for synthesising aggregate-level evidences may have 
profound implications on medical decision analysis.  Clinicians spend a large 
proportion of their time reviewing the medical literature in search for evidential 
support of their actions.  The published evidence or existing data from secondary 
sources effectively form the basis for medical decision making.  These may be the 
quickest available “objective evidence” at hand as it is often beyond the scope of the 
clinicians to conduct a new observational or experimental study to justify his 
hypothesis or claim.  Thus, the proposed random-effect hierarchical models designed 
for handling aggregate-level evidences is deemed to be an indispensable tool for 
achieving this aim.  They are also capable of combining evidences from different 
published sources.  On the other hand, the relational models that utilises patient-level 
evidences are also extremely helpful in situations where prior information of all the 
model coefficients are not available or obtainable.  Instead of fitting non-informative 
priors to the coefficients, these models only require the most critical priors be 




Next, the beta distribution is duly credited for its versatility in evidential 
analysis.  Unlike the conventional Bayesian approach, beta is applied in this 
dissertation as both a prior distribution for quantifying previous/expert evidences and 
as a likelihood function for summarising collected data.  Beginning to gain popularity 
among mainstream statisticians in recent years, this dissertation hopes to popularise 
its use in applied medical research.  
On a broader perspective, the discussion of the nature of medical evidence has 
also helped to shape a more complete definition of evidence, the cornerstone of 
medical decision analysis.  Conceptually, evidence refers to observational, 
experimental and inferential information forming part of the grounds for upholding or 
rejecting claims or beliefs relevant to medical decision making.  Forming the basis of 
reasoning, evidence is thus referred to any explicit warranted reference given in an 
appropriate and specific context for supporting or rejecting a hypothesis, claim or 
belief.    
The new notion of evidence could bring enormous contributions to EBM.  The 
protagonists of EBM place case reports near the bottom of the medical evidence 
pyramid alongside editorials and opinions [27], even though they may be the primary 
source of information one can apply in some decision problems.  In view of the 
profound implications of the Bayesian framework, the current definition of EBM [25, 
28-29] must be revised and this will help EBM practitioners to recognise the practical 
importance of such evidence that has hitherto deemed to be falling short of the 
“scientific standards of proof” [27].  The proposed Bayesian probability-encoding 
models are able to accommodate these evidences and synthesise with those generated 
from randomised controlled trials, analytical observational studies and uncontrolled 
experiments.  Such practice is desirable in view of the broader scope of evidence.  
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This may in turn help to shed light on some of the unresolved issues of EBM [30] and 
consequently, lead to a paradigm change in its practice.   
Subjective medical evidence—so often intertwined with medical dogma, 
which is derived from untested hypotheses and uncritical assessment of research 
findings—bears a poor reputation and this in turn shapes the traditional scientific 
thinking, with empirical investigation universally recognised as the only undisputable 
source of evidential organisation and interpretation.  However, one ought to think 
twice before discounting all subjective evidence in scientific investigations.  In view 
of the earlier discussion, it must be reckoned that effective decision making draws 
upon a broad spectrum of clinicians’ capabilities that include their shrewd application 
of fellow scientists’ testimony.  In fact, clinical instincts and independent thinking—
developed through personal experience and communication with experts—are 
essential attributes of a competent clinician.  Nothing, not even the best form of 
education, can replace the role of experience.  It is an asset that all clinicians earnestly 
strive for.  With experience, clinicians are able to approach problems confidently and 
identify feasible solutions quickly.   
Summarising the views put forth above, this dissertation asserts that scientific 
medicine is a decision-oriented discipline about evidentiary interpretation.  Clinicians 
are ardent users, organisers and interpreters of medical evidence.  Thus, they must pay 
special attention to the way their decisions are formulated.  This may in turn 
transform the way medicine is practiced in future. 
Inevitably, the supreme authority of clinicians in decision making is 
challenged and eroded with the application of decision analysis.   Although scientific 
medicine has always maintained that patients are fresh and blood and should be 
treated as such, many clinicians are often more interested in the diseases than in the 
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patients who suffer from the diseases.  Clinicians have always had power and 
exclusive, if not elusive, knowledge about health issues.  They possess specialised 
knowledge about diseases, drugs, remedies and treatments not accessible to the public 
at large.  They have let it be thought that they know exactly what they are doing even 
they may not necessary be so and this may undermine patients’ autonomy.  
Unfortunately, this is detrimental to medical care as it fails to recognise patients’ 
preferences.  Clinicians must begin to realise that their interests are intertwined with 
that of the patients.  Moreover, patients have the basic need to explain their concerns, 
hopes, fears, desires and misfortunes. While clinicians are experts in healthcare 
matters, patients are owners of their health.  They also have the right to understand 
every single detail about the decisions made on them.  Through medical decision 
analysis this dissertation hopes to correct the dogmatic attitude of contemporary 
clinical practice, which has become more and more depersonalised in recent years.  
On the technical aspect of medical decision analysis, there is a wrong 
perception that clinicians will not comprehend the beauty of complicated quantitative 
analysis and mathematically-trained professionals will not understand the profound 
medical practice.  As such, this dissertation is prepared to enable clinicians to 
appreciate decision science, especially Bayesian probability encoding.  Hopefully, this 
dissertation provides some useful ideas to meet the growing demand for the highly 
technical and yet easy-to-follow procedures of Bayesian analysis.  Likewise, the 
choice of case studies featured in this dissertation should also benefit well-informed 
non-medical professionals who want to know more about contemporary medical 





1.6 Outline  
This chapter begins with a burning issue facing the current medical practice, that is, 
how to ensure clinicians make good decisions.  Following the recommended routine 
use of structured decision analysis in solving medical problems, the objective of the 
dissertation is explicitly defined.  Taking into account the persisting nature of 
uncertainties, this dissertation aims to develop a versatile framework for probability 
encoding useful for routine applications in the clinical context.  The Bayesian 
framework is judged to be the most appropriate framework for quantifying the 
uncertainties underlying all medical decision problems, in view of the multi-faceted 
and profuse nature of medical evidence.  A revised definition of medical evidence is 
also given in an attempt to accommodate a broader evidential scope, and this in turn 
lends support to the application of Bayesian models in decision analysis.   
A systematic review of the proposed Bayesian modelling framework and all 
related philosophical and technical issues are given in the next chapter.  The general 
aspects of Bayesian analysis is reviewed in the first two sections, followed by the 
specific modelling strategies related to the Bayesian probability-encoding models to 
be developed and applied in the dissertation.  These include the generalised linear 
model, survival model, hierarchical model and meta-analysis. An overview of the 
computational issues often encountered in Bayesian analysis is given.  It also provides 
some clarification to the controversy of the Bayesian framework in scientific research.   
Then, the specific Bayesian probability-encoding models are developed in 
Chapter 3.  They are designed for different types of evidence collected for decision 
analysis.  As described before, there are two such classes of models.  The first is 
designed for analysing subject-level evidences while the second helps to synthesise 
aggregate-level or published evidences.  The reason for not considering the empirical 
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Bayes technique for handling aggregate-level evidences is presented.  .In addition, 
issues concerning Bayesian model evaluation are discussed.   
In Chapter 4, the models are illustrated with 10 clinical applications involving 
patient-level as well as aggregate-level evidences.  The studies cover several common 
diseases and medical conditions in Singapore and these include depression, 
osteoporosis, colon cancer, dengue fever, intracerebral haemorrhage (stroke), obesity, 
ischaemic heart disease, asthma, end-stage renal failure and breast cancer.  Some of 
these illnesses are regarded as the major causes of death among Singaporeans.  In 
terms of medical disciplines, the case studies cover psychiatry, public health, 
oncology, infectious disease, ophthalmology, respiratory medicine, surgery, 
nephrology, emergency medicine and cardiology.  
The final chapter is devoted to the discussion of the nature of scientific 
medicine and the future practice of EBM.  Several related philosophical questions, 
such as the nature of medical truth and the correspondence between knowledge and 
truth, are surfaced and discussed based on the proposed probability-encoding 
framework.  A number of future methodological research topics are also presented. 
Readers may realise that all views are expressed and addressed in the context 
of EBM.  This stance is shaped by the following reasons.  First, EBM explicitly 
highlights the importance of medical evidence, which is viewed as the cornerstone for 
medical practice and decision making.  As such, all discussion concerning the use of 
medical evidence must make reference with EBM.  Second, EBM is fast becoming an 
encompassing field that integrates clinical practice with decision analysis and public 
health.  As a budding field in the medical discipline, EBM will serve as a good testing 
ground for new developments in decision analysis, especially in the area of 
probability encoding.   





2.1 The Bayesian Framework 
Contemporary medicine is perceived as a probabilistic activity [26].  Probability 
encoding in medical decision analysis clings on the availability, collection, 
organisation and interpretation of relevant medical evidence.  Uncertain, truncated 
and obscure in nature, medical evidence seldom exist in isolation.  Medical-evidence 
seekers must consciously embark on an intriguing investigative process to unlock the 
latent relatedness among bits and pieces of elusive clues that are often inadvertently 
tampered, under-utilised or suppressed.  One needs to emancipate evidence from all 
forms of confinement before its hidden meaning becomes interpretable, albeit a 
provisional or incomplete one.   
To discover or unearth its meaning, one must follow the rules of systematic 
inquiry which may be loosely described as scientific methodology.  Offering a 
systematic framework in which collected evidences are organised, the Bayesian 
methodology seeks to interpret the obscure evidential meanings based on the union of 
two distinct sources, which adequately reflect the data-capturing process and the 
salient nature of medical evidences.  The details are given below. 
In applying evidence to make medical decisions, one effectively conducts 
investigations on some unknown parameter, say θ.  Statistically speaking, a parameter 
is an unknown quantity that characterises the features of a population where evidences 
are drawn.  An example is the extent of transmission of foot-and-mouth disease 
among school children within a city over a period of one month.  In the context of 
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clinical trials, the parameter could be the difference in survival rate between two 
groups of patients who are randomised to receive different therapeutic treatments.   
Note that θ may be a vector with multiple component parameters investigated 
simultaneously.  Following the celebrated Bayes’ Theorem [26], the proposed 
framework may be formulated as: 
 
 
P[θ | evidence]  ∝ P[θ]  × L[evidence | θ]    




The prior distribution, P[θ], summarises what is believed, aware or known of θ before 
observing the collected evidence.  The likelihood, L[evidence | θ], contains evidence 
provided by observations, given a probability model with θ as the parameter.  The 
posterior distribution, P[θ | evidence], gives the final analysis and interpretation of θ 
after observing the evidence.  The parameter θ is considered as a random variable 
since one is not certain about its “true” value. 
Intuitively, the Bayesian approach suggests that the prior evidence support 
fuses with the data support (likelihood) to produce the posterior evidence support.  
With more evidence built into the analysis, one expects the Bayesian framework to be 
more appropriate and useful than the conventional framework, which considers the  
likelihood of collected evidence as the only basis for analysis.  There is a rich volume 
of well-cited theoretical and methodological literature on the conventional framework 
[31-34].  Statisticians often refer to the conventional framework as the frequentist or 
classical approach.  
The following summarises how the Bayesian approach is implemented in 
evidential analysis: 




 select the most relevant and appropriate probability model for the problem 
 specify the joint probability distribution for all quantities (observed and unknown) 
in the problem 
 use prior evidence explicitly as part of that specification 
 condition on the observed evidences, compute the conditional probability of the 
unknown quantities of interest 
 evaluate the model 
 
These are the premises upon which Bayesian evidentiary organisation, investigation, 
analysis and interpretation are based.   Collectively, the steps serve as the conceptual 
framework for building advanced statistical models for analysing the association 
between variables, which is the crux of probability encoding in most medical decision 
problems.   
Another way of dealing with an uncertain event is to form its odds.   The odds 
of an event (A) is defined as the probability of A happening divided by the probability 








, thus illustrating the one-to-one correspondence between odds and 




∈[0, ∞).   In the medial 
context, it is sometimes more helpful to inform the patients what are the odds of 
suffering from a complication should they decide to receive a particular medication.   
According to the logic of Bayes’ Theorem [26],  
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posterior odds = prior odds × likelihood ratio 
           (2.2) 
 
 
The likelihood ratio is often referred to as the Bayes factor (B).  It contains the 
evidence relevant to the question about the occurrence of event A.  As readily seen, 
B=posterior odds / prior odds, or the amount of evidence that changes the prior odds 
to the posterior odds.  If B>1, then the evidence has made us believe that event A is 
more probably to happen than we first thought.  On the other hand, if B<1, then the 
evidence has given us more reasons to believe that event A is less probable to occur 
than we originally perceive.   
In most clinical studies, the aim is to ascertain if there is an association 
between exposure to a factor E (say, following a medication plan) and the prognosis 
(R).  The subjects face 4 possible scenarios: 
 
 exposed (E) and recovered (R) 
 exposed (E) and not recovered (~R) 
 unexposed (~E) and recovered (R) 
 unexposed (~E) and not recovered (~R) 
 
One is then able to compute two odds, namely odds(R | E) and odds(R | ~E).  The 
ratio of these odds is known as odds ratio (OR).    If OR is unity, one reports that the 
exposure (E) is not associated with prognosis (R).     If OR>1, then one claims that the 
patients benefit from the exposure (E).  On the other hand, the exposure brings 
negative impact to the patients if OR<1.   As such, OR allows direct comparison of 
the odds of recovery (R) between the exposed and the non-exposed groups.  One may 
also compute the OR for ascertaining the relationship between exposure to a harmful 
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agent and the onset of disease or the association between a treatment and the status of 
mortality. 
If the evidences about an OR are available, then one is able to form the 
likelihood of OR with a suitably chosen distribution.  Suppose also that some prior of 
the OR is obtained.  The following can be formulated according to the Bayes’ 
Theorem [26]: 
 
posterior OR = prior OR × likelihood OR 
           (2.3) 
 
 
It is useful to clarify here that it is sometimes difficult to encode probabilities directly 
from statistical models supported by patient-level or aggregate-level evidences, so it 
may be more relevant in some clinical contexts to present the odds ratio (OR) instead.   
In the example presented, the odds ratio is the ratio of odds for two different events 
that differ only in one variable (E).  In advanced statistical modelling it is possible to 
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2.2 Some Insights 
Although the Bayes’ Theorem [26] has been applied in statistical inference for more 
than two centuries, the Bayesian interpretation of probability is a fairly recent 
endeavour.  The following discussion provides a thorough inspection of the nature 
and features of the proposed Bayesian framework.  Supported by literature review and 
some generalisations from current philosophical thinking, the discussion focuses on 
the framework’s conceptual set-up, evidential-updating property, nature of inferences, 
probabilistic interpretations and the benefits in evidential analysis.  The literature 
review and its following discussion provide the impetus for advocating the application 
of Bayesian analysis in medical decision making.  However, the discussion is not 
entirely one-sided.  Some of the common problems and criticisms concerning the 
application of Bayesian models are also highlighted.  Inevitably, the discussion also 
draws some comparison with the conventional framework of evidential analysis. 
First and foremost, the Bayesian framework’s evidential-updating property 
reflects how knowledge is accumulated and is very much in agreement with the 
hermeneutic circle [35-36].  Hermeneutics is a philosophical concept of interpretation 
and understanding of phenomena.  One always forms an incomplete picture of the 
phenomenon, when observed, with his subjective horizon of understanding (prior).  
Through observed evidence, the subject develops a revised understanding of the 
phenomenon and the final interpretation is achieved with the fusing of the subjective 
and objective horizons. The procedure allows one to change his probability 
assessment after observing or obtaining new evidence. The final understanding 
(posterior) incorporates the subject’s pre-understanding and his revised understanding 
of the phenomenon.  This Bayesian property requires the new evidence be 
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incorporated by a process of “refute and rescale” [37].  By allowing prior evidence be 
integrated with observed evidence, it offers great merit in medical decision making.  
The incorporation of a prior in evidential investigation immediately suggests 
that Bayesian analysis is at odds with the more established conventional framework, 
where scientific objectivity is given a paramount status and should be preserved at all 
costs.  In fact, the objectivity of the conventional scientific approach is achieved by 
disregarding all forms of prior knowledge about the phenomenon under investigation.  
In practice, there are usually some reliable priors, say based on expert opinions, that 
can be quantified.  This is common in legal investigation where eyewitness testimony 
is often the primary source of information that the court must consider in order to 
reach a verdict [27].   
Inevitably, evidential interpretation based on the Bayesian framework is 
subjective in nature, as it depends on the subject who initiates the investigation.  
While this may seem at odds with our conventional understanding about mathematics 
and science, the subjective nature of probability is not new to theorists.  In fact, it is 
now widely accepted as the modern view [38].  This view was contributed by several 
forefront mathematicians and statisticians [39-41].  The treatise of de Finetti 
(1930/1974) [39] begins with the provocative statement that “probability does not 
exist”.  This means that probability never exists in an objective sense.  Rather, 
probability exists only subjectively within the minds of individuals.  The view is also 
shared by Ramsey (1950) [40], Savage (1954) [41] and Anscombe and Aumann (1963) 
[42].  
As such, the interpretation of probability as a long-run relative frequency is 
only one of the interpretations.  Based on degrees of belief, the Bayesian decision 
analysts interpret probability as a quantified judgement of an individual.  This notion 
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has some profound impact on our interpretations of evidential investigation and 
statistical modelling.   
Despite the works cited above [39-42], the conceptual framework of Bayesian 
is not universally accepted in statistical science and the debates between the 
Bayesians and their critics, notably the conventional statisticians, shape the history of 
development of the subject.  While conventional statisticians agree with the 
implication of the Bayes’ Theorem [26], they generally do not accept subjective 
evidence, other than the likelihood function, as a source of information for inference.  
As a result, the conventional approach makes no room for the use of subjective 
evidence and is severely limited in the context of decision analysis.  On the other hand, 
the Bayesian framework makes use of all available information and leaves no room 
for data omission in analysis.  The prior evidence, if available, reflect the available 
knowledge about the phenomenon under investigation before the collected evidence is 
obtained.  There is a large volume of literature on the elicitation of prior distributions.  
See references [43-46] for details.  However, it is worthwhile to note that the issue of 
probability elicitation is not free from controversy [47-48] and the assignment of 
priors is viewed as a “critical issue” in all inductive inference [49].  On a practical 
ground, it is true that the prior distribution is difficult to specify reliably, despite the 
fact that complete ignorance or absence of prior information may not exist [50].   
 Some Bayesians argue that evidential interpretation with prior assignment may 
not be as private as it seems.  The priors may be formulated in unambiguous 
mathematical terms and communicated to others.  Subjective priors may be obtained 
from a team of experts with guidance from trained analysts.  In addition, the details of 
prior elicitation may be documented and reported alongside the main analysis.  It is 
crucial to note that the Bayesian framework is also not as deterministic or dogmatic as 
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it is perceived because the prior is described in probabilistic terms.  It reflects the 
variable degree of uncertainty involved in using prior evidence.   
 Moreover, the prior distribution may also be generated from relevant evidence 
obtained from past studies.  In this sense, Bayesian analysis is “objectified” with the 
use of an objective prior [51].  One may also perform Bayesian analysis using a 
constant prior distribution for the unknown parameters, as suggested by Reverend 
Thomas Bayes (1702-1761) and Marquis Pierre-Simon Laplace (1749-1827) [26, 52], 
the earliest Bayesians. A recent article shows that objective Bayesianism does allow 
learning to be facilitated from experience [53], a long-lasting criticism from the 
devoted subjective Bayesians who interpret probability as “the degree of belief” or 
“quantified judgement of individuals”.  In actual fact, it is difficult to follow the 
subjective school strictly as most subjectivists do make at least some use of objective 
Bayesian methods in practice [54].  This prompts some researchers to believe that the 
objective Bayesian methods offer the most promising route to unify the Bayesian and 
the frequentist frameworks [55].  The chief exponents of the objective school are 
Jeffreys (1965) [56], Jaynes (2003) [57] and Berger (2006) [54].  A full discussion of 
the subjective and objective Bayesianism can be found in references [58-67].  
Despite its reliance on prior evidence and distributions, the Bayesian 
framework also offers a solution to evidential analysis in situations where there is no 
prior evidence.  As mentioned before, the analyst may choose a distribution that has 
little or no influence on the likelihood [68].  Such priors are known as non-
informative.  Not surprisingly, the result is identical to that produced by the likelihood 
alone.  This is because with no prior knowledge, the posterior is solely based on 
evidence summarised by the likelihood.  That means, Bayesian analysis is applicable 
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in situations where there is no available prior knowledge about the phenomenon.  
Thus, the Bayesian framework offers a very versatile approach for decision analysis. 
The Bayesian framework also generates more intuitive and meaningful 
concepts for inductive inference.  As mentioned before, population parameters (θ) are 
specific to the decision problem and are not generally subject to random variability.  
According to the conventional framework, population parameters are uncertain only 
because of lack of knowledge.  Therefore, they are not recognised as random and all 
probabilistic statements about them are deemed to be meaningless.  However, the 
Bayesian framework asserts that it is perfectly legitimate to make probabilistic 
statements about the parameters simply on the ground that they are unknown [69].  
Thus, a quantity is regarded as a random variable even when its uncertainty is not due 
to randomness but to imperfect knowledge.  In the context of hypothesis testing, the 
probability-value generated from the conventional approach does not say how likely 
the null hypothesis is based on the collected evidence.  On the other hand, the 
Bayesian framework is able to attach a valid probabilistic statement and hence a more 
direct interpretation about how plausible the hypothesis might have been in light of 
the evidence.  Obviously, the Bayesian approach offers a more intuitive interpretation 
of unknown quantities.  
 According to the conventional methodology, the only source of uncertainty 
admitted to analysis is sampling uncertainty.  A fundamental advantage for applying 
the Bayesian framework to decision analysis is that both prior and posterior estimates 
are described in probabilistic terms and therefore offers a more realistic procedure for 
dealing with the myriad sources of uncertainty faced by decision makers in real-life 
applications.  As a result, the Bayesian framework is well-suited for decision making.  
What makes decision hard is uncertainty.  The Bayesian framework can quantify 
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these uncertainties using subjective or personal probabilities.  This quantification of 
uncertainties may be seen as a crucial component of rational, evidence-based decision 
making [69]. 
The Bayesian theory provides a solution to the famous Hempel’s paradox [70], 
which discovers a serious challenge to inductive logic.  Implying the arbitrariness of 
all human knowledge, the paradox highlights that inductive logic violates intuition 
and is bound to result in various absurdities. According to the paradox, the evidence 
(E) that an object is a non-black non-raven confirms the hypothesis (H) that every 
raven is black.   The standard Bayesian resolution suggests it is to a minute degree 
that E confirms H [71].  However, the argument is based on an assumption that the 
probability of H should not be affected by evidence that an object is non-black. A 
recent resolution shows that this assumption is not plausible, but the Bayesian concept 
is still able to cope with the paradox [72].   
On the philosophical ground, Bayesian estimators are found to be “theoretical 
simple” according to the Minimum Message Length (MML) [73], thus confirming the 
Bayesian practitioners’ persistent claim that Bayesian analysis is elegant [69]. The 
Bayesians are now equipped with a wide range of established methods for handling 
diversified issues in data analyses, and these include sample size determination [74-
77], point estimation [78], probability computation [79], hypothesis testing [80-84], 
clinical trial design and monitoring [85], model evaluation [86-87] and statistical 
modelling [88-90].   
Applications of Bayesian methods in biomedical research can be found in 
well-cited journals like Bayesian Analysis, Biometrics, Journal of the American 
Statistical Association, Statistics in Medicine and the various Journals of the Royal 
Statistical Society.   
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2.3 An Overview of Bayesian Models 
The different Bayesian models to be reviewed may be classified in terms of their set-
up and the nature of data analysed.  This will in turn determine what research 
questions can be answered by the models.  Loosely speaking, a relational model 
(more commonly known as regression in the statistical literature) is applied to 
quantify the association between an outcome variable Y with a vector of covariates or 
predictors (X).  The following discussion adheres to the convention that a random 
variable be denoted by a capital Latin letter and its value by a corresponding lower 
case letter.  All Greek alphabets represent unknown parameters or coefficients to be 
estimated. 
If properly modelled, these relational models enable one to generate reliable 
predictions about the outcome in probabilistic terms. The outcome concerned may be 
continuous (symmetrical as well as non-symmetrical), categorical (e.g., counts and 
nominal) and censored (e.g., time to event).  In situations where evidences are 
clustered or collected repeatedly over time, one of the most critical modelling 
assumptions called i.i.d. is violated, and some kind of hierarchical or multi-level 
relational models must be applied.  The assumption of i.i.d. refers to the situation 
where the observations are independently and identically distributed.  Last but not 
least, if evidences from various sources are to be synthesised to address a research 
question or hypothesis, a meta-analysis is conducted.   
 
2.3.1 Generalised Linear Model 
In the context of Generalised Linear Model (GLM) [91], which underlies most 
of the statistical analyses in biomedical research, the observed outcome variable Y is 
assumed to be generated from a probability distribution belonging to the exponential 
2. Literature Review 
 35 
family that includes binomial, Poisson, normal, gamma and inverse-Gaussian, etc.  It 
is applicable to a wide class of qualitative and quantitative outcome variables (counts, 
rates and continuous outcomes). GLM aims to unify a large family of statistical 
models that are applied for relational analysis.   
Consider a sample of n independently and identically distributed (i.i.d.) 
observations or measurements.  The GLM model requires the expected value of the 
underlying distribution, µi. be dependent on covariates xi (i=1, 2.,…, n) through 
E[Yi]=µi=κ(x′iβ), where κ is known as the link function and β is the coefficient vector 
that quantifies the association between xi and yi.  The idea is to estimate β so that the 
magnitude and direction of the association between xi and yi can be deciphered.  The 
variance of Yi is a function of the mean such that V[Yi]=V[µi]=V[κ (x′iβ)].   
In summary, the GLM has three components: 
 
 a distribution from the exponential family 
 a linear component ηi=x′iβ 
 a link function such that E[Yi]=µi=κ(ηi) 
 
The link function provides the relationship between the linear component (ηi) and the 
mean of the distribution function. There are many commonly-used link functions, and 
the choice should reflect the nature of the outcome variable and the desired 
interpretation of β. 
 Under the conventional modelling framework, β is estimated with the 
maximum likelihood (MLE) method.  As the name implies, the iterative procedure 
seeks to identify the solution that maximises the likelihood function.  Most statistical 
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software implements the Newton-Raphson algorithm for the root-finding problem.  
Theoretically, the MLE of β is asymptocally normally distrbuted.   
On the other hand, an appropriate prior distribution for β must be fitted should 
the model be analysed with the Bayesian framework.  Data are then collected to 
update the prior specifications and the resultant posterior serves as the basis for 
inference.  One advantage of the Bayesian framework over its conventional 
counterpart is that knowledge from previous sources or derived from theoretical 
considerations may be incorporated into the model.  For example, one might want to 
restrict the signs of certain covariates in the model. Such knowledge, if incorporated 
as “informative priors”, may help to improve the precision of the estimates of β.  
Detailed discussions on model specification, estimation, hypothesis testing, model 
selection and diagnostics for various parameters of interest from a Bayesian point of 
view is now available in references [92-93].   
While theoretically appealing, finding reliable priors for fitting Bayesian GLM 
is a daunting task.  Very often in practical situations, non-informative priors are fixed 
and the resultant posterior distribution is essentially dominated by the likelihood.  As 
such, the Bayesian estimates are numerically identical to the conventional estimates.  
Nevertheless, more complex model specifications and state-of-the-art computational 
methods are explored in recent years to meet the needs of biomedical and industrial 
research.  For example, flexible semi-parametric approaches are now available to 
model the link functions [92].  Splines are used for handling nonlinear covariates [94].  
In addition, some robust procedures can also be incorporated to provide reliable 
estimates in the face of outlying or influential observations [94].   
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There are a number of other excellent Bayesian references that address the 
modelling issues (such as the popular linear regression model) in a more accessible 
manner [80, 95-96].  While their presentation is not necessary adhering to the GLM 
approach, the discussion does provide readers with some glimpses of the power of the 
related models.   
 
2.3.2 Survival Model 
The next relational model for analysing i.i.d. subject-level data deals with time 
to event data.  Commonly known as survival analysis in biostatistics [97-98], such 
models have one salient feature: the time to event is skewed and censored.  Generally, 
the term “censoring” refers to an individual’s time is partially observed and not 
followed through to its completion [94].  Such situations include patients’ premature 
withdrawal from the study, or simple because the outcome is not observed before the 
study ends. 
 Suppose an individual’s time to event, yi, follows f(yi, θ).  The cumulative 
distribution function (cdf) is F(Y<yi).  There are two scenarios at a particular time, 
say yi.  First, there are patients with an event reported (death, readmission, etc.) and 
they form the risk set.  In addition, there are patients who do not encounter an event 
by time yi and they are represented by the survivor function S(yi)=P[Y≥yi]=1−F(Y<yi), 
which reports the probability of surviving beyond time yi. These subjects are 
“censored” because no event is observed in them.  To examine the effects of the 
subjects’ multiple covariates on their survival the hazard function is derived.  














i− [98].  The hazard rate is at the 
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heart of modern survival analysis [99].  One models this hazard rate as a function of 
the baseline hazard at time yi and the effects of the identified covariates, which may 
be fixed throughout the observation period or time varying [94].  The hazard rate may 
also be interpreted as the instantaneous event rate or conditional event rate [99].   
Thus, the likelihood is made up of two components, namely the non-censored 
f(yj) and the censored S(yj).  The censored component is in turn made of three 
possible portions: right-censored, left-censored and interval-censored.  Right 
censoring is most common in biomedical research.  Putting these components and 




















where UC, RC, LC and IC refer to the subsets of uncensored, right-censored, left-
censored and interval-censored observations, respectively.  Interpreted as hazards 
ratios, the effects β are estimated by maximising the above-mentioned likelihood 
function. In practice, the likelihood function is less complicated because the study 
designs may only allow at most one type of censoring.   
 A particular sub-class of the survival or time-to-event models is the 
proportional hazards model [100], under which the mean function of the covariates is 
independent of the time function.  This is a simplifying assumption applicable to most 
survival densities [94].  Under the proportional hazards assumption, the hazard ratio is 
constant over time, provided that the covariates do not change over time [101].  For 
example, if taking drug A halves a patient’s hazard at time 1, it will also halve his 
hazard at time 2.  Sir David Cox (1924—) shows that if the assumption of 
2. Literature Review 
 39 
proportional hazards holds, then the effects (β) can be estimated without considering 
the hazard function [100].   
 The common time-to-event distributions for Bayesian analysis are exponential, 
Weibull, gamma, Gompertz, log-normal, log-logistic and extreme-value, which are 
compatible with the proportional hazards assumption.  Bayesian survival analysis 
begins with the specification of priors on the parameters of the chosen distribution.  
The model specification is usually very complicated, in view of the nature of the 
problems encountered in survival analysis and the choice of distributions. 
As in the case of GLM, Bayesian survival analysis is becoming popular in 
recent years and a large number of research activities is conducted.  For example, it is 
well-known that the selection of a particular model may be subjected to errors, so a 
Bayesian averaging process is proposed [102].  Model based on other lifetime 
distributions such as Pareto may also be considered [103].  Attempts to produce more 
flexible specification with piecewise hazard models are presented in reference [104].  
Following the proportional hazards assumption, these models utilise several types of 
nonparametric/semi-parametric prior processes [101, 104].  Thanks to the latest 
development in computational algorithms, these models can be implemented 
efficiently in practice.  
It is legitimate to assert that Bayesian survival models may be presented under 
the wider GLM framework.  However, survival analysis has now become common 
and well accepted in practice that it has cast in a language all its own [99].  Bayesian 
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2.3.3 Multi-Level Model 
Some medical evidences are measured over time or clustered.  In the former 
case, the outcome values are no longer independently and identically distributed (i.i.d.) 
as they are contributed by the same subject at different time points (e.g., follow-ups) 
[105].  Such studies are usually known as longitudinal design with repeated 
measurements.  With two or more levels of observations in the clustered scenario 
(multi-centre trials, studies involving paired observations, etc.), the outcome values 
are likely only to be independent conditional on the clusters.   
The immediate implication is that the issue of dependence within clusters must 
be modelled appropriately with a suitable likelihood. That is, care must be taken for 
constructing the hierarchical data structure, with cluster-specific parameters and some 
covariance matrices incorporated into analysis.  These cluster-specific parameters are 
usually assumed to be random effects either drawn from independent distributional 
functions or from some multivariate distributional functions. 
Consider outcome yij related to predictors xij for observations i=1, 2, …, nj 




jn =n.  While the clusters are likely to be 
independent, the evidences within each cluster are not.  In clinical studies involving 
paired observations, say vision and kidney failure, the first and second level data refer 
to the paired observations and individual patients, respectively.  In the case of multi-
centre clinical trials, the first and second levels are individual patients and their 
belonging centres, respectively.  While there is no theoretical restriction to the number 
of levels that can be specified in the hierarchy, the practical restriction is that in 
specifications that have greater than three to four levels, the interpretation of the 
estimated coefficients can be challenging [96].  Frequently, there is no good reason to 
go beyond a two-level model [96]. 
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 A surge in biomedical research activities involving such hierarchical or multi-
level models with the frequentist perspective is observed in recent years [105-110].  
The Bayesians are quick to respond and a number of excellent references are now 
available [92, 94, 110-111].  These hierarchical models may be perceived as an 
extension of the more established GLM framework [92, 112].  Many survival models 
may also be carried out with the hierarchical modelling strategy [113].   
 In reality, many Bayesian models exhibit a hierarchical structure in 
specification.  This is because the underlying likelihood function may contain a 
number of parameters, thus requiring a series of priors to be fitted.  Collectively, the 
likelihood and the priors form a hierarchical structure in the model [80].   
 
2.3.4 Meta-Analysis 
 The conventional approach of systematic literature review in EBM involves 
discussion of results from a number of published studies that have investigated a 
common question.  Such review considers the evidences from individual studies one 
at a time.  There are some obvious drawbacks to this approach.  Evidence from 
individual isolated studies may be inconclusive because they lack power.  Moreover, 
the studies may differ in quality in terms of their sample sizes and rigor of analysis.  
This may be resolved by pooling the evidences with a suitably-chosen weighing 
scheme that quantifies the quality of each selected study.  
In statistics, a meta-analysis combines the results of several studies that 
address a set of related hypotheses [114-115].  The combined effect could be a risk 
ratio, odds ratio, continuous outcome or probability concerning some uncertain events 
(death, recovery, relapse or development of a complication).  Ideally, the studies 
considered in a meta-analysis should be similar in terms of the population of 
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subjects/patients, end-point outcomes, study designs (case-control, cross-sectional, 
cohort, randomised clinical trial), nature of treatments and statistical analyses.  
However, it is very rare for two published studies to be identical in all aspects.  
Consequently, certain inclusion criteria must be defined so that the selected studies 
are “sufficiently similar” and the pooled evidence are meaningful and generalisable.  
This may help to minimise the effects of clinical heterogeneity [116-117].   
 The biggest challenge for all meta-analysis concerns the availability of 
unbiased published evidences.  The most potential source of bias concerns the 
publication process.  Studies which report a relatively dramatic result are more likely 
to be published in journals and cited in other relevant publication [118]. The dire 
consequence is obvious.  One may be deprived of the less dramatic but accurate 
results and the combined evidence may then give a distorted picture concerning the 
significant effects of a therapeutic treatment.   
 Nevertheless, meta-analysis remains a realistic approach for quantifying 
systematic review of biomedical studies.  If properly conducted, it may provide EBM 
practitioners a very useful and least expensive solution to many medical decision 
problems.  Conventionally, there are two approaches to conducting meta-analysis.  
The first assumes no obvious heterogeneity in the selected studies.  In contrast, the 
random-effect methods consider the effects to vary randomly about a population.  
Usually, this approach is more realistic in view of the large degree of heterogeneity in 
reported studies.  Moreover, the common statistical method for detecting 
heterogeneity often lacks power and may report no significant heterogeneity even if 
the selected studies differ in many aspects.  The conventional approach to meta-
analysis is found in reference [119]. It is also possible to cast the meta-analysis in a 
regression approach [120]. 
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 While meta-analysis is an indispensable tool for systematic reviews, the 
Bayesian paradigm is not fully recognised in EBM practice.  At the point when the 
dissertation is prepared, there is no published textbook on Bayesian meta-analysis.  
While the Bayesian updating formula is often cited and applied in encoding 
probability for decision analysis [6], the approach is often too simplistic that it fails to 
take into consideration the nature of underlying heterogeneity in reported medical 
evidences.  Such desired models are multi-level in nature as the various sources of 
heterogeneity are captured and described as random effects, thus exhibiting a 
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2.4 Conjugacy and Monte Carlo Markov Chain 
Given a model with the prior and likelihood determined, the computational phase of 
the Bayesian inference requires a practical method for summarising the posterior 
distribution.  In simple cases, the estimators for unknown posterior parameters may be 
obtained analytically after some tedious mathematical manipulations based on 
integration.  However, this is generally not the case for most Bayesian analyses.  
Usually, such posterior is mathematically non-tractable.  Thus, analysts must rely on 
advanced simulation techniques for providing the solutions.   
It follows that the choice of distributional forms for priors and likelihood is a 
critical feature of Bayesian analysis. It is well known that the posterior distribution 
might not have an analytically tractable form if the priors are freely chosen.  A way to 
guarantee that the posterior has a calculable form is to specify a conjugate prior. 
When the posterior has the same distributional family as the prior, one says that the 
prior and the likelihood distributions are conjugate.  While adequately elegant and 
computationally simple for expressing an analyst’s opinion, it may be worthwhile to 
point out that the use of conjugate priors has no real theoretical advantage.  Before 
1990s, conjugacy was crucial to the ability to apply Bayesian methods because non-
conjugate priors usually lead to posteriors that are not analytically tractable.  With the 
advent of the Markov chain Monte Carlo (MCMC) techniques [122-128], this 
limitation becomes greatly reduced.   
It is worthwhile to provide a brief review of MCMC here, as EBM 
practitioners will find it extremely useful for conducting Bayesian analyses.  The 
MCMC technique provides an approach for simulating the posterior distribution in 
complex multi-parameter scenario without resorting to integration techniques or a 
search for close-form solutions.  In short, MCMC is used to estimate integrals in high 
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dimensions.  Instead of making direct simulation from the posterior distribution, 
MCMC simulates values from a stationary Markov chain, which describes an 
idealised pattern of movement or transitions through a set of states.
.
   As the name 
implies, the process moves from a state v at time t to state w at time t+1 depending 
only on state v.  The method is called “Markov chain” because each generated 
parameter value is used to generate the next.  It is “Monte Carlo” because it 
repeatedly simulates parameter values from the posterior distribution.  As such, it 
offers a less painful approach for finding solutions as the posterior may be extremely 
complex. Stochastic in nature, MCMC runs the chain until convergence is achieved.  
If the chain is run for a long time, simulated values of the chain can be used as a basis 
for summarising features of the joint posterior (or conditional posterior) of interest
.
  In 
contrast to classical simulation, MCMC generates samples where successive 
observations are non-independent of the previous observation.   
A specific MCMC technique known as Gibbs sampler [123] is advocated in 
this dissertation.  As the most widely used MCMC technique [96], the Gibbs sampler  
generates a Markov chain by cycling through the conditional posterior distributions 
instead of the full posterior.  In many situations, it is possible to define and derive the 
conditional posterior of the unknown parameters, thus making the implementation of 
the Gibbs sampler fairly straight-forward.  With the true posterior distribution of 
parameters as its limiting distribution [96], the Gibbs sampler converges under very 
mild conditions [127]. If the Gibbs sampler possesses the property of irreducibility 
(i.e., the existence of a path between any two points in the space), convergence is 
assured of the n-step-ahead distribution to the invariant distribution for almost all 
starting points [124].  This justifies the practical use of the Gibbs sampler to start from 
any arbitrary chosen initial condition and the sampler averages to approximate 
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integrals of the posterior.  In fact, the Gibbs sampler converges at a geometric rate: 
the total variation distance between an arbitrary time and the point of convergence 
decreases at a geometric rate in time [96]. The application of Gibbs sampler will be 
discussed in details with the introduction of the Bayesian hierarchical meta-analysis 
models useful for synthesising aggregate-level evidences for probability encoding 
(Chapter 3).   
An alternative MCMC algorithm, known as the Metropolis-Hastings, is based 
on the generalised rejection sampling scheme.  Values are drawn from arbitrary 
distributions and “corrected” so that they “behave” as random observations from the 
target distribution asymptotically [122].  A fairly easy-to-follow discussion of MCMC 
and some of its practical implementation issues, such as the number of iterations, 
starting point determination and graphical modelling is found in reference [128].   
However, conjugacy continues to be highly appreciated by analysts as it offers 
a systematic framework for finding priors with little pain and effort.  Consequently, 
conjugate priors are still extremely useful in practice and they are an excellent 
expository tool [51].  Convenience is a powerful argument for justification of the use 
of conjugate priors, which serve as user-friendly representations of prior evidence.  As 
discussed in the next chapter, it is more an art than a science in fitting conjugate priors 
for Bayesian statistical modelling.  In practice, both conjugacy and MCMC are 
applied as complimentary tools.  The selection is based on practicability. 
Statistical theory shows that likelihoods in the exponential family of 
distributions always possess conjugate priors [129].  Comprising a number of widely-
cited distributions like binomial, poisson, normal, beta, exponential and gamma, the 
exponential family’s unique mathematical form means that combining an exponential 
family likelihood and prior will always result in an exponential family posterior that is 
2. Literature Review 
 47 
promised to be more concentrated (less diffuse) than either the likelihood or the prior.  
This is a very appealing feature of the exponential family, and it further supports the 
use of conjugate priors in data analysis involving GLM.  One may refer to references 
[80, 84, 87, 94-95] for further information on how conjugate priors may be chosen 
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2.5 The Unfounded Controversy 
The idea of Bayesian thinking is reasonably straight-forward.  When properly 
presented, it is an uncontroversial probabilistic concept.  It is not difficult to 
understand that no other approaches can provide a more unified treatment of inference 
and decision, while accounting for parameter and model certainty.  Unfortunately, 
Bayesian methodology has not been universally accepted in the statistical discipline in 
spite of the compelling logic behind its approach.  In fact, specific uses of the 
Bayesian concept have been the subject of continued controversy for several centuries, 
giving rise to a steady stream of polemical arguments in methodological science.  So 
why do such controversies persist?  Why do conventional likelihood-based statistics 
dominate Bayesian usage in data analysis?   
There are several reasons to explain the above-mentioned controversies.  First, 
several prominent figures in the development of modern statistics, notably Professor 
Ronald Fisher (1890-1962), had strong prejudices against the Bayesian ideas.  See 
referenced for his criticism of inverse probability—the old name for Bayesian 
inference [130-131].  This was largely caused by the misunderstanding of the nature 
of Bayesian’s post-data interpretations.  Although the definition of probability is well 
accepted by almost every statistician, its interpretation or the sense attributed to it 
varies considerably. Despite its overwhelming popularity, the interpretation of 
probability as a long-run relative frequency is only one of the interpretations. 
Bayesian theory offers a more realistic approach in which personalised beliefs can be 
incorporated into the context of uncertainty, with the aim of developing rules and 
procedures for consistent and convenient decision making. The probabilistic 
statements of Bayesian analysis is interpreted as a degree of belief or a quantified 
judgement of the individual.  It emphasises the subjective basis for analysis and a 
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post-data basis of inference.  By allowing personalised beliefs be incorporated into the 
contexts of uncertainty, the Bayesian theory should be seen as the most appropriate 
framework for medical decision making. 
 A related reason for the under-appreciation of Bayesian methodology lies with 
the use of priors in analysis.  In fact, many present-day applied statisticians and EBM 
practitioners are reluctant to use Bayesian methodology because of the requirement of 
a prior distribution.  From a practical point of view, the prior is an extremely difficult 
requirement [69] that the investigator must meet and this imposes some costs on the 
use of Bayesian methods.  As described earlier, others are unwilling to utilise prior 
evidence based on concerns of violation of “objectivity”.  In the case where the prior 
evidence reflects the personal opinions of individual investigators conducting the 
research, or possibly those of an expert who has immense knowledge of the subject 
matter, Bayesian statistics is subjective in nature.  However, when the prior 
information is a direct result of previous studies, or when prior information reflects no 
knowledge about the problem at hand (non-informative), the Bayesian analysis 
becomes objective [54].  As such, it is not fair to allege that Bayesian methodology is 
purely subjective.  The prior is also not as deterministic as it is perceived, given that it 
is presented in probabilistic terms.  Moreover, EBM practitioners often find 
themselves devoid of usable evidence for decision making.  The use of priors, based 
on elicited expert opinion evidence, offers a practical approach for solving problems.  
Following a similar line of argument, the process of prior elicitation helps EBM 
practitioners to collect, organise and document the thoughts of the consulted experts.  
In view of this, the use of priors in decision analysis is not really a cost but is actually 
a benefit [80]. 
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  Another important reason for the dominance of conventional likelihood-based 
statistics lies with the complexity of Bayesian analysis.  The development of a 
Bayesian model requires complicated modelling specifications and tedious 
computations.  In the case of linear regression with conjugate priors, the estimators 
for regression coefficients can be derived analytically after some tedious 
mathematical manipulations (see Chapter 3).  However, this is generally not the case 
for most Bayesian analyses.  The resultant posterior, which is the heart of all Bayesian 
analyses, may be mathematically intractable and extremely complicated.   Thus, 
analysts may have to reply on advanced simulation and numerical techniques for 
finding the solutions.  This imposes another cost on the use of Bayesian models.   
Such impracticability stems from our computational deficiency.  As such, 
there is no accident that the recent rejuvenation of Bayesian statistics coincides with 
the development of computer-intensive techniques.  With the wide applicability of 
high-speed computers, the new ideas offered by Bayesian statistics have captured the 
imagination of researchers.  These methods have a wide range of potential 
applications, especially in EBM, as a result of the increasing complexity of problems 
and data structures. Their analysis and refinement will be a formidable prospect for 
the EBM community in the coming years.  It must be emphasised that while 
computers can never be as wise as people, they can explore a forest of possibilities 
faster than we can comprehend.  To this end, Bayesian analysts utilises the latest 
computational breakthroughs to the fullest and this immediately makes Bayesian 
models extremely attractive in real-life applications.  Thus, the cost of computational 
disadvantage is significantly reduced, thanks to the current technological 
advancement. 
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The new millennium has witnessed a burst of research activities in applying 
Bayesian methods to solving medical problems [14, 102-103, 113]. The appealing 
features offered by Bayesian analysis unleashes a revolution in data analysis and 
triggers powerful impulse to continue to apply such approach to problems hitherto 
considered forbidden and unthinkable.  
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CHAPTER 3 




Adhering to the earlier discussion about medical decision analysis (Chapter 1) and the 
Bayesian framework (Chapter 2), a useful model for probability encoding must not 
only enable the analyst to organise observed evidence, but also to quantify individual 
judgement and opinions about the uncertain quantities.  With such requirement in 
mind, this dissertation proposes to develop various Bayesian models for probability 
encoding in medical decision analysis.  With subjective probabilities attached, it is 
believed that one may obtain more useful results and insights than if a pure empirical 
approach is adopted.  In fact, the Bayesian approach may be recognised as the 
underlying or unifying philosophical theory of decision analysis. 
From the gathering of data to the cross-examination of expert opinions, the 
Bayesian framework offers a practical methodology upon which evidence is organised 
and presented with meanings elucidated from the traces of clues.  An acceptable 
statistical or methodological process should help to probe the details, discern relevant 
facts from baseless information, exclude the impossible from the possible and crack 
the useful meaning(s) of evidence.   
A good probability-encoding model should also reflect the evidence-capturing 
process and all salient features of evidence under question.  Furthermore, such model 
must also be simple enough for routine use in clinical decision analysis.  This is, 
unfortunately, a view which conventional methodologists, in particular mainstream 
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statisticians, fail to appreciate and understand.  It is also erroneous to think that a good 
model must be sophisticated.  With this in mind, the specific Bayesian models 
developed in this dissertation are catered for routine use in different aspects of 
medical practice.   
First, three relational models within the Bayesian GLM framework are 
developed for handling subject-level or patient-level evidence. These relational 
models seek to encode the probabilities for medical decision analysis based on the 
estimated relationship between an outcome variable of interest and a set of identified 
covariates or predictors.  Second, if the observed evidences are presented in aggregate 
form, say results based on a number of independent secondary sources, the full 
Bayesian random-effect hierarchical models are recommended for performing the 
necessary meta-analysis.  The observed evidences are mainly published results in 
journal articles.  With some ideas about these results, a prior is organised and 
presented to combine with the published results to generate a posterior for probability 
encoding.  The second category of Bayesian models is extremely useful in situations 
where EBM practitioners or medical decision makers do not have raw data at hand.  
The two classes of models—Bayesian GLM and meta-analysis—are developed based 
on the first principles and several related theorems [26, 129].  
Note that nothing is said about prior elicitation.  The main focus of this 
dissertation is to develop models for probability encoding relevant to medical decision 
analysis.  Thus, it is beyond the scope of this dissertation to give a more detailed 
treatment of prior elicitation.  For further information one may refer to the relevant 
literature [43-46].  
Probability encoding, according to the protocol developed by the Decision 
Analysis Group, Stanford Research Institute, Stanford University [1], is one of the 
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steps of the full spectrum of probability assessment.  Its accuracy depends largely on 
the communication among the analyst, domain expert and decision-maker(s) 
(motivating phase), unambiguous structuring of the uncertain quantity to be elicited 
(structuring phase) and unbiased judgement provided by the encoders (conditioning 
phase).  In encoding probabilities, the analyst must make sure the domain expert 
utilises his knowledge to the fullest, anchor his assessment on the right basis, able to 
provide an assessment representative of the event in question and state all 
assumptions made.  The experts should also try their best not to assign probabilities to 
an event based on the ease with which they can fabricate a plausible scenario that 
would lead to the occurrence of the event.   
While the main emphasis of this dissertation is to encode probabilities from 
the recommended Bayesian models, subjective assessment of probability may also be 
sought from identified experts if there are no available data for model building.  This 
include discrete approximation should the underlying probability distribution is 
continuous in nature.  Upon completion of probability encoding, the decision analyst 
must verify that the model(s) employed are accurate, reliable, and interpretable.   The 
results may be plotted as a cumulative distribution function and probability density 
function.  If necessary, the entire process outlined above—motivation, structuring, 
conditioning and encoding—may be repeated.   
To facilitate discussion, the following symbols and notations are used.  U(•), 
L(•), f(•), F(•), g(•), pi(•) and pic(•) refer to the utility function, likelihood function, 
pdf, cumulative distribution function (cdf), prior distribution, full posterior 
distribution and conditional posterior, respectively. The other common functions may 
be written as κ(•), ν(•), ψ(•) or γ(•).  However, Γ(•) is exclusively used as a gamma 
function.  Likewise, S(•) represents survival function.  Greek alphabets are used for 
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representing parameters, with θ reserved specifically for the parameter of primary 
interest.  β refers to the vector of parameters concerning a relational model; its 
estimator βˆ  is based on conventional statistical procedure (e.g., maximum likelihood 
or ordinary least squares); β* its Bayesian counterparts and β0 the specified parameter 
of the relevant prior.  The lowercase alphabets, say a, b, u and v are used for the 
specified parameters of a prior distribution. The symbol p means proportion or 
probability.  The full data design is [y X], with X the matrix of covariates or 
predictors and y the vector of outcome variable.  Letters in bold prints refer to 
quantities either in vector or matrix forms.  η is the systematic component or function 
of a relational model which connects x with β.  The letters n and m are sample size 
and number of iterations for an algorithm, respectively.  To make a distinction, k 
refers to the number of studies selected for combining published evidences.  The 
subscripts i and j refer to the i-th observation and j-th category, respectively.  Last but 
not least, the postscript t refers to the t-th iteration of a computational algorithm.   
All analyses and computations are carried out with Microsoft Excel 2000 
(Microsoft Corporation, U.S.A.), R (R Project; http://cran.r-project.org/), Stata 9.0 
(Stata Corporation, Texas, U.S.A.; http://www.stata.com), WinBUGS (Medical 
Research Centre, University of Cambridge, U.K.; http://www.mrc-
bsu.cam.ac.uk/bugs/), LOTUS 2.3 (National University of Singapore and University 
of Wisconsin-Madison) and DPL
TM
 4.0 (Applied Decision Analysis LLC, U.S.A.). 
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3.2 Relational Modelling for Subject-Level Evidence 
3.2.1 The Modelling Approach 
The following discussion is devoted to illustrate how a useful conjugate prior can be 
found for relational models.  A pdf of observed data yi, is said to belong to an 
exponential family characterised by a set of multiple canonical parameters θi if it is 
presented as follows: 
 
 




where ψ(•) and γ(•) are known functions.  The form of conjugate priors can be easily 
determined.  The parameters θi are related to the model’s coefficients by the link 
function θi = κ(ηi), with ηi = x′iβ (systematic linear component).  Here, x′i is a 1×p 
vector denoting the i-th row of predictors and β is a vector of p coefficients.  These 
coefficients quantify the association (direction and magnitude) between yi and x′i.  It 
follows that the conjugate prior distribution for θi is  
 




where the normalising constant C=C(u, v) is selected such that g(θi) is a proper 
distributional function characterised by two natural parameters u and v.  This in turn 
formulates the posterior distribution of θi as follows: 
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where the link function may now be considered as a monotonic transformation of θi.  





) = κ′(ηi)≠0, 
where κ(•) is a twice differentiable monotonic function.   Consequently, the posterior 
for ηi is given as: 
 
 









Next, performing logarithmic transformation on both sides of (3.4) one obtains  
 
 









= 0, one shows that  
 
 







 = 0  















Hence, the mode for the posterior of ηi is derived. That means, one can generate the 
solution for the desired posterior based on estimates of the relational model. 
 The above discussion suggests that the Bayesian models for relational problem 
may be derived with Jacobian transformation and some simple algebraic 
manipulations.  Unfortunately, this may not be the case for situations where the priors 
are specified differently or when the data structure becomes more complicated.  But 
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such limitations should not be amplified.  The specific details of Bayesian modelling 
are discussed in the remaining sections. 
  
Under the generalised linear model set-up (subsection 2.3.1) [91], a generic 
relational model involving the exponential family designed for analsysing subject-
level data is:  
 
 
f(yi; θi, τ) = exp{ν
-1




where yi, θi, ψ(•) and γ(•) have their usual meanings, τ is the scale parameter and ν
-1 
(•) is a known function.  As in (3.1), the canonical parameters θi are related to the 
model’s coefficients β by the link function θi = κ(η), with ηi=x′iβ, where x′i is a 1×p 
vector denoting the i-th row of the covariate matrix X.  Essentially, the data are 
connected with the coefficients β through ηi, the systematic linear component.  
Bear in mind the primary objective for modelling y is to estimate β, which 
quantifies the relationship between X and y.  By inserting ηi into (3.4) and (3.7) the 
likelihood function and posterior for β are as follows: 
 
 
Likelihood  L(yi | β, τ) ∝ exp{ν
-1
(τ)[κ(x′iβ)yi − ψ[κ(x′iβ)] + γ(yi, τ)]}  
Posterior     pi(β  | yi, τ) ∝ L(yi | β, τ) × g(β) 










with β∼Normal[β0, Σ0] as the chosen prior.  The posterior is analytically non-tractable.  
As such, MCMC techniques must be employed for estimating β.  With β estimated 
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and x′i given, iη =x′i βˆ  is formulated for encoding the required probabilities for 
medical decision analysis.  Model (3.8) may be used for handling a number of 
different pdfs such as binomial, normal and poisson.  











, j=1, 2,.., J, 
the likelihood and posterior may be formulated as: 
 
 





















where Σ is the covariance matrix and βˆ  may be the maximum likelihood estimator 
(MLE) for β, the posterior mode.  Σ could be the Hessian of the likelihood evaluated 
at βˆ .  It is also possible to model outcomes which are ordinal or polychotomous in 
nature [132]. 
 
3.2.2 Binary Counts 
A special case based on the above set-up (3.9) is known as logistic regression 
or logit [133], where yi∼Binomial[ni, pi], pi∈[0,1].  Logit is arguably one of the most 
frequently used and widely-reported statistical techniques in medical research.  With 
yi∈{0, 1}, logit is suitable for predicting the probability of binary or dichotomous 
outcome (e.g., alive/dead, recover/relapse, improve/deteriorate, successful/fail).  The 







 (logit) where it has a very meaningful 
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interpretation—log odds.  See section 2.1 for a discussion of odds.  The systematic 
linear component is κ(ηi)=ηi=x′iβ, such that κ′(ηi)=1 and κ′′(ηi)=0.  
In the case where pi∈[0, 1] is the unknown parameter of interest and where its 
prior is available, the likelihood based on binomial pdf may be reformulated as: 
 
 
























































































 is the logit link.  As before, the systematic linear component is 
ηi = x′iβ = θi .  In fact, κ(ηi) = ηi, so κ′(ηi) = 1 and κ′′(ηi) = 0. 
Since pi∈[0,1] is a bounded quantity, the most suitable conjugate prior for the 









































































































































− ] where C=1, 
a=uv, u=(a+b)/ni and ψ(θi) = )e1log(n ii
θ+ , according to (3.2).   





















































































      ie
η [ni + b − yi] = yi + a 














Taking logarithmic transformation on both sides yields  
 
 
























where β* is the posterior estimator.  It is not difficult to show that if yi∼Bernoulli[1, 
pi], a special case of the binomial distribution, then  
 
 









where X=[x1 x2 …xp]′ and y=(y1, y2,…yn)′ , p<n, are the data matrices.  As readily 
seen, the posterior estimate β* is dependent on the choice of Beta[a, b], where a and b 
are the shape parameters.  Unlike (3.9), such model produces closed-form solution for 
β.   
 The celebrated Bernstein-von Mises Theorem [134] provides the clue to the 
construction of the credible or probability interval (P.I.) for β*.  It guarantees that β* 
are consistent and asymptotically normal.  Since the posterior distribution of √n(η-




] when n→∞, where I(η0)
 
is the Fisher’s information [135] 
with η0 as the true value, then the posterior distribution of  
 
√n (β− nβˆ ) → Normal[0, (X′X)
-1




as n→∞, where Σ is a diagonal matrix with elements 2iσ =nI(η0)
-1
.  As such, one is 
able to construct the 100(1−α)% P.I. for β when n is sufficiently large.  The issue of 
Bayesian estimators’ rate of convergence is documented in literature [136].  
Incidentally, Bayesian modelling with the above-mentioned strategy was also 
explored in reference [137] when this dissertation was prepared.  
 Such intervals are conceptually different from the conventional confidence 
intervals (C.I.).  In the conventional paradigm, the interpretation is that 100(1-α)% of 
the intervals contains the “true” parameter value.  Moreover, the computation is based 
on the sampling distribution of the underlying distribution of the estimator, or how it 
varies over all possible samples.  It does not depend on the particular sample where 
computation is made.  However, the Bayesian P.I. has a more intuitive interpretation.  
It makes a probabilistic statement about the parameter from the computed interval.  
Furthermore, it summarises one’s beliefs about the parameter value that could 
possibly or credibly believed given the observed evidence.  This gives a post-data 
interpretation as opposed to the conventional C.I.  
 
3.2.3 Rates 
Poisson regression [138], on the other hand, deals with rates, an important 
entity for quantifying risk in medical research.  The most appropriate distribution for 
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rates, say yij, is Poisson[µi], i=1, 2, …n, j=1, 2, …, k.  Here, µi>0 is the unknown 
mean parameter.  The appropriate link is log(ηi) = x′iβ. 




ijY is a sufficient statistic for µi, such that Ri ∼ Poisson[kµi], 
the likelihood of Ri is: 
 
 




which is clearly a member of the exponential family.  It follows that the appropriate 




















θ−θ ) where 
a=uv, u=b/k and ψ(θi)= )exp( iθ .  Take ηi = θi, then 
 
 
















Also, ψ′[κ(ηi)]=ψ′(ηi)= )exp( iη , so 
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 is the posterior mode.  Finally,  
 
 










 The use of Poisson regression requires one crucial assumption, that is, the 
mean and variance are equal.  In most cases, this assumption may not be valid and it 
leads to a problem commonly known as over-dispersion.  When such problem arises, 
it is more appropriate to use negative binomial [139] as the underlying distribution. 
 Suppose yi∼Negative binomial[r, pi], then 
 
 


















.  With prior pi∼Beta[a, b], the 
posterior is Beta[a+r, yi +b].  Therefore, the posterior mode is  
  
  









According to (3.6), the posterior estimator for β becomes  
 
 
β* = (X′X)-1X′ iηˆ  











The 100(1−α)% P.I. for β of both the Poisson and Negative binomial regression 
models are based on (3.17). 
 The above-mentioned Bayesian estimators (3.16, 3.22 and 3.25) are applied 
for analysing binary counts and rates with subject-level evidences. 
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3.3 Models for Combining Evidences from Published Sources 
3.3.1 The Generic Approach 
The following Bayesian models are developed for combining the published results of 
k>1 studies while allowing for each study to have its own effect.  Known as meta-
analysis in biostatistics (subsection 2.3.4), these models are used for encoding the 
probabilities for medical decision analysis based on relevant reported evidences.  
They may also serve to produce the priors for the above-mentioned relational models. 
Such models are also “hierarchical” because, loosely speaking, more than one 
level of likelihood and/or prior is specified. In this case, a particular observed quantity 
depends on an unknown parameter, which in turn follows a second-stage prior.  This 
sequence of priors and parameters constitute a model with an extended or hierarchical 
structure.  
When combining evidences from relevant reported studies which are 




 different subject characteristics (age, racial mix, disease severity) 
 different study designs (retrospective vs. prospective; experimental vs. non-
experimental; randomised clinical trial vs. observational cohort; single-centre 
vs. multi-centres) 
 different sampling schemes 
 different inclusion and exclusion criteria (demographics, disease progression) 
 different safety and quality considerations 
 different study periods 
 different end-point outcomes (30-day mortality vs. 90-day mortality) 
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 different reported statistical analyses (crude vs. adjusted results; univariate vs. 
multivariate analyses)  
 
 
The idea is to combine the reported evidences (yi) to estimate the overall effect 
θ—a hyperparameter.  The combined evidence θ in turn facilitates probability 
encoding for medical decision making. It is the combined overall effect that is of 
primary interest in such exercises.   
Unlike the relational models discussed earlier, the hierarchical model designed 
for handling aggregate-level evidences is not concerned with the estimated association 
between X and y.  It is primarily concerned with the combination of all relevant yis, 
which are reported in academic literature.  In each reported study, a specific yi may be 
generated from a relational model or some simpler analysis.  But in the case where 
they are combined, the concern is to generate θ for probability encoding. 
The proposed method for combining reported study effects, commonly known 
as meta-analysis in the biostatistical literature, requires the observed study effects (yi) 
to vary around some unobserved/latent study-specific effect (ϕi), which in turn belong 
to a distribution characterised by the overall or combined effect (θ).  As such, this is 
also a random-effect model, where the study effects vary randomly around their 
respective study-specific effects.  Each of the study-specific effects, with its specific 
parameters, describes the populations where the reported study effect is generated.   In 
a similar fashion, they are also allowed to vary randomly around a parent distribution 
characterised by θ.  Consequently, the model consists some hierarchical structure 
where the observed study effects precede the unobserved study-specific effects, which 
in turn precede the unobserved overall effect. 
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Taking into account the various sources of heterogeneity underlying the 
reported evidences, the hierarchical structure is the most critical and desired feature of 
the proposed Bayesian meta-analysis model.  It is theoretically wrong to ignore the 
intermediate study-specific effects (ϕi).  The inclusion of the study-specific effects 
serves to capture the salient features of the underlying sources of heterogeneity 
described above.  The model is severely misspecified should the study-specific effects 
are suppressed.   The nature of the proposed model is depicted in Figure 3.1.  
To cast the above-mentioned features in the form of a Bayesian model, the 
following is proposed: 
 
 














where y=(y1,y2,…yk)′, ϕ=(ϕ1,ϕ2,…,ϕk)′ and g(θ) are the vector of observed effects, 
study-specific effects and prior of the overall combined effect, respectively. 
characterised by θ, (3.26) is the joint posterior distribution of interest.  Once the joint 
posterior is derived the combined effect θ emerges simultaneously.  In most instances, 
there may be more than one prior involved, depending on what distribution is used for 
representing the study-specific effects.  If it is a multi-parameter distribution one may 
need to specify more than one prior. 
The idea of specifying a random-effect model is not new in statistics.  The 
conventional analysis of variance (ANOVA) model [34], multi-level model 
(subsection 2.3.3) and meta-analysis (subsection 2.3.4) may incorporate some random 
effects for dealing with latent variables in data analysis.   
 









Figure 3.1: Proposed modelling framework for combining study effects 
f(y1 | θ) 
Parent population  
characterised by  
parameter θ 
. . . 
f(y2 | θ) f(yk | θ) 
. . . 
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In practice, the joint posterior distribution is extremely complicated and it is 
sufficient to consider the conditional prior distribution of θ, given the observed study 
effects but does not depend on the unobserved study-specific effects ϕ.  A conditional 
posterior distribution is the posterior for one parameter given the values of the other 
parameters, and is obtained from the joint posterior by treating the other parameters 
fixed.   













.  Following 














.  This is unlikely to be mathematically 
tractable and to estimate T(θ), MCMC (section 2.4) must be executed.   
As mentioned before, the most popular MCMC technique is Gibbs sampler 




Generate θt given y and ϕt-1 from pic(θ | y, ϕ
t-1
) 
Generate ϕt given y and θt from pic(ϕ | y, θ
t




Essentially, the technique generates a sequence of (θ1, ϕ1), (θ2, ϕ2), …, (θm, ϕm).  The 
value of ϕt-1 is updated for generating θt which in turn generates ϕt.  Under general 
conditions, the distribution of the chain stabilises or reaches the equilibrium (limiting 
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converges to E[T(θ)|y] as m→∞. 
The strength of the proposed hierarchical model is that it leverages on relevant 
studies conducted in the past.  It is often possible to pool estimates from relevant 
studies to increase precision, accuracy and generalisability. EBM practitioners and 
clinicians do not need to conduct new studies for encoding the required probabilities 
for decision making.  Moreover, the random-effect hierarchical model produces a 
more sensible estimate than one which ignores the underlying random effects.  It is 
also more superior than the MLE which treats each yi as an isolated entity.  Note that 
the idea is not exclusively restricted to models designed for combining published 
evidence.  It is also applicable for subject-level relational models as described earlier. 
The posterior result may be an end in itself, or serves as the prior for relational 
modelling involving patient-level evidences.  Three specific models are described 
below. 
 
3.3.2 Continuous Combined Effect 
The following model is useful for combining or summarising effects which are 
continuous in nature.  To facilitate discussion, let 
yi = observed effect in study i 
ϕi = study-specific effect in study i 
θ = overall combined effect 
2
is = within-study variance of yi 
φi = within-study precision of yi (=l/
2
is ) 
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2σ = between-studies variance 
τ = between-studies precision (=l/
2σ ) 
k= total number of studies under consideration 
 
 
Only two quantities, namely yi and 
2
is , are observed (φi is derived), while ϕi, θ and 
2σ are unobserved and unknown.  Since the studies are conducted at different 
locations and times, it is reasonable to assume yi∼iid[ϕi, 
2
is ] and  ϕi∼iid[θ, 
2σ ].   
These observed samples in turn form the likelihood function for generating the 
posterior distribution, which is the ultimate source of information required for any 
Bayesian analysis.   In a random-effect setting, priors must be established for the 
unobserved quantities, i.e., θ and τ=1/ 2σ .  Following (3.26) and collecting terms with 
reference to the sequential nature of Bayes’ Theorem [26], one yields the following 
joint posterior distribution: 
 
 














where y=(y1,y2,…yk)′ is the vector of observed study effects, φ=(φ1,φ2,…,φk)′ the 
within-study precision, ϕ=(ϕ1,ϕ2,…,ϕk)′, the vector of individual study-specific 
effects belonging to a distribution characterised by θ, g(θ) the prior for θ, g(τ) the 
prior for τ, f(yi; φi| ϕi) the individual sample distribution for yi and f(ϕi | θ) the 
distribution for study-specific effects.  The first two terms on the R.H.S. of (3.28) are 
likelihood functions.  The priors may be based on initial subjective assessment before 
observing the published evidences. 
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Usually, normal distribution is appropriate for yi and the priors are chosen 
within the related conjugate family such that θ∼Normal[a, 1/b] and τ∼Gamma[c, d].  
Assuming normal distribution for yi is valid for a wide class of applications.  As a 
result, the joint posterior distribution may be written as: 
 
 














































where Γ(•) is a gamma function. Theoretically, inferences about θ should be made 
from this joint posterior by integrating out the other unknown parameters.  
Unfortunately, its complicated form makes computation extremely difficult and it is 
more efficient to work on the conditional posteriors.  Such treatment will become 
clear when the Gibbs sampler is presented.   
In a complex hierarchical model such as (3.29) the conditional posteriors are 
simpler in structure.  For example, the posterior of major concern 
 
 


























is a normal distribution.  Similarly, ϕi occurs in only two terms and its posterior 
conditional on other parameters is:  
 
 






























where ϕ-i represents the vector of all other study-specific effects in studies other than i.  
This is a product of two normal distributions.  Last but not least, the conditional 
posterior for the between-studies precision, τ, is: 
 
 
























which can be identified as a gamma distribution.   Consequently, the posterior of each 
individual parameter conditional on the values of other parameters is a good starting 
point and this helps to avoid working on the original joint posterior.  
As mentioned before, the Bayesian approach attempts to encode prior 
knowledge of the parameter through subjective probability based on a prior 
distribution.  In the above-mentioned case, the decision-maker and analyst must 
specify quantities a, b, c and d for the prior distributions.  
While there are different ways to construct a Markov chain that converges to 
the posterior distribution, the most popular scheme is Gibbs sampler [123].  The 
algorithm works by sampling from the conditional posteriors of the parameters.   
Several practical issues must be observed in order to achieve quick convergence from 
performing Gibbs sampling.  First, one may start the chain by setting the initial 
parameter values equal to the conventional maximum likelihood estimates (MLE),  
such as the sample means.   Next, it is advantageous to select conjugate priors as in 
some Bayesian analyses. This is because it is more efficient to run the Gibbs sampler 
with standard distributions. Third, calculation of sample features from a Markov chain 
should not commence immediately as each chain needs a burn-in period to reach 
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equilibrium.  This is because early results from the Gibbs sampler depend on the 
initial values and are not representative of the posterior distribution.  While one may 
examine the autoregressive structure of the iterative results, the simplest way to 
determine the number of burn-ins is to set a very large number.  In addition, a large 
number of updates after burn-in should also be specified.  As the number of samples 
becomes large, the later elements of the sequence will come close to having the 
stationary distribution.  To ascertain if stationary is achieved, one may plot the history 
of the chain.  Analysts are reminded that it is a good practice to fix the number of 
burn-ins and updates before kicking off the computation. 
The following discussion deals with the Gibbs sampler for working with the 
conditional posteriors outlined earlier. Once the joint posterior and the conditional 
posteriors are derived and with the initial values specified (usually based on MLE), 
the MCMC Gibbs sampler algorithm works in the following manner: 
 
 

















ii. draw each ϕi randomly using its conditional posterior and the current values of 
θ and τ 
iii. draw θ randomly using its conditional posterior and the current values of ϕ 
and τ 
iv. draw τ randomly using its conditional posterior and the current values of ϕ 
and θ 
v. record the current values of ϕ, θ and τ 
vi. repeat steps ii. to v. for a sufficiently large number of times, say m=100-1000 
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vii. summarise θ from the generated sample of posteriors by computing its mean, 
median, mode and variance (with P.I.s) 
 
 
Properties of Gibbs sampling can be found in references [140-142].  As 
mentioned before, the advantage of this elegant yet computationally-demanding 
approach is that it enables medical decision analysts to encode probability without 
resorting to the complicated joint posterior (3.29).  Even if it is possible to generate 
directly from the joint posterior, the Gibbs sampler produces a more efficient manner 
in producing the required results.  
The above model is also suitable for summarising any reported evidences 
analysed with maximum likelihood.  This is because MLEs are asymptotically 
normally distributed if the underlying density satisfies certain regularity conditions 
[143].  This important result suggests that the above-mentioned model is versatile. 
The proposed model also differs from the highly popular empirical Bayes 
method [144] in several ways.  Although the latter is hierarchical in nature, the 
element of random-effect is not adequately captured.  As mentioned before, the 
random-effect is a critical issue while combining evidences from different published 
sources.  Instead of attempting to model the parameter with a pdf as in the proposed 
random-effect Bayesian model, the empirical Bayes technique works as follows: 
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The likelihood function ∫
∞
∞−
ϕθϕϕ d)|(g)|y(f is then established, with ML technique 
applied for generating the required estimates.  Though attractive in many ways, the 
empirical Bayes technique is found to be inappropriate for combining evidences from 
published sources. 
 
3.3.3 Combined Effect as Proportions 
In situations where the observed study effect is a proportion (yi=counts/sample 
size; 0≤yi≤1), the most appropriate underlying pdf is Beta[q1i, q2i], where both q1i, q2i 
are the shape parameters.  With yi bounded, the beta distribution is a flexible 
distribution that takes various shapes (see Figure 3.2).  It may be tempting to use 
model (3.29) for combining reported proportions as they are continuous and 
distributed as normal asymptotically.  However, one must bear in mind that 
proportions are bounded and this property makes beta distribution a more appropriate 
underlying distribution.   

















where B(q1i, q2i)=Γ(q1i+q2i)/Γ(q1i)Γ(q2i) is the beta function.  State without proof, the 
mean and variance of the distribution are E[Yi] = q1i/(q1i + q2i) and V[Yi] = qi1q2i/[(q1i 
+ q2i)
2
(qi1+ q2i+1)] = (E[Yi])(1−E[Yi])/(q1i+q2i+1), respectively.   
 



























f(y; q1, q2) 
q1=q2=5 
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Note that the variance is a function of the mean and a dispersion parameter (q1i+q2i+1).  
Denoting φi as (q1i+q2i) and ϕi as the mean, the beta pdf (3.34) may be re-written as: 
 
 










The required model for combining proportions is then constructed as: 
 
 















i )1(  




where θ, ϕ, τ, φ and y have their usual meanings.  The prior for θ is Beta[a, b].  
Without loss of generality, the prior of τ is taken as Exponential[1].  The conditional 
posteriors are as follows: 
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τ   
(3.37) 
 
The Gibbs sampler algorithm may be executed in the following manner: 
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ii. draw each ϕi randomly using its conditional posterior and the current values of 
θ and τ 
iii. draw θ randomly using its conditional posterior and the current values of ϕ 
and τ 
iv. draw τ randomly using its conditional posterior and the current values of ϕ 
and θ 
v. record the current values of ϕ, θ and τ 
vi. repeat steps ii. to v. for a sufficiently large number of times, say m=100-1000 
vii. summarise θ from the generated sample of posteriors by computing its mean, 
median, mode and variance (with P.I.s) 
 
3.3.4 Combined Effect as Rates 
The combination of effects of rates (yi) works in a similar fashion.  It is a well-
known fact that if a rate yi follows Poisson(µ), then the conjugate prior of µ is 
gamma(a, b), where a, b>0.  In the case of the full Bayesian random-effect 
hierarchical model, the observed effect, yi, follows Poisson(µi), and  µi follows 






, a>0, θ>0.   
The joint posterior for µ and θ given y is: 
 
 






















The conditional distribution for µ is: 
 
 































which is a gamma function.  The conditional for θ is more complicated, but it can be 
simplified as follows: 
 
 












































 The Gibbs sampler is executed as follows: 
 
 








µ   
ii. draw each µi randomly from its gamma conditional posterior and the current 
values of λ 
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iii. draw λ randomly from its gamma conditional posterior and the current values 
of µ 
iv. record the current values of µ and λ 
v. iterate the process ii. to iv. for a specified m times 
vi. summarise θ based on the back-transformation of λ by computing its mean, 
median, mode and variance (with P.I.s) 
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3.4 Other Relational Models 
Three additional classes of Bayesian relational models are presented in this section.  
They are useful for analysing continuous outcomes, time to event data and clustered 
and hierarchical observations.  These models are chosen based on a detailed literature 
review given in Chapter 2 and their usability in the case studies to be presented in 
Chapter 4. 
 
3.4.1 Continuous Outcome 
The linear regression model is most familiar to medical data analysts.  Based 
on a linear link function, it is suitable for modelling continuous yi like body weight, 
temperature, size of tumour and glucose level, etc.  It is legitimate to apply (3.8) for 
modelling yi in this case, but a more straight-forward approach makes use of the 
distributional property of the residuals (ui), e.g., distance between the actual 
observation and its predicted value.   
A very attractive feature of such formulation is that it generates closed-form 
solutions for β [51, 88, 96].  Formulate the linear model as: 
 
 
yi = x′iβ + ei      
(3.41)   
 
 
where residual ui~Normal[0, σ
2
].  With conjugate priors β∼Multivariate Normal[β0, 
Σ0] and σ
2∼Inverse Gamma[a, b], the joint posterior distribution of β and σ2 becomes 
 
  





 (y − Xβ)'(y − Xβ)]  








 (β−β0) ] × σ
-(a-p-1)
exp[−b/σ2] 





















by making use of the fact that βˆ=(X'X)-1X'y and 2σˆ = (y−X βˆ )'(y−X βˆ )/n−p−1, where 
X=[x1 x2 …xp]′ and y=(y1,y2,…yn)′ , p<n, are the data matrices.  βˆ  is in fact a MLE.  
As readily seen, the posterior (3.42) is extremely complicated despite its simple set-up 
(3.41).   Fortunately, it is mathematically tractable with suitable substitution and 
transformation. Re-express the joint posterior as: 
 
 


















-1 β0 + X'X βˆ )  
σ* = 2b  + 2σˆ (n−p−1) + (β0
 −β*)' Σ0




The joint posterior is now recognised as a normal-inverse gamma distribution. The 
quantity β* may now be used as the estimator for β.  This Bayesian estimator is also 
known as an “shrinkage estimator” because the MLE βˆ  is “shrunk” towards the prior 
β0.  With suitable transformation the marginal posterior of β is derived: 
 
 
pi(β | X, y)  ∝ [σ* + (β−β*)'(Σ0
-1
 + X'X)(β−β*)]-(n+a)/2   
(3.45) 
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which is easily recognised as a multivariate-t distribution.  Therefore, the mean and 
covariance of the posterior coefficient estimates are given by: 
 
 
E[β | X, y] = β* 








Using the same line of argument, one can deduce that the joint posterior of β and σ2 
with non-informative priors, say c and 1/σ, respectively:  
 
 













with the following marginal posterior of β:  
 




which can again be easily recognised as a multivariate t-distribution.  Thus, E[β | X, Y] 
= βˆ =(X'X)-1X'y and COV[β | X, y] = 2σˆ (X'X)-1 where 2σˆ  is usually taken to be 
(y−X βˆ )'(y−X βˆ )/n−p−1.  The 100(1−α)% P.I. for β can thus be constructed 
accordingly.   The above result is not surprising and it illustrates an important feature 
of all Bayesian models, that is, β* reduces to the conventional estimator ( βˆ ) if non-
informative priors are fitted.   
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3.4.2 Time to Event 
The next relational model is designed for analysing subject-level time to event 
data (yi).  Recall from subsection 2.3.2, if the underlying skewed distribution for yi is 
f(yi), then the cumulative distribution function (cdf) is F(Y<yi) and the survivor 
function is S(yi)=P(Y≥yi)=1−F(Y<yi).  These subjects are “censored” because no 








ii )S(y)f(y where δi takes the value 0 if the subject is censored and 1 if 
otherwise. 
Bayesian analysis requires a suitable distribution, say Weibull[α, λ], to fit the 
data.  Like the beta distribution, Weibull is extremely flexible.  In this case, α and λ 




f(yi | α, λ) = α
1
iy
−α exp[−λ−exp(λ) αiy ]  yi,  α, λ>0,  
S(yi | α, λ) = exp[−exp(λ)
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where the priors are α∼Gamma[α0, κ0] and λ∼Normal[µ0, 
2
0σ ].  Then introduce the 
predictors through λ, i.e., λi=x′iβ.  Let the prior β∼Normal[β0, Σ0], the joint posterior 
is derived:  
 
 




























Estimation of β is carried out with MCMC. Weibull is a versatile distribution, with 
exponential as its special case (λ=1).  With suitable parameterisation, it can be 
converted to an extreme-value distribution.  Gamma, exponential and log-normal 
distributions are other candidate distributions for modelling time to event data. 
 
3.4.3 Longitudinal and Clustered Data 
In situations where the data are clustered or collected repeatedly over time, 
then some hierarchical structures are present.  See subsection 2.3.3 for details.  To 
facilitate discussion, consider outcome yij related to predictors xij for observations i=1, 
2, …, nj within clusters j=1, 2, …, k.  In this case, while the clusters are likely to be 
independent, the evidences within each cluster are not.  Conditional on the cluster 
effect υj, yij belongs to the exponential family distribution.  The posterior is developed 
as below [110]: 
 
 
f(yij; θij | υj) = exp{[θijyij - ψ(θij)] + γ(yij)} i=1, 2,…, nj;  j=1, 2, …, k 
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where υ=(υ1, υ2,… υn)′ and Σ are the cluster-effect parameters and covariance matrix, 
respectively.   
It may be useful to consider the conditional posteriors in modelling: 
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The conditional posterior (pic) of a particular parameter is derived by holding other 
parameters fixed.  With specific distributions and functions chosen, the above set-up 
allows analyst to model clustered data with different nature, say counts, rates and 
continuous.  MCMC is required for summarising the posterior results. 
The above-mentioned two-level hierarchical data structure is a special case of 
the multi-level framework.  But it is realistic enough to handle many real-life 
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3.5 Specific Modelling Issues 
3.5.1 Sensitivity Analysis 
The quality of a Bayesian model depends on several criteria.  Besides being 
parsimonious and interpretable, a reasonable Bayesian model should be resistant to 
departures in the specification of prior distribution.  A common criticism of Bayesian 
analysis is that the prior distributions can never be correctly quantified, elicited and 
fitted, especially when time is limited.  The allegation is not unfounded.   
 Therefore, it is important to assess the appropriateness of prior distribution in 
Bayesian analysis.  The most straight-forward approach is to employ sensitivity 
analysis, a standard term refers to the process of investigating changes in the 
conclusions (posterior) caused by changes in the initial assumptions (prior).  
 Global sensitivity analysis is a broad approach that evaluates a wide range of 
alternative prior specifications, forms of the link function, error sensitivity and 
perturbations of the prior specifications and the likelihood. Unfortunately, this idea is 
too broad to be useful in practice.  In a narrower sense, the analyst may specify an 
alternative non-informative prior over the support of the parameter of interest and 
compare it with the stipulated informative prior.  A substantive change to the form of 
the posterior is a signal for caution.   
 In local sensitivity analysis, one specifies a more diffuse form of the prior than 
that originally specified.  If no appreciable changes to the posterior are observed, one 
is confident that the initial prior is not specified incorrectly.  Compared to the global 
approach, this approach incurs a lower cost in terms of effort and reporting.  
It must be pointed out that if the initial prior is supported firmly on theoretical 
ground, then large changes to the posterior, as indicated by the sensitivity analysis, are 
not a sufficient reason to discard the chosen prior. 
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3.5.2 Robust Analysis 
A different approach to minimise the effect of misspecified prior on posterior is based 
on the concept of robustness.  It is not uncommon for clinicians to specify a wrong 
prior as they might base their prior evidence on faulty reasoning or beliefs.  They may 
also be presented with past evidences that were generated from different contexts.  
With strong confidence in the prior, one may specify a highly precise yet incorrect 
prior.   
 The suggestion offered by the robust approach is to introduce a mixture prior: 
 
 
gmixture(θ) = p0g0(θ) + p1g1(θ) p1=1 − p0   
(3.53)   
 
 
where g0(θ) is the initial prior, g1(θ) the more widely-spread alternative prior, p0 the 
probability that g0(θ) is correct and p1 the probability that g1(θ) is correct.  One 
usually fixes p0 with a high value, say above 0.9, thus reflecting the belief that the 
initial prior is correct.  This also means that one is giving a small chance that the 
initial prior is misspecified.  
According to the Bayes’ Theorem [26], the respective posteriors are pi0(θ | y) 
and pi1(θ | y), and the mixture posterior is: 
 
 




The mixture posterior is thus a mixture of two posteriors.  Note that p′0 and p1′ are 
based on observed evidence and are proportional to the prior probabilities (p0 and p1) 
multiplied by the probability density evaluated at the evidence that has occurred.  
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Also note that the mixture indicator, 0 for initial prior and 1 for alternative prior, is 
marginalised out.   
If the initial prior is correct, the mixture posterior is very close to the initial 
posterior.  However, if the initial prior is very different from the likelihood, the 
posterior probability p′0 will turn out to be very small and the mixture posterior will 
then be dominated by the likelihood.   
The use of mixture prior provides some protection against a misspecified 
initial prior.  This is the essence of robust statistics [145], a branch of methodological 
thought that flourished in the 1980s. 
 
3.5.3 AdaBoost 
The next issue concerns a Bayesian model’s predictive ability.  It is useless to 
have a sophisticated model that provides an excellent fit to the data but fails to predict 
future or out-of-the-sample observations adequately.  
The logit model (3.16) described above may be called a classifier as it helps to 
determine how patients are classified (e.g., alive/dead, recover/relapse, 
improve/deteriorate). Classifier is a technique that develops well-defined rules for 
assigning observations.  The following section concerns a machine-learning algorithm, 
known as AdaBoost [146], that might help to improve its predictive performance. 
The Bayesian logit classifier described earlier is “global” in the sense that it is 
designed to apply to the entire data set over all the variable space.  Since a single 
classifier may not be ideal, a combination of classifiers from the same data set may 
help to identify more special features of the misclassified observations.  Therefore, 
one may view such combination of classifiers as a way of improving the performance 
of single “weak” classifiers (see Figure 3.3). 
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To facilitate discussion, define x as the vector of predictors, y the observed 
outcome and n the sample size.  Unlike the usual logit models, y∈{-1,1} in this case.  
Initially, each of the observations (xi, yi) is assigned an equal weight, such that wi=1/n.  
At each stage of the iterative process, a classifier is constructed using the weights wi, 
which reflects the probability of occurrence of the observations. In the process, 
misclassified observations are up-weighted, while correctly-classified observations 
are down-weighted.  An error index, corresponding to the sum of weights of the 
misclassified observations is then computed.  It is noted that the weights 
corresponding to misclassifed observations always increase and the classifier is 
updated with these weights.  The AdaBoost procedure is summarised as follows: 
 
 
i. initialise the weights wi=1/n, i=1, 2,…, n. 
ii. for m=1, 2,…, M, construct a classifier ϖ(x) from the training set with weights 
wi; compute em as the sum of weights wi corresponding to misclassified 
observations; if em>0.5 or em=0 then terminate the procedure, otherwise set 
wi=wi(1−em)/em for misclassified observations and renormalise the weights so 
that they sum to unity, and continue the process. 
iii. for a two-class classifier, in which η(x)>0 implies x∈c1, otherwise c0, form a 











and assign x to c1 if ωˆ>0, where cj is the outcome 
class or level.   
 
 
The final classifier is a linear combination of the classifiers from each stage of 
the process.  The condition of em>0.5 ensures that smaller weights, i.e. lower 
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log(1−em/em), are attached to classifiers with larger number of misclassified 
observations.   
The underlying notion driving combined classifiers is that if the results are 
averaged (based on the weighting scheme), more accurate and stable models may be 
produced.  Research on combining classifiers in a single analysis has demonstrated 
that there are potentially very substantial gains in predictive accuracy.  The reduction 
in error rates for well-known data sets typically ranges from 5 to 40%; albeit, it is 
important to realise that improvements are not always guaranteed.  Moreover, when 
classifiers are combined, the final product is no longer visually appealing and 
comprehensible.   
Nevertheless, the algorithm may also be applied routinely to check if a single 
Bayesian classifier has produced the “best possible” predictive performance.  
However, one should note that the AdaBoost algorithm can be applied to any model 
and is not exclusively a complementary tool for Bayesian modelling.   
 
3.5.4 Receiver Operating Characteristic Curve 
The predictive accuracy of a model can be expressed quantitatively in terms of 
sensitivity and specificity. Sensitivity is the proportion of truly diseased patients 
identified by the predicting model, while specificity is the proportion of non-diseased 
patients correctly identified as non-diseased by the model.   
Apparently, these two measures are inversely related.  A graphical display of 
this relationship is called a Receiver Operating Characteristic (ROC) curve [147-148].  
Potting sensitivity against specificity provides a visual interpretation to the predictive 
accuracy of a model.  The model’s predictive accuracy is quantified by the area under 
the curve (AUC).  The higher the AUC the more accurate is the model’s prediction.  
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To compare the predictive accuracy of two or more models one compares the 
differences in AUCs.  A common practice is to generate the respective confidence 
intervals (C.I.) for the AUCs and declare a significant difference in the models’ 
predictive accuracy if the C.I.s do not overlap.  This is, however, a crude approach.  
One should take into account not only the numerical difference in AUCs and their 
standard errors, but also the correlation between ROC curves [149].  This is because 
the models are applied to the same data set.   
ROC has other uses in data analysis.  It is also useful for identifying the 
optimum cut-off, characterised by the highest possible sensitivity and specificity, of a 
screening index or a diagnostic test. 
 
3.5.5 Elicitation of Utilities  
To complete the formulation of a decision problem, the analyst must elicit the 
preferences and utilities from the decision-maker.  Utilities are the numerical ratings 
of the desirability of health states that reflect a patient’s preferences.   




 list the possible outcomes that could occur 
 rank the outcomes in order of decision maker’s preference 
 assign utility values to the boundary conditions (1: most preferred outcome, 0: 
least preferred) 
 create a scenario such that the decision maker is indifferent between the  
            boundary conditions (x0.5) 
 choose an appropriate utility function characterised by the risk tolerance 
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            parameter (ρ) 
 estimate ρ based on x0.5 
 generate utilities for all identified intermediate outcomes 
 




















where x is the condition, H and L the boundary conditions, and ρ the risk tolerance.  
There are existing tables for generating the required values for ρ.   
The alternative with the highest expected utility (EU) is chosen as the 
preferred decision.  See section 1.2 regarding the rationale of applying EU as the basis 
of decision making, despite the serious challenges posed by competing theories [8-12].  
Since the objective of this dissertation is about probability encoding, less emphasis is 
given to utility elicitation, which may actually pose a bigger challenge to decision 
analysts in many real-life applications.   
Relying on known utility to generate unknown utilities for all intermediate 
outcome states, the easy-to-use technique outlined above may be seen as a modified 
version of the full standard reference gamble approach [7], where patients are 
presented with a series of hypothetical scenarios.  It is also different from the time 
trade-off technique [7] where patients are asked to express their attitudes towards 
various lengths of time in ill health.  Both the time trade-off and the full standard 
reference gamble are not recommended in this dissertation because of their difficulty 
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in applications.  A number of hypothetical scenarios must be generated in order to 
elicit the patients’ utilities and this often adds unnecessary confusion to the patients 
and clinicians.  
 






The following analyses utilised evidences scoured from case reports, medical 
textbooks, disease registries, audited pamphlets distributed by drug manufacturers, 
abstracts of scientific conference proceedings, peer-reviewed journal articles 
(randomised clinical trials, case-control studies, cohort studies, systematic reviews, 
etc.), government and health agency bulletins and other relevant published documents.   
The first 5 studies involved clinicians as the principal decision makers.  No 
patients were involved in decision making as the primary objectives were to i) 
identify the risk factors associated with the medical conditions of interest, ii) evaluate 
the comparative effectiveness of drugs and treatment procedures, iii) develop 
screening tools for early detection of diseases, iv) identify complications of certain 
diseases, and v) compare performance of predictive models, etc.   
The above-mentioned analyses are decision problems in the broad sense, but 
the results may then be applied as either prior evidence for future analyses or encoded 
as probabilities for the chance nodes in problems involving patients as the primary 
decision makers.  Making decisions about medical care is believed to be most 
effective when a clinician and a patient work together.  The optimum decision is made 
when the clinician’s experience, knowledge and access to evidence are combined with 
patient’s values, wishes and understanding of his problems.   
With this in mind, the remaining 5 case studies focussed on helping patients to 
deal with their health conditions. With their preferences and utilities elicited, the 
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Bayesian models were applied to generate probabilities for quantifying all 
uncertainties identified in the relevant decision trees or influence diagrams.  The prior 
evidences were either gathered from reviews of published information or elicited from 
domain experts. 
 The choice of the case studies is based on the current challenges faced by local 
EBM practitioners.  It is a well-known fact that more and more Singaporeans are 
suffering from depression, osteoporosis, colon cancer, dengue fever, strokes, obesity, 
heart diseases, renal failure and breast cancer.  These case studies are original 
research in their own right.  They were conducted not merely to illustrate the 
properties and features of the proposed Bayesian models.  They help to shed light on 
specific medical problems faced by EBM practitioners and the evidences may serve as 
the cornerstone for future medical guideline development. 
 In the Bayesian literature the terms “weak” or “strong” likelihood are 
commonly used to describe widely-spread or concentrated likelihood, respectively 
[69].  In the case when the observed evidences are pointing to a similar direction or 
supporting a particular hypothesis, the resultant likelihood is said to be “concentrated”.  
However, there is no objective measure of a likelihood’s “concentration”.  To 
preserve the vividness of such descriptions, the terms are retained in the following 
case studies.  But more commonly-used descriptions are also provided for readers 






4. Case Studies 
 100 
4.1 Evaluation of Antidepressants’ Tolerability  
4.1.1 Aim 
Depression is a common disorder that is becoming better understood as an illness that 
can be chronic, recurrent, and refractory to treatment [150].  Generally defined as a 
mood disorder that impairs normal functions, depression may be caused by many 
factors, including biochemical disorders.  The onset of depression may be affected by 
certain medications, hormones and the occurrence of medical illnesses.  Losing a 
loved one, financial concerns, work stress, or relationship problems may all contribute 
to depressive disorders.  One is also at risk if there is a family history of depression.   
 People with the condition typically have problems regulating certain brain 
chemicals called neurotransmitters.  By working within the brain to increase the levels 
of either noradrenaline, serotonin or both, antidepressants help to reduce the 
symptoms of anxiety and negative thoughts usually experienced by sufferers. 
However, they do not act immediately and the lifting of moods typically takes up to 2 
weeks or longer.  
There is a wide class of antidepressants available for treating all forms of 
depression regardless of cause.  The most common antidepressants are selective 
serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs).  Widely 
regarded as one of the most effective antidepressants, the latter had been the first-
choice medication for over 30 years.  TCAs work by preventing the uptake of 
norepinephrine and serotonin, thus building up the concentration of these transmitters 
and improving the communication between neurons.  However, there are a number of 
problems with TCAs as their effects in the brain are not restricted to alleviating 
depression.  They also interact with a number of other brain receptors, thus causing 
side-effects like dry mouth, drowsiness, dizziness, blurred vision, constipation, 
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urinary difficulties, tremor and tachycardia.  In addition, they tend to lower blood 
pressure and consequently cause a feeling of faintness.  Morbidity and mortality 
caused by TCA overdose are also widely reported [151-152].  As such, TCAs are 
usually prescribed in severe cases of depression.  
On the other hand, SSRIs work only on the serotonin system.  Introduced in 
the 1980s, SSRIs possess an improved side-effect profile over TCAs with their 
selective mode of action [153].  While retaining good clinical efficacy, they have few 
of the anticholinergic, antihistaminergic and cardiotoxic effects [154] and are 
probably safer in overdose than TCAs [155].  As a result, SSRIs are recognised to be 
better tolerated and more acceptable to patients [156-160]. However, there are other 
well-documented side-effects associated with the use of the drugs.  These include 
nausea, vomitting, diarrhoea, decreased appetite, fatigue, increased sweating, sleep 
disturbances and impotency [159].  Moreover, SSRIs may also interact with other 
drugs so extra care must be taken in prescription. 
Both TCAs and SSRIs achieve similar efficacy, with 60% to 80% of patients 
responding adequately [161-162].  However, their side-effect profiles vary 
substantially, so the choice of medication for treating depression depends primarily on 
patients’ tolerability. As such, the main objective of this case study was to conduct 
meta-analyses on the tolerability of SSRIs and TCAs.   The results of the proposed 
Bayesian hierarchical models (3.29-3.32) were compared with those of the 
conventional model.  
 
4.1.2 Selection of Published Studies 
There were two sets of analyses.  The first was concerned with primary-care 
patients’ premature discontinuation from treatments due to drug-related side-effects.  
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It is important to investigate patients’ tolerability in the primary care setting since the 
majority of depression cases are first seen and treated in general practice [163-166].  
Randomised controlled trials investigating the efficacy and tolerability of SSRIs 
(fluoxetine, fluvoxamine, paroxetine, sertraline and citalopram, etc.) against a TCA or 
an antidepressant with identical mechanism of action (amitriptyline, imipramine, 
dothiepin, clomipramine and lofepramine, etc.) in patients with depressive disorders 
were identified through MEDLINE and Cochrane Library search up to May 2004, 
previous meta-analyses [162, 167-172] and literature review.  The patients’ depressive 
disorders were assessed by means of the Research Diagnostic Criteria (RDC), 
Diagnostic Systems (DSM-III), Hamilton Rating Scale for Depression (HRSD), 
Clinical Global Impression Score (CGI), Clinical Anxiety Scale (CAS) and 
Montgomery-Asberg Depression Rating Score (MADRS), and so on.  No language 
restriction was imposed in the search.  Studies were excluded from analysis if there 
were insufficient information on study design, description of treatments and 
tolerability, source of patients, and so on.   
In the second analysis, the Bayesian model was compared with a reported 
result published in the Cochrane Database of Systematic Reviews [172].  This 
analysis serves to provide a more complete assessment of the comparative tolerability 
of the antidepressants in the general setting.  The published result was based on a 
search on the Cochrane Collaboration Depression, Anxiety and Neurosis Controlled 
Trials Registers (1977-1999), MEDLINE (1966-1999), EMBASE (1974-1999), 
specialist journals, previous systematic reviews, conference abstracts, government 
documents and reference lists of relevant papers [172].  
For the abovementioned analyses, the parameter of interest was the overall or 
combined odds ratio (OR) of premature withdrawal from treatments due to drug-
4. Case Studies 
 103 
related side effects.  The combined and study-specific ORs were computed such that a 
value above unity suggests that SSRIs were better tolerated than TCAs. To allow 
direct comparison with published results, the odds ratios were computed by Peto’s 
Observed-Expected (O-E) method [173].  In order to provide more insights into the 
issues, several priors reflecting different views of the comparative tolerability of the 
antidepressants were applied in the proposed Bayesian analyses. The data were 
entered into Stata 9.0 for analysis and all statistical tests were conducted at 5% level 
of significance. 
 
4.1.3 Discontinuation from Primary-Care Due to Side-Effects  
The data were extracted from 7 randomised double-blinded clinical trials [174-
180].  The trials, mostly conducted at multi-centres, involved a total of 2,524 patients 
(SSRIs: 1,386, TCAs: 1,138).  Information concerning drug treatments, inclusion 
criteria and basic demographics of the patients is depicted in Table 4.1.  Several 
studies, including those reported in a similar meta-analysis [170, 181], were omitted 
from analysis because of insufficient information.   In addition, 2 trials which 
recruited only elderly patients aged 65 years and above [165, 182] were also excluded.  
Three of the selected studies, notably those with large sample sizes, were in 
favour of SSRIs (Table 4.2 and Figure 4.1).  Combining all 7 studies, the conventional 
model [115-116, 183] produced an overall OR of 1.35 (95% C.I.: 1.06—1.73) (Table 
4.3), thus suggesting that SSRIs were better tolerated than the TCAs.  The 
conventional fixed-effect model was applied here because the assumption of 
homogeneity could not be discarded (p-value: 0.09). 
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Gender: 70% female 
Mean age: 41.7 





8 weeks Gender: 66.5% female 
Mean age: 42.8 





6-22 weeks Gender: 70% female 
Age range: 19-65 






6 weeks Gender: 70.5% female 
Mean age: 47.1 





6 weeks Gender: 71.3% female 








8 weeks Age range: 18-65 





12 weeks Gender: 73.5% female 
Mean age: 42.6 
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Table 4.2: Primary-care patients discontinued from treatments due to side-effects 









OR (95% C.I.) 
Corne 1989 
 
7/49 2/51 0.29 (0.07—1.12) 
Stott 1993 
 
35/243 49/262 1.36 (0.85—2.18) 
Rosenberg 1994 * 
 
43/380 16/92 1.74 (0.87—3.46) 
Doogan 1994 
 
5/83 2/96 0.35 (0.08—1.60) 
Moon 1996 
 
5/60 4/62 0.76 (0.20—2.94) 
Christiansen 1996 
 
9/71 9/73 0.97 (0.36—2.59) 
Ravindran 1997 
 
54/500 84/502 1.65 (1.15—2.36) 
Total 
 
158/1386 166/1138  
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(95% Interval Estimate) 
Conventional Fixed–Effect Model 
 
1.35  (1.06—1.73) 
Bayesian Model in favour of SSRIs 
(Prior OR: 1.50) 
 
1.47  (1.21—1.77) 
Bayesian Model in favour of SSRIs 




Bayesian Model with ‘Non-informative Indifferent’ Prior 




Bayesian Model with ‘Non-informative’ Prior in favour of TCAs 
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However, the result must be interpreted with care.  The combined OR was 
largely influenced by one trial that favoured SSRIs strongly [180].  Omitting this trial 
would reduce the combined OR to 1.15 (95% C.I.: 0.83—1.60), thus suggesting that 
SSRIs were not significantly better tolerated than TCAs. 
The Bayesian models were built next.  Recall that 4 parameters must be fixed 
for the prior distributions for θ (combined odds ratio) and τ (between-study precision).  
Different prior values for θ reflect the different beliefs of the comparative tolerability 
of SSRIs and TCAs.  To induce normality, the observed ORs were logarithmically 
transformed and the prior for θ refers to combined log OR.  The final results were 
reported as OR by performing the necessary back-transformation.   Next, the priors 
for τ were standardised as Gamma[c:0.01, d:0.01].  The choice of this distribution 
reflected the lack of prior information regarding between-study precision.  Also, the 
number of burn-ins was set a priori at 500 and the Markov chain would thereafter be 
run another 1,000 times before the final analyses were conducted.  
In the first attempt, the prior for θ was chosen as Normal[a:0.4055, b:100].  
This reflects a highly-concentrated normal distribution with the overall OR believed 
to be 1.50, i.e., the SSRIs were better tolerated that TCAs.  The selection of this prior 
was based on the general beliefs that SSRIs were associated with a significantly lower 
risk of toxicity [151].  The combined OR turned out to be 1.47 (Table 4.3).  Since the 
95% P.I. does not contain unity, SSRIs were interpreted to be better tolerated than 
TCAs. 
In the second attempt, suppose an expert reported that SSRIs were better 
tolerated that TCAs, so the prior combined OR was fixed at 1.25, i.e. 
Normal[a:0.2231, b:100].  The combined posterior OR turned out to be 1.23 (Table 
4.3).  This is somewhat lower than that reported in the previous analysis. 
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In the next exploratory Bayesian analysis, a prior suggesting that SSRIs and 
TCAs were identical in terms of their tolerability was fitted.  In this case, the 
“indifferent” prior for θ was chosen as Normal[a: 0, b: 0.000001].  Due to the low 
precision of 0.000001, this flat prior resembled that of a uniform distribution, thus 
suggesting that there was little prior information regarding θ.  As shown in Table 4.3, 
the combined OR turned out to be 0.53 and the associated 95% P.I. was 0.11—2.52.  
As a result, one may interpret that SSRIs were not significantly better tolerated than 
TCAs.  The fairly wide interval estimate was a result of the inclusion of 2 non-
informative priors. 
To further illustrate the properties of the proposed Bayesian model, a prior 
suggesting that TCAs were better tolerated than SSRIs was fixed next, i.e, Normal[a: -
0.2877, b: 0.000001].  This was a “non-informative” prior, with OR fixed at 0.75.  
The result was identical to the previous analyses based on “indifferent” prior (Table 
4.3). 
Although the above analyses are unable to encode the probabilities for 
decision analysis directly, they do provide useful evidence on the risk of suffering 
from side effects by taking SSRI, while in comparison with TCA.  For example, the 
Bayesian model favouring SSRI with a prior OR of 1.5, would deduce that a 
depressed patient is 1.47 times more likely to suffer from intolerable side-effects with 
SSRIs, when compared with his counterpart who is prescribed with TCAs. 
The above analyses based on Bayesian models shared a very important 
common feature.  The posteriors were dominated by their respective priors.  This was 
the result of a less-concentrated likelihood, in view of the small number of selected 
trials.  Moreover, Table 4.2 also shows that almost all individual ORs contain unity in 
their respective 95% C.I.s.  (based on conventional model). Consequently the 
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combined posterior ORs were largely similar to the prior ORs.  However, this point 
was not explicitly highlighted by the conventional model.  In this case, the Bayesian 
analysis revealed more details of the data.  It must also be emphasised that the above 
were conducted as sensitivity analysis.  One must decide which prior to be fixed for 
final reporting.   
In passing, note that the resultant posteriors based on the 4 different sets of 
priors were fairly normal and the Markov chains exhibited no obvious pattern of 
divergence after the burn-in values had been discarded (Figure 4.2).   
 
4.1.4 Discontinuation from Treatment in the General Setting 
It was not feasible to perform sub-group meta-analysis by drug class in the 
primary-care example as there were too few studies.  In the next example, SSRIs were 
compared with 3 tertiary TCAs (amitriptyline, imipramine and clomipramine) 
separately.   For all analyses, the priors for θ and τ were fixed as Normal[a:0.2231, 
b:100] and Gamma[c:0.01, d:0.01], respectively.  The choice of priors reflected the 
belief that SSRIs were better tolerated than TCAs [184-185].  In addition, both the 
number of burn-ins and updates were set a priori at 1,000.  
In the case where SSRIs were compared with amitriptyline, 31 studies were 
identified and selected.  The conventional fixed-effect model was chosen to compare 
with the Bayesian model because statistical test suggested no strong evidence of study 
heterogeneity (p-value: 0.79).   Both models showed favourable results for SSRIs but 
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Figure 4.2: Iterative history of meta-analysis of the tolerability of  
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A similar observation was made for comparison with imipramine where 29 
studies were included for analysis.  The Bayesian model’s posterior combined OR 
was almost identical to the prior OR. The random-effect model was chosen for 
conventional analysis because there was strong evidence of study heterogeneity (p-
value<0.01).  In passing, note that the lower ends of the 95% C.I.s and P.I.s for both 
conventional and Bayesian analyses were close to unity. 
Last but not least, there was again a large disparity in results when SSRIs were 
compared with clomipramine.  Dominated by the prior, the posterior combined OR of 
the Bayesian model reported a less favourable effect for SSRIs when compared with 
the fixed-effect conventional model.  With only 9 studies selected, there was no 
strong evidence of study heterogeneity according to the conventional analysis (p-
value: 0.18).  
The Markov chains exhibited no obvious pattern of divergence in the above-
mentioned Bayesian analyses (figures not shown). 
 
4.1.5 Discussion & Decision 
Replication of experimental results has long been a central feature of scientific 
inquiry, and it raises questions concerning how to combine the results obtained.  
Meta-analysis is often defined as the statistical analysis of a collection of results from 
individual studies for the purpose of integrating the findings [186].  It involves the 
combination of quantitative evidence from studies that have investigated a common 
question.   
The theoretical details of the conventional model for meta-analysis are well 
known [115-116, 118-119, 183, 187-188].  Following the rationale of conventional 
statistical theory, the parameter of interest is considered as an unknown but fixed 
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quantity that can be accurately estimated from data obtained from a proper literature 
search. Motivated by the current need for evidence-based medicine, the Bayesian 
model differs from the conventional approach in 2 aspects.  First, it allows prior 
information—in the form of expert opinion—to be incorporated into analysis.  
Though subjective in nature, such information, it is argued, may provide a more 
realistic approach in data analysis.  Many biomedical researchers may have 
accumulated a large amount of experience through practice and it is costly to ignore 
such information. Second, the analysis is conducted on the posterior distribution 
which summarises all the information, both prior- and data-based, that the analysts 
have about the unknown parameters.   
As described, the proposed Bayesian model allows observed ORs to vary 
around their individual study-specific ORs, which in turn belong to a distribution 
characterised by the combined OR.  It was preferred over a fixed-effect model for the 
above-mentioned analyses because there were differences in treatments (e.g., types of 
antidepressants, dose of drugs and treatment duration), types of patients (e.g., 
inclusion criteria, culture of drug compliance), experimental designs (e.g., with or 
without a placebo group) and type of statistical analyses applied.  Consequently, it is 
naïve to assume that study heterogeneity does not exist even with the support of 
formal statistical tests.  Moreover, such statistical tests may lack power in detecting 
the underlying differences among studies.    
This case study aimed to analyse the tolerability of SSRIs and TCAs in 
patients with depressive disorders.  As one of the most common illnesses that affect a 
large number of individuals in all countries, depression is a “whole-body” disorder 
affecting the nervous system, moods, thoughts and behaviour.  As both SSRIs and 
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TCAs are effective in treating depression, the choice of medication depends mainly 
on patients’ tolerability.   
 There was no convincing evidence from the primary care meta-analysis that 
SSRIs were better tolerated than TCAs.  Of the 7 clinical trials considered, only 1 
favoured SSRIs significantly.  The Bayesian models demonstrated that the resultant 
posteriors were strongly influenced by the priors fixed before analysis.  As such, the 
primary-care physicians must be vigilant when prescribing SSRIs (fluoxetine, 
praoxetine, citalopram and sertraline in particular). 
 In the general setting, however, the result was slightly more optimistic.  Based 
on current findings, amitriptyline, imipramine and clomipramine were not as safe as 
SSRIs.  This result conformed to the general beliefs.  However, as in the analysis with 
primary-care patients, the posteriors of the Bayesian analyses were strongly 
dominated by the priors. Consequently, the safety of antidepressant therapies should 
be monitored carefully as patients who suffer from depression may experience 
different tolerability profiles. 
The proposed Bayesian model (3.29-3.32) provides biomedical researchers an 
alternative approach for conducting meta-analysis.  For future research, one may 
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4.2 An Alterative Screening Tool for Osteoporosis 
4.2.1 Aim 
Osteoporosis, a systemic skeletal disease characterised by low bone mineral density 
(BMD), causes considerable morbidity and mortality.  Older persons with the 
condition are at much greater risk for developing hip fractures from accidents such as 
falls.  It is estimated that about 26% of the elderly suffering from osteoporotic hip 
fractures would not survive within a year after the injury [189]. 
This becomes a major concern for Asian countries where populations are 
greying rapidly.  It is projected that 50% of the world’s hip fractures will occur in the 
continent by end of year 2050 [190].  In view of the ageing demographic structure and 
rising osteoporotic hip fractures rate, Singapore is expected to experience substantial 
inflation in related health care costs [189, 191].  This poses a serious challenge to the 
nation. 
Due to a natural decline in bone density after menopause, the majority of 
osteoporotic fractures occur in older women.  To permit prevention and early 
intervention, it is therefore important to identify postmenopausal women at risk of 
developing osteoporosis.  However, mass screening using the dual x-ray 
absorptiometry (DXA)—widely regarded as the “gold standard” for diagnosing 
osteoporosis—is not feasible owing to its cost [192-193].  As such, it is useful to 
consider several well-cited indices [194-198] for identifying elderly subjects at risk of 
developing osteoporosis.  These indices aim to assess how the risk factors, such as old 
age, low body weight, low level of estrogen and history of rheumatoid arthritis, are 
associated with low BMD.   
Generally, these indices have moderate to high sensitivity but low specificity 
[199].  While widely applied in the Caucasian and Asian populations, most of the 
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indices were not validated in the Singapore context.  As such, this paper aims to 
compare the sensitivity and specificity of the indices [194-198] for identifying 
Chinese elderly women (aged 55 years and above) in Singapore at risk of osteoporosis. 
 
4.2.2 Data and Indices 
  One hundred and thirty-five free-living ambulant Chinese postmenopausal 
female subjects were recruited from a community in the eastern part of Singapore. 
Using housing type as a surrogate measure for socioeconomic status, the recruited 
subjects were representative of the socio-economic status of Singaporeans and had a 
wide range of body mass index (BMI). The sample size was determined based on 
estimation of the proportions of subjects in the different categories of BMI status 
(50% in the normal range of 18.5-22.9 kg/m
2
, 30% in the overweight category of ≥23 
kg/m
2 
and 20% in the underweight category of <18.5 kg/m
2
) [200-201]. Dropouts 
were replaced by matching the gender, housing type and BMI of subjects. Approved 
by the Medical Ethics Committee, Health Promotion Board (HPB), Republic of 
Singapore, the study took place in March 2003. 
  Upon given their informed consent to participate in the study, eligible subjects 
were invited to Changi General Hospital (CGH), Singapore, to complete a short 
screening questionnaire and BMD measurements. The subjects were interviewed by a 
trained interviewer on diet, physical activity, quality of life, smoking status and 
current medications. 
  BMD measurement of the femoral neck was performed by dual-energy x-ray 
absorptiometry (DXA) using a Hologic QDR 4500W densitometer (S/N 49088).  All 
DXA measurements were conducted by a qualified radiologist. Body weight was 
measured on a calibrated mechanical scale, and height was measured with a wall-
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mounted stadiometer, with subjects wearing light indoor clothing only (without shoes). 
Food intakes were also assessed using a validated interviewer-administered food 
frequency questionnaire (FFQ) [202]. 
The various indices considered in this study were Simple Calculated 
Osteoporosis Risk Estimation (SCORE), Osteoporosis Risk Assessment Instrument 
(ORAI), Age Bulk One or Never Estrogens (ABONE), Body Weight (WEIGHT) and 
Osteoporosis Self-Assessment Tool for Asians (OSTA) [194-198]. Table 4.5 shows 
the indices’ scoring systems and published results. 
SCORE, one of the first attempts to develop predictive rules for screening 
osteoporotic patients, was developed in an American cohort of 1,102 postmenopausal 
women of all ethnic background aged 45 years and above [194].  ORAI was 
developed and validated in the Canadian Multicentre Osteoporosis Study comprising 
926 non-institutionalised female subjects aged 45 years and above [195]. ABONE 
was developed with the data of 1,610 postmenopausal white women [196] and 
WEIGHT was based on 175 randomly-selected women (aged 28-74 years) in Sweden 
[197]. OSTA was developed with 860 postmenopausal Asian women in 8 countries 
(PR China, Taiwan, Hong Kong, Korea, Malaysia, Singapore, Thailand and the 
Philippines) [198].  It had been validated in various studies consisting of post-
menopausal Japanese, Korean and Hong Kong women [198, 203-204].   
The primary outcome considered in this case study was femoral neck BMD on 
the left region determined by DXA.  Based on the World Health Organisation (WHO) 
criteria [205], the subjects were classified as osteoporotic (BMD T-score≤-2.5) or 
non-osteoporotic (BMD T-score>-2.5).  
An OSTA-like index based on age and body weight was also constructed 
based on Bayesian logistic regression (3.16).  This helps to facilitate comparison 
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between Bayesian and conventional analysis.  A concentrated prior Beta[5, 10] was 
adopted after detailed discussion among the investigators, with expert opinion given 
by a consultant chemist specialising in the subject matter.  The choice of beta prior 
reflected the strong belief that about 30% of the aged subjects were osteoporotic. 
With the published cut-off points (Table 4.5), the sensitivity and specificity for 
the indices were computed in the study sample of 135 subjects. The Receiver 
Operating Characteristic (ROC) curves [147-148] were then generated to determine 
empirically the indices’ optimal cut-off points, sensitivity and specificity in the same 
study sample.  The optimal cut-off of an index was identified at the point nearest to 
the top left-hand corner of the ROC curve [206].  The indices were compared by 
means of area under the curves (AUC) at 1% level of significance, taking into account 
the numerical difference in AUCs and their respective standard errors, which in turn 
depend on the correlation between ROC curves [149].  Other things being equal, a 
low correlation will result in a large standard error, thus suggesting the AUC 
difference to be non-significant. 
 
4.2.3 Comparison of Indices 
Interrupted by the SARS outbreak, the study was concluded in August 2003.  
Table 4.6 summarises the characteristics of subjects included in the study.  The mean 
age of the postmenopausal women was about 68 years. Overall, the proportion of 
subjects found to be osteoporotic based on femoral neck BMD T-scores of ≤-2.5 was 




The sensitivity and specificity based on the published cut-off points of the 
indices (with femoral neck BMD) are presented in Table 4.7. SCORE, ORAI and 
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ABONE attained the maximum sensitivity of 100%, but their ability to correctly 
identify non-osteoporotic subjects was far from satisfactory.  The body weight 
(WEIGHT) criterion also had a high sensitivity of 97.0% and a low specificity of 
18.6%.  OSTA had the same sensitivity as WEIGHT, but its specificity was highest 
among all 5 indices (43.1%).    
 The results based on generated ROC curves are presented in Table 4.8.  For 
OSTA and WEIGHT, lower cut-off values represent higher risk of osteoporosis (low 
BMD).  On the other hand, higher values for the other indices, namely ORAI, SCORE 
and ABONE, indicate higher risk of developing osteoporosis.  
OSTA had the highest discriminatory power, with an estimated AUC of 0.82 
(Figure 4.3).  At the cut-off point of -2, OSTA achieved a sensitivity and specificity of 
90.9% and 58.8%, respectively (Table 4.8).  In passing, note that the identified 
optimal cut-off was lower than the published cut-off point of -1 (Table 4.5).  
With Bayesian augmentation, OSTA achieved a marginally higher specificity 
at 62.8% (Table 4.8), while its AUC and sensitivity remained almost unchanged.  One 
possible explanation is that the collected data were fairly consistent.  Unlike the 
original OSTA, the Bayesian-augmented index may be used in the clinical context for 
advising patients with respect to their probability of contracting osteoporosis.  This is 
crucial for making decisions regarding patients’ need to attend special treatment.   
For example, an 80 year-old female weighing 40 kg is deemed to be at risk as 
she has a 36% chance of contacting osteoporosis (Table 4.9). Other probabilities may 
be encoded with different combinations of age and body weight.  The model is found 
to have provided a satisfactory fit to the collected data.  No influential outliers were 
detected that might affect the fit.  Sensitivity analysis with “non-informative” prior, 
say Beta[1, 1], suggested minor changes to the model. 
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The next index with the largest estimated AUC was SCORE, with ≥8 
identified as the optimum cut-off point (sensitivity: 93.9%; specificity: 60.8%). This 
optimal cut-off point, determined empirically from the analysis, was higher than the 
published result (Table 4.5). 
The body weight criterion, with an estimated AUC of 0.78, identified 54.0 kg 
as the optimum cut-off point. As such, the criterion suggests that subjects under 54.0 
kg were at risk. While its sensitivity was about 70%, the criterion managed to identify 
77.5% of the non-osteoporotic subjects correctly. 
With an estimated AUC of 0.76, ORAI correctly identified about 76% of the 
osteoporotic subjects at an optimum cut-off point of ≥20. Its specificity was about 
67%.   
The AUC of ABONE was 0.70. In terms of sensitivity, ABONE correctly 
identified about 82% of the osteoporotic subjects at cut-off point 3 (possible range: 
1—3).  However, its specificity of 55.9% was lowest among the indices considered in 
this study. 
 There was no significant difference in AUCs among OSTA, SCORE, ORAI, 
ABONE and WEIGHT in the abovementioned analysis.   Although the numerical 
difference in AUCs between OSTA and ABONE was more than 10% where femoral 
neck BMD was considered (Table 4.8), the result was not significant in view of the 
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Table 4.5: Indices for identifying osteoporotic subjects 
  
Index Published 










Race: 5 if not black 
Rheumatoid arthritis: 4 if applicable 
History of minimal trauma fracture after age 45 
years: 4 for each fracture of the wrist *, 
hip or ribs (maximum points=12 points) 
Age: 3 times first digit of age in years 
Estrogen therapy: 1 if never used 
Body weight: - 1 times weight in pounds (lb) 










Age: 15 if ≥ 75 years 
                  9 if 65 – 74 years 
                  5 if 55 – 64 years 
Body weight: 9 if < 60 kg 
                    3 if < 60.0 – 69.9 kg            
Estrogen use: 2 if not currently taking estrogen 
 






Specificity not published 
Age: 1 if > 65 years 
Body weight: 1 if < 63.5 kg 
Estrogen use: 1 if never used oral 
contraceptives or estrogen therapy for at 
least 6 months 
 








Body weight ≤ 70 kg 
Osteoporosis Self-
Assessment Tool for 







0.2 × [body weight (kg) – age (years)] 
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Table 4.6: Characteristics of study sample 
 
Variables Mean (sd) * Range 
Age (years)   
             
68.4 (5.5) 
 
56.9 — 80.1 
Body weight (kg)   
     
58.8 (10.1) 
 
35.5 — 86.5 
Height (m) 
     
1.52 (0.05) 
 
1.40 — 1.64 
Body Mass Index (kg/m²) 
 
25.4 (3.9) 15.9 — 35.5 
Femoral Neck BMD (g/cm²) 
 
    Classified Status of Osteoporosis (%) † 
          Non-Osteoporotic 











Current Smoking Status (%) 
     Non-Smokers 







Estrogen Use (%) 
     No 






   
* Unless otherwise specified 
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Table 4.7: Sensitivity and specificity based on published cut-off Points for identifying 
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Table 4.8: Empirically-determined cut-off points, sensitivity and specificity based on ROC 
curves for identifying osteoporotic subjects with femoral neck BMD≤-2.5 
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Table 4.9: Bayesian logit analysis of osteoporosis (based on OSTA findings) 
 Coefficient  95% P.I. 
Age (years) 
 
5.21 × 10-3 1.99 × 10-3—8.44 × 10-3 
Body weight (kg) 
 
-4.36 × 10-3 -6.18 × 10-3— -2.55 × 10-3 
Intercept 
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a. Simple Calculated Osteoporosis Risk 
Estimation(SCORE)

















e. Body Weight Criterion (WEIGHT) 
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Figure 4.3: ROC curves based on femoral neck BMD≤-2.5 
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4.2.4 Discussion 
Simple risk assessment tools provide a quick and inexpensive way for 
identifying persons at risk of osteoporosis and hip fractures.  Such indices are 
extremely useful in communities where access to BMD measurement is limited and 
costly. 
This empirical study showed that the various indices considered were useful in 
identifying postmenopausal elderly Chinese females with osteoporosis.  Based on 
ROC analysis with femoral neck BMD, the sensitivity of the indices was above 69% 
(Table 4.8).  A high sensitivity is essential as it provides reliable evidence for 
clinicians to start early treatment for patients at risk of osteoporosis.  All indices 
yielded a specificity of no less than 55% (Table 4.8).   
Numerically, OSTA yielded the highest AUC at 0.82, with a sensitivity and 
specificity of 91% and 59%, respectively (Table 4.8).  While its AUC was not 
significantly higher than SCORE, OSTA is a more convenient tool in the sense that 
only age and body weight are required in computation.  This is a desirable feature of 
OSTA as other indices require more detailed information such as the use of estrogen 
and history of rheumatoid arthritis.  While more complicated than WEIGHT, OSTA 
yielded a higher AUC and sensitivity.  
There was no significant difference in AUCs among OSTA, SCORE, ORAI, 
ABONE and WEIGHT.  This could be partly due to the limited sample size [200].  
Moreover, the correlations between ROC curves were generally low.  It is also not 
clinically significant in detecting a less than 10% difference in AUCs (Table 4.8). 
It is worthwhile to note that the original published cut-off of OSTA was ≤-1, 
based on femoral neck BMD of a cohort of 860 women in 8 Asian countries (Table 
4.5).  On the other hand, this study suggests a lower cut-off at -2 (Table 4.8).  The 
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difference in cut-off points may be explained by demographic differences in the 
samples.  The cohort in the original OSTA study included younger women (reported 
age range: 45–88 years) while this study only considered postmenopausal women 
aged 55 years and above.  This highlights that OSTA’s optimal cut-off point may vary 
with different age groups.  Moreover, the original OSTA study used sensitivity to 
select the optimum cut-off while this study adopted the conventional approach by 
giving equal attention to both sensitivity and specificity.   
As such, further studies may be carried out to determine how OSTA perform 
in different age groups (e.g., 55-69 years, 70-80 years and ≥80 years) among the 
postmenopausal women. In addition, subjects from other ethnic groups may also be 
included in future studies.  With diversified demographic characteristics in subjects 
and a larger sample, a more conclusive answer to the index’s generalisability and 
applicability may be derived. 
 
4.2.5 Decisions 
This empirical study showed that OSTA is an effective index for identifying 
postmenopausal Chinese women at risk with osteoporosis.  That is, OSTA has a high 
discriminatory power characterised by high sensitivity and specificity.  It is therefore 
applicable in the clinical context.  Further work may be carried out to evaluate its 
performance in different age range and other ethnic groups in Singapore.  The 
Bayesian logit model may also be applied in the development of new indices, which 
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4.3 Sulindac as an Effective Treatment for Colonic Polyps  
4.3.1 Aim 
The colon is the part of the digestive system where the waste material is stored.  
Tumors of the colon are growths arising from the inner wall of the large intestine. 
Benign tumors (polyps) do not invade nearby tissues or spread to other parts of the 
body and can be easily removed from colonoscopy.  However, polyps can become 
malignant if not removed from the intestine.  It is believed that most cancers of the 
large intestine are developed from polyps [207-209].   
Polyps vary considerably in size; the larger the polyp the greater the risk it 
becomes cancerous.  They usually do not cause symptoms, but when they do, the 
most common is bleeding from the rectum.  A large polyp may cause abdominal pain 
or obstruction.  Adenomatous polyps, which consist primarily of glandular cells inside 
the large intestine, are likely to become malignant.  A family history of polyps 
increases the risk of colon cancer and the term “familial polyposis” refers to the 
condition where 100 or more polyps develop through the large intestine during 
childhood or adolescent.  Caused by a germ-line mutation in the adenomatous 
polyposis coli (APC) gene, familial adenomatous polyposis (FAP) is therefore a 
predisposition syndrome characterised by the formation of a large number of pre-
cancerous colonic polyps.   In nearly all untreated people, the polyps eventually 
develop into colon cancer in their middle age. 
Colon cancer is common among Singaporeans aged 50 years and above, as 
over 1,000 incident cases are diagnosed every year.  As such, persons of this age 
group are constantly reminded to screen for the disease.  As mentioned before, 
persons with a family history of colon cancer have a higher risk of developing the 
cancer themselves.  Smoking, over-eating, physical inactivity and insufficient calcium 
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and fiber intake diet are other prominent risk factors.  Exposure to air and water 
pollution, particularly to industrial cancer-causing substances (carcinogens), also play 
a role.  Although it is a common cancer among developed countries, there is no 
proven cure for the disease.  Shrouded with uncertainties, the best advice is to identify 
the cancer early and have it removed before it begins to spread in the body.  As a 
result, early treatment of polyps is helpful. 
This case study aims at reviewing the results of a well-known randomised, 
double-blind, placebo-controlled trial testing whether or not sulindac, a non-steroid 
anti-inflammatory (NSAID) agent, could reduce the size of colonic polyps in patients 
with FAP [210].  The mechanism by which sulindac causes polyp regression is 
unknown [211]. 
Essentially, this case study attempts to re-analyse the published trial data by 
combining with other available evidences. This may shed light on the effectiveness of 
sulindac based on the Bayesian perspective.   
 
4.3.2 Data 
Altogether, 22 patients were randomised to receive sulindac (150 mg orally 
twice daily for 9 months) or placebo in this trial.  There were 13 (59.1%) male 
subjects in the sample.  With an average age of 24.1 (range: 13—50 years), the 
sample contained an equal number of subjects with and without sulindac. The average 
baseline poly size of the sample was 3.29 mm (range: 1.7—5.5 mm).  This was 
reduced to 2.51 mm (range: 0.4-4.4 mm) after 12 months.  The complete listing of 
data can be found in reference [210].  In the following analysis, only the 12-month 
data were considered and the primary end-point was polyp size (mm).  Baseline polyp 
size was included as one of the predictors in the analysis.  
4. Case Studies 
 132 
 To ascertain whether sulindac was effective in reducing the size of polyps, the 
result from a Bayesian linear relational model (3.42-3.44) was compared with that of 
the conventional regression model [91, 206].  Analysed with Stata 9.0, all statistical 
analyses were conducted at 5% level of significance. 
 
4.3.3 Effectiveness of Sulindac 
The conventional model shows that sulindac treatment was effective in 
reducing the polyp size at 12 months (see Table 4.10).   The average polyp size for 
patients receiving sulindac was about 1.3 mm lower than those receiving placebo, 
after adjusting for the baseline measurements.  The analysis was based on 19 
observations (sulindac: 9; placebo: 10) as there were no data recorded for 3 patients at 
12 months.    
However, there are mixed findings from other studies [207-209, 211-212].  To 
be conservative, consider a fairly precise “sceptical” prior β0=[0, 0, 0]' with Σ0:= 
diagonal3×3(10
-1
) for the following Bayesian analysis.  This prior suggests that 
sulindac is not effective in reducing polyp size.  Moreover, baseline polyp size was 
also not associated with the subsequent measurements at 12 months.  The inverse 
gamma distribution for σ2 was fixed as Inverse Gaussian[3, 3].  As shown in Table 
4.10, the posterior coefficients are closer to the priors, with slightly smaller standard 
errors, and consequently narrow 95% P.I.s.   The Bayesian model shows that there 
could be no sufficient evidence suggesting that sulindac is effective in reducing polyp 
size for patients with FAP.  The drug may not have the colon cancer prevention 
properties once hoped for. 
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The residuals of the Bayesian model were fairly symmetrical.  There was no 
evidence of violation of model assumptions such as heteroscedasticty.  No influential 
outliers were identified (Figure 4.4a).   
 
4.3.4 Probability Encoding 
The Bayesian model may be used for predicting the prognosis of patients with 
or without sulindac.  For example, a patient with a baseline polyp size of 2 mm is 
expected to reduce to 1.3 mm after 12 months on sulindac.  However, the expected 
size of polyp is expected to reduce to only 1.6 mm if he were on placebo. 
With these expected values and assuming the underlying normal distribution is 
valid, one is able to develop a prototype decision model (Figure 4.4b).  For the above-
mentioned patient with a baseline polyp size of 2 mm, the probability of reducing the 
polyp size with sulindac at 12 months is 0.71.  This also imply that his condition 
deteriorates with a probability of 0.29.  On the other hand, if the patient decides not to 
have sulindac, his probability of a better prognosis is 0.62.   
Based on expert testimony, the probability of eventual development of colon 
cancer is assessed to be 0.5 should the patient’s condition fail to improve after 12 
months (Figure 4.4b).  By inspection, it is obvious that a rational patient should 
choose sulindac for treatment even without eliciting his utilities. 
 
4.3.5 Recommendations 
However, one must be reminded that this is an incomplete representation of 
the relevant decision analysis as the tree diagram should also include other decision 
and chance nodes like colonscopy procedure, drug safety, future complications or 
side-effects, and possibly the outcomes of surgery, chemotherapy and radiotherapy 
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should colon cancer develops.  Besides taking NSAIDs, polyps may be removed with 
colonoscopy procedure using a cutting instrument or an electrified wire loop.  If the 
polyps cannot be removed during colonoscopy, abdominal surgery may be 
recommended.   
If new polyps appear rapidly the rectum must also be removed.  A patient may 
suffer from much inconvenience in daily life as an opening is created through the 
abdominal wall from the small intestine.  This procedure is called ileostomy.  Body 
wastes are eliminated through the ileostomy into a disposable bag.   
Surgery is the only recommended treatment of colon cancer.  Should the 
cancerous cells divide rapidly and spread beyond the colon, chemotherapy or 
radiotherapy may be applied after surgery.  The former involves the use of drugs to 
kill the cancerous cells, while the latter applies radiation on the original site of the 
cancer in an attempt to control the disease.  
Unfortunately, there is a lacuna of published evidences in the above-
mentioned treatment and surgical procedures.  The results obtained from this analysis 
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Polyp size reduced 0.71 
Polyp size fail to reduce 0.29 
Polyp size fail to reduce 0.38 
Polyp size reduced 0.62 
Cancer 0.05 
No cancer 0.95 
Cancer 0.5 
No cancer 0.5 
No cancer 0.5 
Cancer 0.5 
No cancer 0.95 
Cancer 0.05 
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4.4 Ocular Complications of Dengue Fever 
4.4.1 Aim 
Dengue fever (DF) is a viral infection caused by Flavivirus in humans and the mode 
of transmission is via the bite of an infected Aedes aegypti mosquito [213].  Accounts 
for worldwide cases of illness in excess of 100 million per year, the infection is 
common in the tropics, subtropics and warm temperate regions [214].  With a 
relatively high average temperature at around 28°C, Singapore is a potential breeding 
ground for DF and year-round transmission is often observed.  A surge in cases has 
been observed in 1992, 1998 and 2004, which recorded an alarming annual incidence 
of 9,459 cases [215].  
DF is characterised clinically by abrupt onset of fever after 2 to 7 days of 
incubation.  Patients often suffer from  severe malaise, headache, arthralgia, cough, 
sore throat, nausea, vomitting, anorexia and altered taste sensation. The disease is 
more severe in adults who usually suffer from high fever, headache and intolerable 
body aches.  It is so painful that DF is often described as “breakbone fever”.  A 
transient macular rash may be seen on day 1 or 2 of illness, followed by a second 
maculopapular rash on day 3 to 6 of illness which typically involves the trunks, limbs 
and face but sparing the palms and soles. Blood dyscrasias may include 
thrombocytopenia and neutropenia (leukopenia).  DF is usually self-limiting, but 
patients with the severe form (commonly known as dengue hemorrhagic fever or 
dengue shock syndrome) may present with bleeding and shock.    
Recently, there has been increasing reports of dengue-related ocular 
complications in the literature [216-228]. Many of the reported cases had visual 
symptoms either in the form of blurring of vision or scotomas, which could represent 
one spectrum of the disease in which the ophthalmic complications were significant 
4. Case Studies 
 138 
enough to cause visual symptoms. However, there were some cases who presented 
with no visual symptoms.  Aimed at detecting the incidence of dengue related ocular 
complication, the following analysis involved patients who were diagnosed and 
admitted to the Communicable Disease Centre, Republic of Singapore, with DF from 
late September 2005 to early January 2006.   
 
4.4.2 Methods 
This was a prospective cohort study. The diagnosis of DF was based on a 
combination of clinical findings correlated to positive results from dengue serology 
(dengue immunoglobulin IgM and IgG sero-conversion), polymerase chain reaction 
(PCR) or both. Patients were recruited to the study at day 6 to 8 of illness. This timing 
was chosen because in several of the previous case series it was found that the onset 
of visual symptoms and detection of ocular complications occurred around 7 days 
from the onset of DF [217-219, 224, 228].  
All patients were asked to describe, with the aid of an Amsler grid, any visual 
symptoms experienced, whether they were scotoma, metamorphopsia or any other 
conditions. This was followed by fundus photography using a Zeiss FF450 (Carl Zeiss 
Inc, Germany) fundus camera with a Kodak DCS620 (Kodak Inc, USA) digital back 
to obtain 50° field image per eye. The images taken were reviewed by an 
ophthalmologist on the same day. Patients with abnormal fundal photos were 
reviewed by an ophthalmologist the following day who took detailed history and 
performed dilated fundal examination using slit lamp biomicroscopy. In order to 
eliminate unnecessary confounding factors from the analysis, patients with pre-
existing ocular problems were excluded. Patients with both abnormal fundus 
photography and fundal biomicroscopy were considered as having ocular 
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complication. Further clinical investigation and management were made on a case by 
case basis.  
To determine if the identified factors (age, vasculitis, and visual symptoms, 
etc.) were associated with ocular complications, Bayesian logistic regression (3.16) 
was applied.  To assess the model’s out-sample predictive ability, the original data set 
was randomly split into two sub-samples.  Based on the training sub-sample with 80 
observations, an auxiliary Bayesian logit model was built.  It was applied to generate 
the probabilities of contracting ocular complications and the results were compared 
with the true status in the testing sub-sample.  To quantify its predictability, a ROC 
curve [147-148] was generated.  Analysed with Stata 9.0 and R 2.4.1, all statistical 
tests were conducted at 5% level of significance. 
 
4.4.3 Results 
A total of 131 patients admitted to hospitals during the study period for management 
of fever with clinical suspicion of DF were recruited into the cohort study. Of these, 7 
were later found to be negative for dengue serology and were subsequently excluded 
from analysis.  
Of the remaining 124 patients with DF confirmed by clinical symptoms and 
positive results from dengue serology, PCR or both, 22 (17.7%) reported an abnormal 
fundus photography. Of these, 12 (9.7%) were found to have retinal abnormalities on 
dilated fundal examination using fundus biomicroscopy. The discrepancy between the 
number of patients with abnormal fundus photography and abnormal fundal 
biomicroscopy examination was partly due to photographic artefacts.  
The mean age of the recruited patients was 32 years (s.d.: 9.37; range 16-62) 
and the majority were males (76.2%). Twenty-four patients dropped out of the study 
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either before having fundus photography or fundal examination, for reasons including 
not feeling well enough to undergo the examination or that they were discharged from 
the hospitals before the examination was conducted.  
Of the 100 patients who completed the study, 6 had bilateral retinal 
abnormalities at the time of examination, while 6 were presented with unilateral 
abnormalities. It was also observed that some patients presented with more than 1 
type of retinal abnormality.  As for the types of retinal abnormalities found, 9 had 
retinal haemorrhage, 5 had cotton wool spots, 2 had vascular sheathing, 1 had macular 
oedema and 1 had optic disc haemorrhage.  Four patients reported visual symptoms 
on direct questioning and testing with the Amsler grid. The symptoms included 
blurring of vision (2), scotoma (1) and metamorphopsia (1). Of these 4 patients, 2 
were confirmed to suffer from ocular complications.  
There was no directly relevant prior evidence for analysing the data with 
proposed the Bayesian analysis, although the decision-maker and analysts believed 
that the complication rate could be around 10%.  This was based on case series 
reported prior to the study.  As such, the model utilised Beta[1, 9] as the prior 
distribution.   
DF patients with visual symptoms were found to be likely to develop ocular 
complications when compared with those who were asymptomatic. However, the 
result was not statistically significant (95% P.I.: -0.02—0.41).  Age was also not 
significantly associated with the occurrence of complications (95% P.I.: -2.87×10-3 — 
8.22×10-3).  The results are depicted in Table 4.11.  As there were only 2 patients with 
vasculitis, a disorder developed from inflammation of the blood vessels, the predictor 
was omitted from analysis. 
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Therefore, a 40 year-old DF patient presented with visual symptom would 
have a 12% chance of developing ocular complications based on the Bayesian logit 
model (Table 4.11).  The model was found to be satisfactory, based on sensitivity 
analysis.   Unfortunately, its out-sample predictive ability was far from excellent as 
the area under the ROC curve (AUC) was 0.53.    
 
4.4.4 Discussion 
There is an increasing awareness of the ocular complications associated with 
DF in Singapore [216-218, 229]. Previous data reported in the indexed medical 
literature have been mainly limited to case reports and case series.  To the best of the 
analysts’ knowledge, there has not been any reported data on the incidence of ocular 
complication in DF.  
In this study, the incidence of ocular complications associated with DF was 
found to be around 10%. Bleeding tendency as a result of thrombocytopenia in DF 
may lead to retinal and disc hemorrhages, and the onset of ocular complications was 
closely correlated to the nadir of thrombocytopenia [217-218]. However, some of the 
other ocular complications observed like vascular sheathing and macular oedema 
could point to an inflammatory component of the complication. It has been suggested 
that the pathogenesis of DF could involve immune clearance by way of induction of 
cross-reactive T-cell memory, T-cell proliferation and recognition of dengue viral 
antigens on infected monocytes by sensitized CD4+CD8- and CD4-CD8+ cytotoxic T 
cells, which result in the release of cytokines with vasoactive and procoagulant 
properties [230-231]. However, the exact pathogenesis of ocular complications of DF 
is not clear and is beyond the scope of the present study.  
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The results of this study need to be interpreted with extra care because of 
several limitations. The selection of a cohort group of an inpatient population might 
have reflected one spectrum of the diseased population. Also, the use of fundal 
photography allowed only a limited view of the fundus and abnormalities in the 
peripheral retinal could be missed. Furthermore, the 2-dimensional images obtained 
by fundus photography might not be able to detect subtle changes like macular 
oedema. Finally, ocular complications like anterior uveitis, which has been previously 
described in dengue-related ocular complication would not have been easily detected. 
Nevertheless, the study could serve as a baseline for comparison with further studies.  
 
4.4.5 Decisions 
Healthcare workers dealing with DF patients need to be aware of the ocular 
manifestations of the disease, even in those who reported no visual complaints. There 
is an urgent need to further the understanding of the epidemiology and 
pathophysiology of such ocular complications.  
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4.5 Predicting Mortality after Intracerebral Haemorrhage 
4.5.1 Aim 
Stroke is the third leading cause of deaths in Singapore [232].  Also known as brain 
attack, stroke is a sudden interruption in the blood supply of the brain. Most strokes 
are caused by an abrupt blockage of arteries leading to the brain.  However, 
intracerebral haemorrhage (ICH) occurs when a diseased blood vessel within the brain 
bursts, thus allowing blood to leak inside the brain.  The sudden build-up in blood 
pressure within the brain can cause damage to the brain cells, and subsequently 
unconsciousness and death.  The main risk factors are hypertension, smoking, 
hyperlipidemia and diabetes mellitus, and the disease may occur in all age groups.  
Less common than ischaemic stroke, ICH makes up about 12% of all stroke cases in 
Singapore. This is substantially lower than other countries with a predominant 
Chinese population, such as PR China (46.0%), Hong Kong (27.1%) and Taiwan 
(23.0%).  Different subtypes of strokes have different pathophysiological mechanisms, 
morbidity and mortality. 
This primary aim of this study was to identify the predictors of 30-day 
mortality after ICH.  This is a crucial task to neurologists and the public health service 
at large because stroke patients need to be evaluated closely at all stages. Otherwise, 
the hospitals concerned are unable to gear up to cope with the increase in stroke load.  
The analysis will help the relevant emergency departments to identify patients who 
might benefit from intensive care.  Moreover, a timely prediction of patients’ 
prognosis also enables care-givers to decide what intensive rehabilitation is required 
for post-stroke care. Based on the encoded probabilities, the patients are informed of 
their chance of survival.  For those with an unfavourable prognosis, advanced 
directives (including end-of-life issues) may be established because the recurrence 
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and progression of ICH are unpredictable.  This may help neurologists and other care-
givers to determine the most cost-effective treatment should the patients become 
unable to make decisions.  
 The secondary objective of this study was to evaluate the predictive 
performance of various candidate statistical and data-mining models.   This will not 
only help to determine which model is most reliable and useful in predicting primary 




The data were obtained from a registry established at the National 
Neuroscience Institute (NNI), Republic of Singapore.  Founded in 1999, NNI is a 
national specialist centre for managing patients who suffer from all diseases of the 
nervous system.  The investigation team for this study comprised two neurologists 
and two medical statisticians.   
Multivariate logistic regression (logit) based on maximum likelihood [133] 
was employed to ascertain how the identified factors were associated with mortality at 
30 days (1: dead; 0: alive). Backward elimination was used to identify the optimum 
model.  
The Bayesian logit model based on prior evidences concerning the underlying 
binomial distribution (3.16) was built next.  Expressed as proportions, the prior 
evidences were elicited from published data [233-234] with model (3.36-3.37).  The 
decision makers specified the prior for between-study precision as Exponential[1] and 
that of the underlying proportion of 30-day mortality as Beta[1, 1].  The burn-ins and 
updates of the MCMC (Gibbs Sampler) were taken as 100 and 500, respectively. A 
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thorough search on the MEDLINE identified a relevant article [233].  This in turn 
helped to extract 8 most relevant and recent studies with detailed information on 
prognostic models concerning short-term mortality associated with ICH.  In addition, 
the extracted article also reported the results of 122 ICH patients (aged 18 years and 
above) admitted in the authors’ hospital between January 1988 and December 1997.   
Conventional generalised additive model (GAM) [235] and two data mining 
models, namely Classification Tree (CART) [236] and Logistic Trees with Unbiased 
Selection (LOTUS) [237] were also applied.  To validate the models externally, the 
original sample was randomly divided into two sub-samples (training set: 60%, test 
set: 40%). Receiver operating characteristic curves (ROC) [147-148] were generated 
to compare the models’ predictive accuracy with observations in the test set.  The 
models’ areas under the curves (AUC) were compared [149].  Univariate analyses 
were performed with chi-square tests or Mann-Whitney tests [238].  
Last but not least, the celebrated AdaBoost procedure [146] was proposed as a 
diagnostic check of the predictive performance of the candidate models.   Analysed 
with Stata 9.0, R 2.4.1 and LOTUS 2.3, all statistical tests were conducted at 5% level 
of significance. 
 
4.5.3 Comparison of Models 
The sample characteristics and results based on univariate analyses are 
presented in Table 4.12.  Old age, history of stroke, known atrial fibrillation, use of 
warfarin, glucose level, presenting Glasgow Coma Scale (GCS) [239] and pupil 
abnormality, post-resuscitation GCS and pupil abnormality, 1
st
 International 
Normalised Ratio (INR) and PT results, vomiting, seizure, total volume of clot, 
ventrical extension and hydrocephalus were significantly associated with mortality. 
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Based on the best eye, verbal and motor responses, GCS is a reliable neurological 
scale for measuring the conscious state of a person (GCS≤8: severe coma, 9-12: 
moderate, ≥13: minor).   
Conventional multivariate logit with backward elimination showed that only 
age, presenting GCS, 1
st
 INR result and total volume of clot were significantly 
associated with 30-day mortality (Table 4.13).  The model was found to be 
satisfactory by means of the Hosmer-Lemeshow test (p-value: 0.27) [240].   
Based on selected published references (Table 4.14), the Bayesian logit model 
utilised a prior beta distribution, namely Beta[6, 8], for handling the unknown 
parameter of the underlying binomial distribution.  The prior, generated from the 
published evidences based on model (3.36), was found to be reasonable according to 
the robust analysis.  Figure 4.5 suggests that the Markov chain did not diverge.  The 
close-form estimated ORs of the Bayesian logit model were slightly different from 
that of the conventional logit model and the 95% P.I.s were much tighter (Table 4.13).     
The other candidate models did not generate ORs for analysis.  Instead, they 
generated probabilities for predicting patients’ mortality directly.  For CART, the 
optimal tree was first obtained with a least CP criterion with 1 standard error, after 
pruning with 10 folds of cross validation.  The same result was obtained should the 
deviance was used as the criterion.  Presenting GCS (cut-off≤7.5) was identified as 
the only significant variable.  
In terms of out-sample prediction (Figure 4.6), the AUC for Bayesian model 
was 0.83 (95% P.I.: 0.76—0.90).  This was comparable to the conventional Logit 
(0.87; 95% C.I.: 0.81—0.94) and LOTUS (0.87; 95% C.I.: 0.81—0.92), but lower 
than GAM (0.92; 95% C.I.: 0.88—0.96).  However, it performed significantly better 
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than CART (0.79; 95% C.I.: 0.73—0.85).  In fact, the AUC of CART was 
significantly lower than that of the other 4 candidate models [149].   
There was no obvious improvement in their predictability when AdaBoost was 
applied. The predictive performances based on AdaBoost were identical to their 
respective single models. 
 
4.5.4 Decisions 
This study was conducted in an attempt to supplement the published literature 
on performance of prognostic models for predicting 30-day mortality after ICH, a 
fatal condition faced by millions of patients world-wide.  Unlike the relevant 
published references [233-234], this study employed several models based on 
conventional statistics, nonparametric statistics, data-mining and Bayesian statistics. 
Neurologists should pay attention to ageing ICH patients with hydrocephalus, 
who presented with GSC≤8 (severe coma), high 1st INR result and high total volume 
of clot.  Demmed to have a poor prognosis, these patients were at risk of death 30 
days after suffering from ICH.  For example, a 60 year-old patient with 1
st
 INR=60, 
GSC≤8, and total volume of clot of 60 has a 33.3% chance of death within 30 days. 
However, there was no clear-cut evidence that which candidate model was 
most superior.  As a result, the analyst may choose any of the model (with the 
exception of CART) based on personal preference and ease of implementation.  It is 
also not necessary to perform complicated analyses with the AdaBoost procedure as 
the single classifiers had attained their “best possible” predictive performance.  
However, it is worthwhile to recruit more patients to the on-going study and conduct 
another comparison in future. 
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Table 4.12: Sample characteristics of ICH patients 




Age (years) * 






    Male  







History of stroke * 
    Yes 








    Yes 







Known atrial fibrillation * 
    Yes 







Use of warfarin * 
    Yes 








    Yes 







Glucose level (mmoL) * 
    Mean 







Presenting Glasgow Coma Scale (GCS) * 
    ≤8 







Post resuscitation GCS * 
     ≤8 







Presenting pupil abnormality * 
    Yes 







Post resuscitation pupil abnormality * 
    Yes 







1st PT result * 
    Mean 







1st PT result 
    Mean 







1st INR result * 
    Mean 








    Yes 








    Yes 







Total volume of clot * 
    Mean 







Ventrical extension * 
    Yes 








    Yes 







* Significant at 5% level of significance 
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OR (95% C.I.) 
Bayesian Logit  
OR (95% P.I.) 
Age (years)  
 
1.03 (1.01-1.05) * 1.00 (1.00—1.01) * 
Presenting GCS  





0.11 (0.06-0.22) * 
 
Reference 
0.92 (0.90—0.93) * 
1
st
 INR result     
 
1.44 (1.09-1.90) * 1.01 (1.01—1.02) * 
Total volume of clot     
 
1.03 (1.02-1.04) * 1.00 (1.00—1.01) * 
Hydrocephalus  
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Iterations after burn-ins 
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Figure 4.6: ROC curves for comparing candidate ICH models’  
out-sample predictive performance 
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4.6 Body Weight Reduction  
4.6.1 Background  
Associated with many disorders, obesity is defined as the accumulation of excessive 
body fat.  The body mass index (BMI) is often used to define obesity.  According to 
the latest guideline developed for Asian populations, a person carries a moderate 
health risk with a BMI≥23 kg/m2, while a BMI≥27.5 kg/m2 signifies high risk.  This 
health risk refers to the risk of developing chronic health problems if weight is not 
controlled in the longer term.  In Singapore, the proportion of population aged 18-69 
years with BMI≥30 kg/m2 was 6.4% in 2004. This was higher than the 6.0% reported 
in 1998.   
Becoming common among urban populations in affluent societies, obesity is 
now considered by public health practitioners as a major world-wide health issue.  
“Obesity pandemic” is now used to describe this worrying trend. There are strong 
evidences suggesting that obesity is associated with many life-style diseases and 
disorders (back pain, sleep apnea, depression, high blood pressure, diabetes, heart 
failure, hyperlipidemia, stroke, menstrual disorders, skin disorders, osteoarthritis, gout, 
gallbladder disease and cancers of the ovaries, breasts and uterus, etc.), accelerated 
ageing and excess deaths [241].  Obesity is often caused by consumption of high-fat 
foods, physical inactivity, emotional disturbances, genetic and environmental factors, 
and the use of certain drugs (antidepressants, antipsychotics, and antihypertensives, 
etc.). 
Accumulation of excessive body fats changes overall physical appearances.  
Obese people may also find their physical or social activities restrcited because of 
fatigue, depression, lack of mobility and other complications.  This is a major concern 
among persons who are conscious about their physical attractiveness. The common 
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advice for weight reduction usually concerns lifestyle changes, and these include 
regular exercise and reduced intake of calories.  For those who are severely obese 
(BMI>40 kg/m
2
), clinicians may recommend surgery as the choice of treatment.  For 
persons who are moderately obese, weight-loss drugs and medicinal herbs that aim at 
increasing metabolism and/or to reduce appetite may be prescribed.   
Although usually harmless, the common weight-reducing drugs available in 
the market are reported to be ineffective.  Clinicians usually recommend weight-
management programme as part of the treatment plan.  However, development of new 
drugs, especially those with natural contents, presents a lucrative business for the 
pharmaceutical industry.   
In an attempt to fulfill the objective of this study, the effectiveness of Xändo, a 
widely-publicised drug, was evaluated.  Its advertising strategy included the use of 
popular celebrity spokespersons.  Promised to be a weight-reducing agent of natural 
origin, Xändo comprises a number of ingredients (α-amylase inhibitor, inulin and 
Garcinia cambogia) that work together to capture excess sugars, reduce their storage 
as body fat and eliminate them from the body by excretion [242].  However, the 
statistical analysis presented in the original article was incorrect.  As a result, one is 
not sure if the developer’s claim such as “3× more weight loss” was valid.  This will 
be dealt with in the relevant section. 
 
4.6.2 Aim  
The primary aim of this study was to assist a male obese teenager to decide 
how to reduce his body weight within 3-4 months.  This is a valid concern among 
teenagers because they are likely to remain obese when they grow up.  Young men 
with morbid obesity have a 10-fold excess mortality compared with
 
their normal 
4. Case Studies 
 156 
weight counterparts.  As mentioned before, this study also helped to re-analyse the 
presented data of Xändo [242] with an appropriate Bayesian model.  Next, the study 
made use of data provided by the Singapore Armed Forces (SAF) in order to ascertain 
whether a prolonged basic military training (BMT) for the decision maker would lead 
to reduction in BMI and increase in injury rate.   
 
4.6.3 Decision Problem and Data  
The decision maker of this study was a Chinese, pre-university obese teenager 
(BMI: 35.5 kg/m
2
) who was about to be enlisted.  At the point when the decision 
problem was surfaced he had only about 15 weeks to reduce his excessive body 
weight.  Initially, he was presented with two choices—consume Xändo tablets 
regularly or embark on a weight-management programme.  The first choice was a 
relatively comfortable decision as he only needed to adhere to the developer’s 
guidelines. Table 4.15 depicts the published results of the original article on Xändo 
[242].  With 40 healthy obese volunteers (Xändo: 20, placebo: 20) enrolled, the study 
was concluded in 12 weeks (end-point).  With Xändo, the decision maker did not have 
to make substantive changes to his current lifestyle, but was uncertain of the 
effectiveness of the new drug.  Moreover, there might be complications and side-
effects, although the developer promised there were none [242].  The second choice 
could turn out to be less tolerable as he might have to give up many of his hobbies.  
The clinicians also estimated that there was only a slim chance (0.05) to reduce his 
BMI to the targeted 27 kg/m
2
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Table 4.15: Selected original published results of Xändo 
 Week 0 (Baseline) 
Mean BMI±s.d. 
 





Xändo (n: 20) 
 
31.0 ± 3.2 29.7 ± 3.2 1.3 ± 1.2 
Placebo (n: 20) 
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If he failed to reduce his BMI to below 27 kg/m
2
 he would be required to 
undergo the compulsory strenuous military training designed for obese servicemen.  
He would then face a prolonged service that could delay his discharge, or more 
seriously an enhanced likelihood of suffering from physical injuries. Obesity is 
believed to pose additional risks during strenuous military training.  
In the past, pre-enlistees with BMI≥27.0 kg/m2 underwent a 16-week basic 
military training (BMT). The severe and extreme obese enlistees underwent similar 
training with the mildly and moderately obese recruits. The BMT was then prolonged 
to 26 weeks for the severely obese enlistees in 2004.  The burning question was if an 
increase in duration of training would result in improved weight loss profiles, reduced 
injury rates and improved fitness levels. After BMT, the recruits were given a PES 
grading based on their BMI and/or body fat percentage according to the SAF 
definition of obesity. This PES grading would in turn determine their deployability 
into various military vocations. A reduction in BMI had to be significant enough, 
medically speaking, to result in a change in PES grading. The retrospective data of 
716 recruits with BMI≥35 were analysed (16-week BMT: 338; 26-week BMT: 378).   
Bayesian linear regression model (3.44) was used to analyse the two data sets 
described above in order to encode the required probabilities for the decision problem.  
With non-informative priors, the effectiveness of Xändo was evaluated.  While the 
chemical effects of inulin and hydroxycitric acid (HCA) are fairly well-known, there 
was insufficient evidence of their effectiveness in human bodies.  With this in mind, a 
diffuse prior for the covariance matrix was used, i.e., Σ:=diagonal3×3(1,000).  The 
prior for coefficients was taken to be β0=[0.8, -2.0, 2.0]'.  This prior suggested that 
Xändo might be effective when compared with placebo.  The average active group 
was expected to be 2.0 kg/m
2
 lower than that of the placebo group after 12 weeks.  
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The baseline and end-point BMI were expected to be correlated at 0.8.  This is 
reasonable because the study’s time frame was relatively short.  
The obese recruits’ end-point BMI between training groups, after correcting 
for baseline BMI, were also analysed with informative priors.  In a well-cited study 
involving 27 severely obese subjects (average baseline BMI: 44 kg/m
2
) who engaged 
in an intensive lifestyle intervention composing of physical activity, dietary changes 
and personal development, the 15-week result was significant [243].  Based on the 
evidence, the average end-point BMI was expected to reduce by 1.0 kg/m
2
.  It was 
also expected that the baseline and end-point BMI (26 weeks) were correlated at 0.8.  
As such, the priors were taken as Σ0:= diagonal3×3(10) and β0=[0.8, -0.1, 2.0]'.   
Last but not least, Bayesian logit model (3.16) with informative prior, i.e., 
Beta[5, 5] was applied to analyse the occurrence of injuries (1: yes, 0: no).  The 
relevant priors are provided by a SAF medical officer specialised in weight-reduction 
programmes.  Analysed with Stata 9.0 and Microsoft Excel 2002, all statistical tests 
were conducted at 5% level of significance.  Post-hoc analysis suggested that the 
sample size provided by SAF was sufficient for all relevant statistical testing at 90% 
power and 5% level of significance, after taking into consideration the potential 
correlation between baseline and end-point BMI of the enlistees. 
 
4.6.4 Results 
The demographic characteristics of the recruits in the two training groups were 
comparable (See Table 4.16).  There was no significant difference in average baseline 
BMI between the two groups (p-value: 0.10).  Both groups demonstrated significant 
decline in average BMI at end-point (16-week BMT: 39.0 kg/m
2→34.3 kg/m2; p-
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value<0.001; 26-week BMT: 39.5 kg/m
2→34.4 kg/m2; p-value<0.001).  The baseline 
BMI was normally distributed but became slightly skewed at end-point.   
The decline in average BMI of the 26-week group was significantly larger 
than that of the 16-week group, after adjusting for ethnicity and educational 
attainment (Table 4.17).  The non-informative Bayesian model was found to be 
satisfactory.   
Although there were more injured cases (9.3%) reported for the 26-week 
training group when compared with the 16-week group (8.0%), the difference did not 
turn out to be significant, after adjusting for ethnicity, educational attainment and 
baseline BMI (Table 4.18).  The model made use of an informative prior Beta[5, 5] 
given by the analyst.  There were significantly fewer injured cases among the Malay 
recruits (5.3%), when compared with their Chinese (9.9%) and Indian (17.8%) 
counterparts.  On the other hand, there were more injured cases reported for recruits 
with primary and lower education (40.0%), when compared with those holding higher 
qualifications (secondary: 8.7%, pre-university: 8.9%, tertiary qualifications: 7.3%).   
 The analysis of the Xändo called for some re-construction based on the 
published aggregate evidence (Table 4.15) as no subject-level data was available.  The 
analysis provided by the article was wrong because it failed to compare the groups’ 
end-point BMI directly.  Instead it analysed the groups’ end-point BMI separately. 
Statistically speaking, this is unacceptable. A proper analysis should include the 
baseline (week 0) BMI as it is expected to be associated with the end-point (week 12) 
BMI.  The proposed Bayesian technique required the analyst to compute the 
conventional linear regression model’s coefficients first.  Usually the task is 
impossible without subject-level data but fortunately the original article [242] threw a 
lifeline by providing the standard deviations of change in end-point BMI for both 
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groups.  The most important element is the correlation between baseline (week 0) 
BMI and end-point (week 12) BMI as it is required to compute all the necessary 
quantities (intermediate and final) and coefficients for the regression analysis.  The 
technique works as follows: 
 
i. generate the pooled variance of baseline BMI and end-point BMI of the two 
groups (0: placebo, 1: Xändo) 
ii. compute the pooled coefficient of correlation between the baseline BMI and 
end-point BMI by making use the fact that V[BMI1 – BMI0] = V[BMI1] + 
V[BMI0] – 2(correlation)√V[BMI1]V[BMI0] 
iii. work out all the cross products required for regression analysis based on ii and 
the known features and quantities of the study 
iv. compute the regression coefficients based on ii and iii 
v. generate the coefficients’ standard errors, sums of squares (total, model and 





The re-construction of the regression analysis was based on the known inter-
relationships of all the relevant quantities.  The quantities generated are based on 
exact methods [34]. 
The results are shown in Table 4.19.   It is interesting to note that the 
developer’s claim was fairly valid, i.e., there was significant change in subjects who 
took Xändo, when compared with those on placebo.  The end-point BMI of the Xändo 
group was about 0.86 kg/m
2
 significantly lower than the placebo group.  The 
conventional model provided a good fit to the data as the covariates were able to 
explain about 90% of variations in end-point BMI. 
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Table 4.16: Sample characteristics of SAF recruits 
   





    Chinese 
    Malay 
    Indian 
    Others 
  
Educational attainment: 
    Primary & below  
    Secondary 
    Pre-University 
























Occurrence of injuries: 
    No 








Baseline BMI (kg/m2) 
 
39.0 (s.d.: 4.0) 
Range: 32.7—58.8 
 






)  34.3 (s.d.: 3.6) 
Range: 27.5—52.5 
34.4 (s.d.: 4.0) 
Range: 24.8—49.6 
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0.83 — 0.90 
 
Group *: 
     1: 16-week BMT 








-0.78 — -0.26 
Constant  
 
4.21 -1.47 — 2.29 
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-1.03×10-4 — 3.59×10-3 
Ethnicity: 
    Chinese 
    Malay * 
    Indian 










-0.03 — -1.11×10-3 
-4.83×10-3 — 0.06 
-0.06 — 0.06 
Educational attainment *: 
    Primary & below 
    Secondary 
    Pre-University 










-0.17 — -0.04 
-0.18 — -0.04 
-0.18 — -0.05 
 
Group: 
     1: 16-week BMT 








-0.01 — 0.02 
Intercept * 
 
-0.11 -0.21 — -0.01 
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Table 4.19: Reconstruction of conventional linear regression analysis 




















33.35 37 0.90  Adjusted R2 0.90 
Total 341.84 39 8.77  F (p-value) 171.11 (<0.01) 
       
Covariates Coefficients Standard error t-value  p-value 95% C.I. 
Baseline BMI * 
 
0.89 0.05 17.81  <0.01 0.79—0.99 
Group * 
     0: Placebo 
















-1.49 — -0.26 
Intercept  
 
2.90 0.03 108.76  <0.01 2.84 — 2.95 
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With the conventional model’s coefficients generated the analyst was able to 
compute the Bayesian coefficients (3.44) since the latter are “shrunk” estimates of the 
former and the priors (Table 4.20).  Again, Xändo was shown to be effective in 
reducing subjects’ body weight after 12 weeks.  In passing, note that the results were 
almost identical to that of the conventional model because the data were fairly 
consistent.   
 
4.6.5 Decision 
With the probabilities generated from the Bayesian models (Tables 4.17-4.18, 
4.20), the tree diagram was completed (Figure 4.7).  The encoded probabilities 
illustrated on the chance nodes are bracketed. The most preferred and least preferred 
scenarios were meeting target with Xändo (BMI<27 kg/m
2
) in 12 weeks and picking 
up an injury with target unmet (BMI≥27 kg/m2), respectively.  Complication due to 
Xändo was not featured because the published article [242] reported no side-effects 
observed in the obese subjects in 12 weeks.   
Based on some close discussion with the decision maker the following 
exponential utility function was derived: 
 
 
u(x) = 1.78(1 – e 
–x/12.16




The procedure is documented in subsection 3.5.5.  With his utilities elicited, it is 
obvious that he might benefit from choosing Xändo to reduce his body weight.  The 
expected utility derived from using Xändo was 0.46.  This was higher than that 
derived from participating in the weight-management programme.  However, it was a 
rather formidable task to achieve his target (BMI<27 kg/m
2
) within 12-15 weeks, 
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given his initial BMI of 35.5 kg/m
2
.  The probability of achieving the target was only 
0.12 with Xändo.  Perhaps he should have started his weight-reduction programme 
earlier.  With his height at 1.80 m, reducing a BMI by 8.5 kg/m
2
 was equivalent to 
reducing his body weight by 27.5 kg. 
 
4.6.6 Discussion 
Xändo seemed to have fulfilled its promise of helping obese consumers to 
attain significant weight loss after 12 weeks, although the original analysis presented 
in the article [242] was conceptually and technically wrong.  However, nothing was 
said about its long-term effects. The problem of weight regain after termination of a 
therapy is a well documented issue.  On average, most patients regain about 30% to 
35% of their lost weight
 
one year after on treatment.  Published reports also suggested 
that 50% or more
 
of participants would return to their baseline weight approximately 
3 to 5 years after therapy [244-246].  One pair-matched study involving 24 subjects 
reported that they regained 11 kg 4 years after losing 10 kg [247]. 
Future studies may consider other weight-management programmes and more 
established weight-reducing drugs. The US Food and Drug Administration (FDA), as 
well as an expert
 
panel convened by the National Heart Lung and Blood Institute,
 
have recommended that weight-reducing medications be used only as
 
an adjunct to a 
comprehensive program of lifestyle modification
 
that includes diet, physical activity, 
and behavior therapy. Two medications,
 
sibutramine and orlistat, are currently 
approved by the FDA
 
for long-term use in obesity management.  Sibutramine is a 
CNS
 
agent that inhibits the reuptake of norepinephrine and serotonin.
  
By contrast, 
orlistat is a gastric and pancreatic lipase inhibitor
 
that works by blocking the 
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absorption of fats contained in a meal, and with the undigested fat excreted.  Both 
sibutramine and orlistat have been used successfully in the induction of weight loss.
  
One limitation of the analysis based on SAF data was that the study was 
retrospective in nature.  It did not allow for randomisation to ensure uniformity in the 
2 study groups. This was, however, partially compensated with the use of multivariate 
statistical models, which adjusted for ethnicity, education attainment and baseline 
BMI. The 26-week BMT did prove to produce a more significant decrease in BMI, 
when compared with the 16-week group.  This could be attributed to the additional 10 
weeks of physical training in a controlled environment.  However, as there was 
minimal change in training programme or diet between the 2 groups, the difference 
merely reflected weight loss as a result of overall increase in amount of exercise. It 
may be prudent to design a specific BMT training programme for the 26 weeks that 
addresses intensity, graduated increments as well as dietary alterations to fully exploit 
the benefits of the additional training.  
While the chosen decision may seem straight-forward and obvious in view of 
the simple structure of the problem, it does illustrate the usefulness of the 
incorporation of various Bayesian models for probability encoding.    
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Table 4.20: Informative Bayesian linear regression analysis of recruits’ 














     0: Placebo 







-1.42 — -0.30 
Intercept 
 
2.36 -0.61 — 5.34 
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4.7 ACE Inhibitor for treating Ischaemic Heart Disease 
4.7.1 Background 
Angiotensin Converting Enzyme (ACE) inhibitors are a group of pharmaceuticals 
used primarily for controlling blood pressure and treating congestive heart failure.  
They help to slow down the enzyme activities, which in turn halt the production of 
angiotensin II, a potent chemical responsible for causing high blood pressure 
(hypertension). Also useful for preventing kidney damage in patients with 
hypertension or diabetes mellitus (DM), ACE inhibitors have become an important 
class of drugs for preventing death resulting from heart failure or heart attack.  In 
addition, it is able to reduce the progress of diabetic nephropathy independent from 
their blood-pressure lowering effect. 
 The highly-regarded European Trial on reduction of cardiac event with 
Perindopril (EUROPA) demonstrated that ACE inhibitors significantly improved 
patients’ prognosis, with or without hypertension and diabetes, and irrespective of age 
[248].  Involving patients from 424 centres across Europe, the trial was randomised, 
double-blinded, and placebo-controlled.   
 There are variations among the ACE inhibitors, such as salfhydryl-containing 
(capoten), dicarboxylate-containing (perindopril) and phosphate-containing 
(fosinopril).  The difference lies in how they are eliminated from the body.  Some 
inhibitors need to be converted into an active form in the body before they function.  
Others may inhibit ACE directly in the tissues rather than that present in the blood.  
However, there is no reported evidence on the relative effectiveness of these different 
inhibitors. 
 ACE inhibitors have few interactions with other drugs, but it is advised that 
they should not be taken with potassium supplements, salt substitutes and other drugs 
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that may increase the body’s potassium levels.  Aspirin and other non-steroid anti-
inflammatory drugs (NSAIDs) may also weaken the effects of ACE inhibitors.  While 
relatively well-tolerated by most patients, therapy with ACE inhibitors requires 
careful monitoring as it may cause dizziness in patients who are overdosed or less 
tolerated with rapid reduction in blood pressure.  Other common adverse effects 
include hyperkalemia, headache, fatigue, hypotension and renal impairment in 
patients with renal artery stenosis.  Some patients may also develop angioedema due 
to increased bradykinin levels.   
 
4.7.2 Aim 
The following decision analysis concerned an anonymous 45-year old Chinese 
male professional suffering from ischaemic heart disease (IHD) and Type-II diabetes.  
Unlike Type-I diabetes, which is caused by autoimmune disorders, Type-II diabetes is 
usually developed in adults above 40 years of age.  Although there are exceptions, 
Type-II patients are usually overweight.  The existence of Type-II diabetes has been 
shown to have brought adverse impact on patients with congestive heart failure (CHF).  
CHF, also known as congestive cardiac failure (CCF) is a condition in which the heart 
fails to pump enough blood to the body’s other organs.  This can be caused by narrow 
arteries, past myocardial infarction, high blood pressure, heart valve disease, genetic 
family history, and heart defects present at birth.  IHD is a specific heart disease 
characterised by reduced blood supply to the heart.  Typically, there is blockage to the 
coronary arteries which reduces the blood supply to heart muscles.  IHD patients may 
experience sudden heart attack, which results in long-term damage to heart muscle 
and structural damage to the organ.  There are evidences showing that diabetes was 
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associated with ICH and eventual heart failure mortality [249-251]. Suffering from 
diabetes for 5 years, the patient was not on insulin. 
 The proposed analysis could help the decision maker to decide whether he 
should consider ACE inhibitors, while taking into consideration its relative 
effectiveness with other drugs such as beta-blockers and spironolactone.  The end-
points were hospital re-admission and survival. 
Over the past few decades, preventive and therapeutic measures have 
substantially improved the prognosis of IHD patients.  Nevertheless, the risk of 
cardiovascular complications remains high and progression can be halted in few 
patients despite regular treatment with established drugs like beta-blockers, aspirin 
and statins.  The analysis also helps to show whether ACE inhibitors could 
significantly reduce IHD patients’ risk of hospital re-admission and mortality, a topic 
of paramount interest to cardiologists.   
 
4.7.3 Data 
The data were obtained from 1,668 patients who were enrolled to the National 
Healthcare Group (NHG) Multidisciplinary Heart Failure Disease Management 
Programme, Republic of Singapore, from October 2003 to September 2006.  There 
were definite evidence of CHF in these subjects, on the basis of clinical findings 
and/or the Boston Criteria, with documented LV systolic dysfunction.  The patients 
had LV ejection fraction (EF) below 40%.  However, patients with advanced 
malignancy, severe renal failure, severe pulmonary disease, psychiatric or cognitive 
disorders, and who were on cardiovascular interventional procedures were excluded.   
All patients enrolled to the programme were educated on dietary and fluid 
management, and were followed-up by CHF specialists at regular intervals.  They 
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were advised to exercise regularly, quit smoking, and reduce excess body weight and 
cholesterol.  In addition, they were also placed on telephonic case management by 
CHF-trained nurses, and contacts were made on a monthly basis. 
This was essentially a prospective cohort study, where patients were followed-
up for 24 to 48 months (mean duration: 36 months).  On entry to the programme, the 
patients’ baseline demographic and clinical characteristics were recorded.  Other 
information included quality of life (Minnesota Living with Heart Failure score), 
medication use and physical functionality (New York Heart Association 
Classification).  Information on hospitalisation for any cause at the emergency 
departments was collected prospectively by checking the in-hospital admission list 
and the attendance charts on a daily basis.  Evidence of death was collected from the 
Singapore Registry of Births and Deaths.  The primary end-points of interest were 
hospital re-admission due to heart failure and all-cause mortality. 
Collated and managed by a full-time executive, the data were further validated 
by two consultant cardiologists and a principal medical statistician during analysis.  
To ensure that the analyses were reliable, the investigators met regularly to fill up the 
missing data. 
The proposed decision analysis involved 1 decision node (use of ACE 
inhibitors vs. other drugs), 4 deterministic nodes (gender, ethnicity, age and kidney 
damage), 2 chance nodes (hospital re-admission and survival) and 1 value node 
(patient’s utilities). The decision node concerned comparison between ACE inhibitors 
and other drugs such as beta-blockers and spironolactone.  Beta-blockers, which work 
on the heart and circulatory system, has been downgraded as 4
th
-line treatment by the 
United Kingdom in 2006 as there was reported evidence that frequent users at usual 
dose could carry an unacceptable risk of provoking Type-II diabetes [252].  However, 
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it is associated with clinically meaningful reductions in mortality [253].  Both ACE 
inhibitors and beta-blockers have shown to be helpful in reducing mortality in patients 
with or without renal insufficiency [254].  Suspected to be associated with stomach 
bleeding, spironolactone is a synthetic 17-lactone steroid used primarily for treating 
liver disease, low-renin hypertension and hypokalemia.   
Glomerular filtration rate (GFR), based on plasma creatinine, is a measure of 
patients’ kidney function.  Diabetes and high blood pressure are among the most 
notable risk factors for kidney disease.   Patients are deemed to be suffering from 
kidney disease if his GFR falls below 90.   
Three demographic variables, namely gender, age and ethnicity, were included 
as either risk factors or confounders in the proposed analysis.  Ageing is expected to 
affect the patient’s prognosis.  Gender is also suspected of associating with congestive 
heart failure mortality [251].  Generally, females have a longer life span than males.  
There is also evidence showing ethnic differences in acute myocardial infarction 
events in Singapore, with Malays having the highest case-fatality [255]. 
Last but not least, the patients’ functionality was quantified by the New York 
Heart Association (NYHA) Classification, a well-regarded functional and therapeutic 
classification for prescription of physical activity for cardiac patients.  A patient with 
no limitations of activities is graded as Class I.  At Class II, the patient has slight 
limitation of activities, but is comfortable with rest or mild exertion.  At Classes III 
and IV, however, the patient concerned is either limited with daily activities or require 
complete rest (confined to bed or wheel-chair).  Since the decision maker was not 
functionally restricted, the proposed analysis excluded all data from patients with 
NHYA>2. 
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Analysed with Bayesian logistic regression (3.16) and Weibull survival model 
(3.50), all statistical tests were conducted at 5% level of significance.    The priors for 
the effect of ACE inhibitors and beta-blockers in the Weibull model were taken as 0.7 
and 0.8, respectively.  These are interpreted as hazard ratios (HR), with values below 
unity as beneficial effects on survival.  The associated variance-covariance matrix was 
chosen to be Σ0:=diagonal3×3(10), thus reflecting a conservative stand.  There were 
either dubious or short of direct evidence concerning the effects of the drugs in 
published references [251, 256-259].  In reference [256] the investigators failed to 
recognise the multicollinearity effect revealed in the analysis and reported an adverse 
impact of ACE inhibitors on mortality (HR=1.53, 95% C.I.: 0.86—2.75). In fact, the 
investigators wrongly expressed the HR as odds ratio (OR).  It is suspected that ACE 
inhibitors’ beneficial effect was “masked” by that of beta-blockers (HR=0.77, 95% 
C.I.: 0.54—1.09), whose effect was “expected” but non-significant. This is a common 
problem encountered in real-life data analysis and investigators ought to pay special 
attention to unexpected signs.  One prospective study reported that survival rates after 
1, 3 and 5 years, as determined by the Kaplan-Meier curves, were found to be around 
78.9%, 57.2% and 39.0% [257].  Another reference presented figures on 6-month 
mortality only [259].  There was also no direct and confirmative result concerning 
hospital readmission due to heart failure [249].  Estimated to be 40%, the logit 
analysis of hospital readmission used a prior Beta[2, 3]. Though restricted to patients 
enrolled at NHG, this was the largest hospital-based CHF cohort study in Asia.   
 
4.7.4 Results 
The patients’ profiles are depicted in Table 4.21.  Altogether, 411 NYHA≤2 
patients with IHD and diabetes were included for analysis.  No patient was prescribed 
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with insulin.  Since there were relatively few patients in the “other” ethnic group 
(2.2%), they were discarded from all analyses below. 
Table 4.22 shows that the use of beta-blockers was beneficial in reducing 
hospital readmission due to heart failure.  However, the effect of ACE inhibitors was 
dubious.  Careful analysis showed that there was indeed no significant result observed.  
The non-significant result was not caused by multicollinearity among the predictors.  
Demographics (ethnicity, gender and age) and occurrence of kidney disease) were not 
significantly associated with hospital re-admission. 
On the other hand, Table 4.23 suggests that there were some protective effects 
against death by the use of ACE inhibitors, beta-blockers and other drugs, according 
to the Weibull Bayesian survival analysis.  However, their effects were non-
significant in explaining the time to death.  Their individual effects on mortality might 
be more directly explained by hospital re-admission. Sensitivity analysis with several 
informative priors did not change the result drastically (details not shown). 
The patients’ probability of death was well below 25% throughout the 4 years 
(approximately 1,500 days) of follow-up (Figure 4.8).  The 6-month (180 days) 
mortality was similar to published results in reference [259].  The prognosis was 
substantially better than most of the reported results in references.  This is not 
surprising because the local sample excluded patients who were physically dependent 
(NHYA>2).   
4. Case Studies 
 178 
Table 4.21: Sample characteristics of diabetic IHD patients 
 n (%) 
Ethnicity: 
    Chinese 
    Malay 
    Indian 
    Others 
  
Gender: 
    Male  
    Female 
 
Age: 






























Kidney damage (15-89) 













All-cause death within 4 years 
No 
Yes 
       ≤6 months 
       6 months to 2 years 
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Table 4.22: Informative Bayesian logit analysis of hospital re-admission 









    Chinese 
    Malay 
    Indian 
     
Gender: 
    Male  
















-0.07 — 0.06 




-0.07 — 0.04 
 
-3.69×10-4 — 5.04×10-3 
 









-0.05 — 0.09 
 









-0.17 — -0.03 
GFR 
Normal (≥90) 







-0.02 — 0.12 
Intercept * 
 
-0.77 -0.95 — -0.58 
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Table 4.23: Non-informative Weibull Bayesian survival analysis of 










    Chinese 
    Malay 
    Indian 
     
Gender: 
    Male  























































Hospital readmission * 
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4.7.5 Decisions 
Based on a close discussion with the patient the following exponential utility 
function was derived (see subsection 3.5.5 for details): 
 
 
u(x) = 1.30(1 – e 
–x/67.70




His most preferred situation was no relapse and stayed alive.  The worst scenario was 
readmitted to hospital and died within 6 months.   
 The Bayesian logit model (Table 4.22) suggests that his probability of re-
admission (due to heart failure) after being treated with ACE inhibitors and beta-
blockers were 0.12 and 0.11, respectively.  There was little practical difference 
between the two drugs in terms of re-admission.   
Moreover, if he did not re-admit to hospital his probability of survival was 
0.86 with ACE inhibitors (Table 4.23).  His chance of death was 0.05 within 6 months 
and 0.09 beyond 6 months.  On the other hand, his chance of survival with beta-
blockers and without readmission was slightly higher at 0.9.  The probability of death 
was 0.05 for both within 6 months and beyond 6 months.     
Based on Figure 4.9, there was no significant difference in utilities in choosing 
ACE inhibitors or beta-blockers.  However, beta-blockers seemed to be a more 
effective drug for reducing hospital re-admission due to heart failure for diabetic ICH 
patients. 
 
4.7.6 Future Study 
 Future analysis may include glycemic control (indexed by HbA1c).  A recent 
study suggested that poor glycemic control might be associated with increased risk of 
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cardiovascular events (hospital readmission and death) and new onset heart failure in 
patients with diabetes [260].  The impact of HbA1c on prognosis in patients with 
established systolic heart failure has not been previously investigated.  This presents a 
new direction for clinical research on diabetic ICH. 
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4.8 Peritoneal Dialysis for treating End-Stage Renal Disease 
4.8.1 Background  
Kidney failure is the inability of the kidneys to filter metabolic wastes (creatinine and 
blood urea nitrogen) from the blood and regulate the salt/water content of the body 
adequately.  Common causes include diabetes mellitus, high blood pressure, 
autoimmune disorders and other abnormalities (such as polycystic kidney disease and 
glomerulonephritis).    
The incidence and prevalence of end-stage renal disease (ESRD) are expected 
to grow throughout the world [261].  There are two forms of treatment for ESRD: 
dialysis and transplantation.  In the latter, a kidney from a living or brain-dead donor 
(cadaveric) is removed and implanted to the patient.  Known as the best form of 
treatment, the average waiting time for receiving a kidney transplant from a cadaveric 
donor is 7 years or more in Singapore.  It is understood that the transplantation rate is 
influenced by socio-economic, religious, and cultural attitudes [261].  As such, the 
more common treatment is dialysis, a process by which the patient’s blood is cleansed 
artificially so that metabolic wastes and excess fluids are removed from the body.  
Nephrologists recommend dialysis when the patient’s kidney failure is causing 
abnormal brain function, inflammation of the sac around the heart, high level of acid 
and potassium in the blood, and total body fluid overloaded, etc.   
There are two types of dialysis, namely haemodialysis (HD) and peritoneal 
dialysis (PD).   In the former, blood is removed from the body and pumped by a 
machine outside the body into a dialyser, which helps to filter metabolic wastes and 
then returns the purified blood to the patient.  Complications of HD include fever, 
infection, low blood pressure, abnormal heart rhythms, bleeding in the intestine and 
life-threatening allergic reactions.  In PD, a membrane that lines the abdomen and 
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covers the abdominal organs acts as the filter.  It creates a space within the abdomen, 
where fluid and waste products are drained. Complications of PD include 
inflammation of the abdominal cavity (peritonitis), bleeding, leakage of fluid, low 
level of albumin, constipation and hernias of the abdomen and groin.   
Compared to HD, PD is a more convenient dialysis as it can be performed at 
home, thus eliminating the need to travel to a dialysis centre.  There is mixed 
evidence suggesting that HD has a higher survival advantage over PD [262-267], and 
it is believed that survival differences vary substantially according to the underlying 
causes of ESRD instead [268].  Various techniques are used for PD.  In automated 
peritoneal dialysis (APD), a machine is needed to fill and drain patient’s abdomen.  
With continuous ambulatory peritoneal dialysis (CAPD), a patient does not require a 
machine and may even walk around with the dialysis solution in his abdomen.   
 
4.8.2 Aim 
The primary aim of this analysis was to enable a newly-diagnosed 36-year old 
Chinese female patient with diabetic ESRD to decide the mode of PD treatment, i.e., 
CAPD vs. APD.  She was recommended by her nephrologist to receive PD in view of 
her lifestyle, co-morbid conditions and financial status.  The incidence and prevalence 
of ESRD are well-known to be linked to the funding of dialysis [269].  Moreover, PD 
is better tolerated than HD, and she did not have recent abdominal wounds or surgery.  
Like the majority of new PD patients in Singapore, she was scheduled to dialyse 
regularly at a restructured hospital.  To manage her condition and lifestyle better, she 
also participated in a detailed and systematic PD training.    
The decision node was the use of a specific mode of dialysis (1. APD; 2. 
CAPD).  The chance nodes were occurrence of peritonitis and mortality.  PD 
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frequently results in peritonitis, an inflammation or infection of the abdominal cavity.  
This is usually caused by an infection gaining access through the drains placed in the 
abdominal cavity. Unless contamination persists, peritonitis usually does not progress 
and can be healed with proper treatment.  However, it might cause a lot of discomfort 
to the patient on dialysis and if not attended to properly, death may be the potential 
outcome.   
 
4.8.3 Data 
There were relevant local data concerning the occurrence of peritonitis among 
patients on CAPD and APD.  An on-going prospective observational study based on 
100 ESRD patients with diabetes (mean age: 63.1; gender: 64.3%; mean dialysis 
duration: 20.7 months) dialysed with APD or CAPD from 1 March 2001 to 31 July 
2006, was conducted.  It collected detailed information on patients’ demographics, 
albumin levels, comorbid conditions and development of peritonitis.   
 
4.8.4 Results & Decision 
Based on the recorded prospective data, the Bayesian Poisson regression 
model with prior Beta[1, 1] (3.22) showed that there was no significant difference in 
developing peritonitis among ESRD patients with DM between APD and CAPD, after 
adjusting for age, gender and conditions like IHD and cerebrovascular disease (Table 
4.24).  The exposure variable was time on PD. 
The patient’s probability of developing peritonitis with APD was 0.04 in 6 
months, 0.09 in 12 months and 0.18 in 24 months.  On the other hand, her probability 
of developing peritonitis was slightly higher with CAPD, i.e., 0.05 in 6 months, 0.11 
in 12 months and 0.21 in 24 months.  Gender was found to be the only significant 
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predictor.  As expected, there was no significant difference in developing peritonitis at 
different time frames between APD and CAPD.  
The patient’s influence diagram is depicted in Figure 4.10.  Her utilities were 
determined from an exponential function (risk tolerance: 52,200).  The most 
favourable and unfavourable outcome were free from peritonitis and occurrence of the 
complication in 2 years, respectively.  Computations show that she might prefer to 
dialyse with APD (expected utility: 0.48).   
 
4.8.5 Discussion 
Future decision analysis may involve information on mortality due to PD 
dialysis, especially for patients who are severely diseased and need to change the 
mode of dialysis or seriously in need of transplantation.  Based on published evidence, 
the survival rate of patients on dialysis was 90.6% at 1 year, 78.8% at 2 years, 62.2% 
at 4 years, and 40% at 8 years [266, 270].  However, the most relevant reference [264] 
suggested that diabetic patients on PD faced a 13.5% chance of death after 1 year, 
48% at 2 years, 66% at 3 years and 67% after 5 years.  Another article also found that 
diabetic patients’ chance of survival was lowered to 29% after 4 years [271].  
Unfortunately, there was no such confirmative and readily available evidence in 
Singapore. 
Reference also suggested that there could be an increase in the chance of 
survival should the patient switched to haemodiaylsis if her condition worsens [272].  
Kidney transplant is a life-saving alternative to dialysis.  It is expected that 90% of 
kidneys obtained from living donors are functioning properly 1 year after operation, 
and 3 to 5% of these kidneys stop functioning during each year that follows.  About 
70 to 90% of the kidneys from donors who has just died are functioning after 1 year, 
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and 5% to 8% stop functioning during each year that follows.  Some references 
showed that the survival rate at 2 years was as high as 95% [270].  Like some other 
countries, the main causes of death of ESRD patients in Singapore were 
cardiovascular disease and infection. 
From published records, about 58% of the total transplantation carried out in 
Singapore were cadaveric [272].  Kidney transplantation is a major operation where 
the donated kidneys is placed in the pelvis through an incision and is attached to the 
recipient’s blood vessels and bladder.  Rejection usually happen within 3 to 4 months 
after operation and the recipient must continue to consume immunodepressants 
throughout her life.  Compared to the general population, kidney transplant recipients 
are about 10 to 15 times more likely to develop cancer.  
The above results and discussion may form the basis for future studies, which 
may in turn help to formulate the medical guideline(s) concerning the treatment of 
end-stage renal failure. 
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Table 4.24: Non-informative Bayesian Poisson regression analysis on the 
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4.9 Treatment of Asthma Patients at Special Centre 
   4.9.1 Aim 
A 15-year old female acute asthma patient seen at a local hospital wanted to decide if 
she required special attention at the Emergency Department Treatment Centre 
(EDTC), a short-stay observation unit designed for serving patients who require more 
evaluation during an emergency visit.  The EDTC was opened in 2001 to ease the 
overcrowding problem at the hospital.   
The proposed analysis involved one decision node (admission to EDTC vs. 
admission to ordinary ward) and two chance nodes (unplanned admission in 24 hours 
vs. discharge, and unplanned readmission within 4 weeks vs. no relapse).  Although 
the EDTC promises to deliver more specialised and high-quality care, the patient was 
more familiar with the ordinary ward where she would receive treatment from her 
familiar clinician.  
 
4.9.2 Data  
The data for encoding the necessary probabilities for the decision problem 
included 248 patients seen at EDTC from January to December 2006 (Table 4.25).  
Only aggregate data were available as the study was not initially designed for medical 
research.  There were also other sketchy but relevant published evidences [273-277] 
useful for setting up the priors for the proposed Bayesian model (Table 4.25).   
 
4.9.3 Results & Decision 
Based on hospital record, a total of 779 asthmatic patients required admission 
during the study period.  Of these, 248 were admitted to EDTC.  The Bayesian model 
(3.36), with 100 burn-ins and 500 iterations thereafter, was employed to combine the 
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prior evidences for encoding the probability for 24-hour discharge from EDTC.  
Based on the following Bayesian equation, the combined prior evidence was then 
updated with the collected hospital data: 
 
 




where n is the total number of patients admitted to the hospital’s EDTC during the 
study, y the number of patients discharged within 24 hours and a and b are the beta 
parameters derived from the combination of prior published evidences.  The same 
scheme works for generating the probability for readmission within 4 weeks.   In the 
case of discharge within 24 hours at the common ward there was only one set of 
evidence available.  As such, the figures were updated directly with the hospital’s 
record with (4.3). 
The results are shown in Table 4.26.  Given the patients’ preferences and 
utilities, she should choose to be transferred to the common ward as her expected 
utility was 1.14.  This was higher than that with EDTC at 0.86.  As described in 
Figure 4.11, the patient had more preferences for the common ward. 
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4.10 Polychemotherapy for Treating Early Breast Cancer 
4.10.1 Background 
Breast cancer is notoriously known as the most common form of cancer among 
women.  The risk of breast cancer arises from a combination of genetic susceptibility 
and environmental factors, including old age, young age at puberty, family history, 
prolonged use of oral contraceptives or estrogen therapy, obesity after menopause, 
exposure to radiation, and presence of fibrocystic breast disease and certain genes 
(BRCA1 and BRCA2). 
In Singapore, about 55 per 100,000 Singaporean women were diagnosed with 
breast cancer from 1998 to 2002, and the incidence rates have increased by 3 times 
since 1968. The pattern of increase over time is also consistent across all ethnic 
groups. Interestingly, the age pattern for 1998-2002 suggests that the highest age-
specific incidence rate is occurring progressively later in life (35-60 years old) and 
54% of all cases occurred in women 50 years and above.  
However, fewer women actually die from the disease now, thanks to early 
detection and major advancements in chemotherapeutic drugs. Early breast cancer or 
carcinoma in situ (non-invasive cancer) is usually removed by surgery and 
chemotherapy (anti-cancer drugs) is used to prevent recurrence.  Currently, 
polychemotherapy (multiple cancer drugs) are at the forefront of therapy, and several 
estrogen-regulating drugs have been developed as well.  New drugs are also under 
development, including those derived from natural products.  
 
4.10.2 Aim 
While the potential for a new drug is thrilling, it may be more practical to 
work with what is currently available.  It is, therefore, timely to compare the 
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effectiveness of prolonged polychemotherapy (6-24 months) and the shorter treatment 
(3-6 months) in terms of recurrence and mortality.  The encoded probabilities would 
help a 52 year-old obese woman, who was trained as a clinician, to decide if she 
needed prolonged polychemotherapy after surgery.  She was diagnosed to have early 
breast cancer and the tumour was less than 2 cm in diameter and had not invaded the 
surrounding tissue or spread to other parts of the body before surgery.  The decision 
problem was simple in nature, involving 1 decision node (prolonged 
polychemotherapy vs. short polychemotherapy) and 2 chance nodes, namely first 
recurrence and all-cause mortality. 
 
4.10.3 Data 
A thorough literature search through MEDLINE and the Cochrane Library up 
to February 2007 [278-280] identified 11 published studies comparing the 
effectiveness of prolonged polychemotherapy and the shorter treatment (Table 4.27).   
Bayesian model (3.36-3.37) was applied to encode the probabilities for first 
recurrence and mortality for the two treatments.   For the analysis of recurrence, the 
prior for overall or combined proportions of prolonged polychemotherapy and shorter 
polychemotherapy were Beta[5, 5] and Beta[5, 4], respectively.  This reflected the 
belief that prolonged polychemotherapy was slightly more effective.  The prior for 
between-study precision was fixed as Exponential[1] for both cases. The burn-ins and 
updates of the MCMC procedure were set at 500 and 1,000, respectively.  On the 
other hand, the probability of death was expected to be 0.7 if the patient suffered 
relapse.   This was substantially reduced to 0.1 if the patient did not relapse.  The data 
was entered into Stata 9.0 for analysis. 
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4.10.4 Decision 
The published data are shown in Table 4.28.  Prolonged chemotherapy is 
shown to be more effective in reducing recurrence than the shorter treatment.  Due to 
the small number of studies involved, the 95% P.I.s are fairly wide.   
Given her preferences and utilities the breast cancer patient should choose the 
shorter treatment (Figure 4.12).  The expected utility with prolonged chemotherapy 
was 0.47, which is lower than that of the shorter treatment at 0.52. 
While prolonged chemotherapy is more effective, it is less tolerant than the 
shorter treatment. This was reflected in the patients’ self-assigned utilities.  This 
example also illustrates the fact that a “better” treatment from the clinician’s point of 
view may not necessarily provides patients with the highest satisfaction. 
 
4.10.5 Discussion 
Breast cancer is not a disease of modern society as it was recognised by the 
ancient Egyptians as early as 1600 BC. Unfortunately, many centuries have passed 
and still no acceptable cure has been discovered. Worst of all, breast cancer is now 
affecting as many as one in eight women during their lifetime. Not only is the 
diagnosis of breast cancer frightening, the therapies used to treat the disease are just 
as daunting—such as surgery or chemotherapy. 
As such, clinicians are also looking for ways to make current drugs more 
effective and less toxic. Patients with early stage breast cancer exhibit promising 
prognoses to polychemotherapy and have also shown to significantly reduce clinical 
recurrence among women of all age groups.  The above analyses, however, suggest no 
significant differences between prolonged polychemotherapy and shorter 
polychemotherapy in terms of recurrence and mortality.  
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Even though the exact cause of breast cancer has not been fully identified, 
diagnosis and treatment have improved dramatically in recent years, and many 
clinicians believe a cure is within reach.  
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Table 4.27: Published evidences concerning first recurrence with polychemotherapy  
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CHAPTER 5 
DISCUSSION & CONCLUSION 
 
 
In medicine and in all other health sciences, there is a constant search for the “best” 
evidence [281].  The Bayesian models developed and applied in this dissertation serve to 
fulfil this aim.  In fact, the application of the proposed Bayesian probability-encoding 
models will bring considerable impact on the way EBM and medical science is practiced.   
The contribution of Bayesian ideas is not limited to the solving of a specific medical 
decision problem.  The Bayesian framework changes our views about current medical 
paradigm, scientific methods, inductive logic, nature of medical evidence, systematic 
review of medical evidences and the roles of patients, clinicians and EBM practitioners.   
 The following discussion revolves around a common theme, that is, what would 
clinical practice and EBM become if the Bayesian framework is adopted.  The discussion 
will also touch on the future directions of methodological research, in view of the latest 
developments in Bayesian statistics and computer-intensive techniques.  As mentioned in 
Chapter 1, EBM—fast becoming an encompassing field that integrates clinical practice 
with decision analysis—will serve as a good testing ground for new developments in 
decision analysis.  
 
5.1 The Scope of Medical Practice  
Modern medicine, better known as scientific medicine, western medicine or biomedicine, 
is based upon whatever its practitioners regard as “scientific knowledge”, which is 
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usually loosely defined as that which is objective, demonstrable, measurable, observable, 
reproducible, or technologically advanced.  While the concept of “what is scientific” 
changes over time and varies across the globe, scientific medicine adopts a more or less 
single-minded, materialistic approach which values accurate observations and 
unambiguous measurements.  It reduces all bodily functions and dysfunctions to 
mechanical and biochemical reactions, knowable material causes and structural flaws that 
can be studied in isolation from the sufferers.  Clinicians’ judgements and decisions are 
the results of such unambiguous, if not entirely flawless, rational deductions and 
empirical investigations.  
Such attitude has brought numerous achievements to mankind.  As long as the 
patient’s disease can be examined and accommodated within the boundary of current 
“scientific knowledge”, it has a good chance of providing a successful cure or at least 
some alleviation.  If it does not, scientific medicine may have little to offer and may even 
cause more harm to the sufferers.  The merits and demerits of contemporary medicine can 
be clearly demonstrated in the different remedial demands of acute and chronic illnesses.  
Scientific medicine is, on the whole, more efficient in treating acute illnesses.  But it 
offers less successful solutions to the chronic diseases (e.g., renal failure, diabetes, 
osteoarthritis, geriatric-related illnesses, immunological disorders, pituitary insufficiency 
and allergy) which require not only therapeutic interventions, but also long-term medical 
care for addressing the whole of patient’s prognosis and quality of life.  What are 
characterised and believed as effective cures may save or transform the lives of 
individuals, but their effects on long-term mortality and quality of life are less impressive 
and there may be devastating side-effects in using them.  Responsible surgeons are also 
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aware that many operations, once considered vital and valuable, turn out to be unhelpful, 
redundant or even detrimental to lives, let alone improving the patients’ general well-
being. Uncertainties pervade all aspects of healthcare, despite the awesome rapid 
advancement of medical science. 
Contemporary medical practice, at first glance, is moving from triumphs to 
triumphs.  It is now possible to examine at every cell in the body and to operate 
instruments by remote control, often far inside the body, perhaps on a heart or blood 
vessel.  Yet, there are, paradoxically, also times of growing dissatisfaction and the 
common public complaints are largely related to the fact that it has become highly 
institutionalised, excessively technological, unaffordable, alien and impersonal.  
Unintelligible jargon, expensive modus operandi, unfriendly medical hardware and 
ineffective communication with the clinicians make it more forbidden to the paying 
patients. Most medical decisions concerning patient care are usually made on behalf by 
the clinicians as the details involved are highly technical and this leaves little room for 
participation by the sufferers themselves. Somehow the more scientific medicine 
achieves, the less it satisfies. We are not only living in times preoccupied by the fear of 
unknown fatal diseases but also in fear of medical treatments.  It is fair to say that 
scientific medicine has many proven means of saving and improving life and these are 
constantly increasing in number and efficacy, given the current technological 
advancement.  However, clinicians must also accept the fact that, while their diagnosis 
and therapeutic methods are successful in general, they do not always provide answers in 
individual cases.     
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Contemporary medicine prides itself on being “scientific”, but is necessarily 
based on the availability of evidence, and clinicians’ judgement, interventionist skills and 
healing expertise.  This immediately creates a number of paradoxes.  Can personal and 
clinical experience be “scientific”?  What is the relationship between medicine and 
science and how does it influence the way medicine should be developed?  More 
specifically, why do clinicians vary so much in their practice?  The differences in their 
judgements and decisions—both about the general guidelines to adopt and what specific 
therapeutic actions to be taken in the course of treatment—are critical to their patients.  
One may question whether standardised guidelines of medical care, which breeds 
consistency among clinicians, can be established in principle, and whether strict 
adherence to such guidelines, if enforced, would ensure successful outcomes.  These 
issues offer much food for thought for the medical community to chew over.   
The root of these questions may be traced to the way medical decisions are made 
and our current understanding of the scope of scientific knowledge and evidence.  
Clinicians make numerous decisions related to their practice on a daily basis and these 
directly or indirectly impact the health and welfare of their patients.  The validity of their 
actions is based on evidential merits.  Evidence is not a decision itself; however, good 
evidence is required for making sound decisions.   
Such notion may bring considerable impact on the way EBM is practiced.  
Founded upon the principle that evidence should guide clinical practice, EBM has 
brought about numerous illuminating contributions to medical practice.  Common 
arguments in support of EBM include improvement in clinicians’ knowledge, better 
communication between clinicians and patients, and more effective use of scarce 
5. Discussion & Conclusion 
 208 
resources. Abandoning the use of uncritically and unsystematically evaluated clinical 
research, EBM also provides a useful framework for gathering, evaluating and 
disseminating medical evidence. However, it is somewhat surprise to learn that  EBM has 
not developed a new concept of evidence [28] despite making tremendous contributions 
to medical practice.  We need to have a broad vision of evidence that embraces the 
inherent complexity of EBM.  It is, therefore, suggested in this dissertation that evidence 
may refer to any explicit warranted reference for supporting or rejecting a hypothesis, 
claim or belief.  Evidence may be tangible or intangible and could exist in both objective 
and subjective states. With this in mind, the established definition that “evidence is a fact 
or datum which is used, or could be used, in making a decision or judgement or in 
solving a problem” [25] is somewhat limited and should be duly modified.   
The conventional notion of empirical observations only skims the surface of 
evidence.  Through the better understanding of medical evidence and the illustration of 
the Bayesian methodology, in which subjective opinions could be combined with 
objective evidence, this dissertation aims to provide an alternative approach to the current 
practice of EBM.  The application of various specific Bayesian models in decision 
analysis, as illustrated in the case studies in Chapter 4, is a small step towards the goal.   
However, a series of epistemological questions remains and there are many gaps 
of knowledge need to be filled urgently.  This requires a proper dissection of the unique 
nature of Bayesian EBM.   
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5.2 Bayesian Evidence-Based Medicine  
The application of Bayesian thinking in medical decision analysis and EBM is a key to 
unlock many of the questions outlined above.  It emphasises the working with “best” 
evidence, although the ideal concept of “best” poses a formidable challenge to the minds 
of most EBM practitioners. The traditional EBM practice suggests that the best evidence 
should be sought from confirmed scientific knowledge, laboratory research, randomised 
controlled clinical trials and large-scale observational studies.  It places opinions of 
respected authorities, based mainly on experience, or reports of expert committees, way 
below evidence obtained from “objective” and “scientific” studies.   
In reality, however, the scope of EBM is wider than what is perceived.  Results 
from case reports, quasi-experiments, qualitative research and descriptive and analytical 
studies concerning screening, diagnosis or prognosis have also contributed immensely to 
our knowledge.  This effectively points out that we have not fully understood the scope of 
scientific knowledge.  As such, the most fundamental issue concerning EBM is none but 
the reconstruction of a complete and unambiguous knowledge of methodology and 
evidence.  This, however, hinges on our understanding of what “science” is and should be. 
Science at large has been immensely influenced, if not completely dominated, by 
the empiricist school of thought—an approach that is primarily concerned with 
observable facts and eschew moral or metaphysical speculations.  Such stance qualifies 
observable phenomena as the only source of knowledge and clinicians are consistently 
reminded to respect observed evidence and warrantable factual records unconditionally.  
Empiricists use the criterion of verifiability to distinguish between medical conjectures, 
theories and decisions.  In the strictest sense, however, such criterion is not verifiable in 
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itself and with this spirit, the proposed Bayesian framework justifies that observations 
may not constitute the only source of knowledge.  Consequently, the empiricists’ position 
may not be tenable.  The Bayesian framework maintains that clinicians’ empirical 
knowledge must be organised according to a prior principle and the subjective nature of 
observation must not be neglected.  In essence, observation depends upon the clinician’s 
preconceptions. This offers an alternative and supplementary approach in knowledge 
acquisition and our picture of the world reflects both a priori organisation of perceptions, 
rational deductions, beliefs, opinions, past knowledge and observed evidence.   
Undoubtedly, the empiricist approach has served the scientific community well 
and will continue to do so.  It provides us with an objective framework for which 
clinicians formulate their decisions and defend their chosen actions.  However, one must 
begin to recognise the underlying limitations of this approach.  Contingent on the 
availability of observable evidence, it is often difficult, if not impossible, to formulate 
sound decision(s) in real practice.  In short, our current understanding of science, very 
much limited by the empiricists’ definitions, is far from perfect.  We need to broaden its 
scope. 
This dissertation offers an alternative approach to EBM by revising the current 
concept of medical evidence. Defining evidence as “an explicit warranted reference given 
in an appropriate and specific context for supporting or rejecting a hypothesis, claim or 
belief”, it encompasses any facts, data or information, whether weak or solid, obtained 
through experience, published results and observational and experimental research.  A 
reference qualifies as evidence so long as it is relevant either to the understanding of the 
problem or to the clinical decisions (diagnostic or therapeutic) made about the case.  In 
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Bayesian EBM, the “best” evidence should be combined with all components of decision 
making, such as expert opinion, knowledge from clinical studies, and patients’ 
preferences and values.   A primary factor affecting the decision-making process is prior 
clinical experience, self-evident intuition, published evidence and testimony from fellow 
clinicians.  These in turn form the basis for formulating expert opinion and generating 
objective evidence from research studies.  As such, the next burning question facing 
EBM practitioners is how to allow subjective expert opinions be combined with objective 
evidence. 
The proposed Bayesian framework offers a wide range of models for probability 
encoding and data analysis useful for medical decision analysis.  It unambiguously 
asserts that one always forms an incomplete picture of a phenomenon with his subjective 
horizon of understanding (prior).  Through observed evidence, the EBM practitioner 
develops more insights to the phenomenon encountered and the final interpretation is 
achieved with the fusing of the subjective and objective knowledge horizons. The 
posterior understanding incorporates the subject’s pre-knowledge and his revised 
understanding of the phenomenon.  During the process, the EBM practitioner tries to 
better understand the phenomenon and correct his “prejudice” caused by his prior beliefs 
and opinions.     
Through the Bayesian framework the synergism between subjective and objective 
evidence come into play, with the EBM practitioners and subject experts actively giving 
valid testimony and searching for relevant evidence useful for decision making. Bayesian 
EBM fulfils the primary and noble objective of the early advocates of EBM by making 
use of the most complete evidence available on diagnosis and treatment.    
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Unlike the conventional scientific approach popularised by the empiricists, 
Bayesian EBM recognises the special contributions of expert opinions in all aspects of 
data analysis. In fact, expert opinions may be viewed as the first-line evidence in decision 
making.  EBM practitioners should give utmost care to such opinions, recognising that 
instincts and independent thinking are invaluable assets of an experienced clinician.  
When presented with a decision problem, the subject expert should illustrate his unique 
prior understanding, which may be based on experience or previous evidence collected 
for a similar purpose.   
This dissertation supports Bayesian EBM not only because of its philosophical 
and pedagogical validity but also its appealing features of data analysis.  The Bayes’ 
Theorem [26] shows how inverse probability could be used to encode probability of 
antecedent events from the occurrence of the consequent event.  Because of this, 
Bayesian models are “optimal” in terms of post-data evaluation, given the evidence that 
actually occurred.  As a consequence, Bayesian models usually outperform the 
conventional quantitative models in the post-data setting.  
In particular, several of the specific models introduced in this dissertation are 
useful for evidential review and literature critique, which is the core business of EBM.  
These models may be applied for analysing existing individual data obtained from 
experimental or observational studies (historical as well as prospective), or for shedding 
light on the obscure meanings of aggregate published data.   
Like all academic disciplines, Bayesian EBM seeks to understand the unknown 
horizon and attempts to make predictions about it, in the hope of controlling the 
uncertainties and providing useful hints for decision making.  Unknown quantity is a 
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generic term referring to any value not known to the investigator in this instance.  The 
ideas that form the basis of the Bayesian approach are as follows: 
 
 
 since one is uncertain about the “true” value of the unknown quantities 
(commonly known as parameters in the statistical literature) one should consider 
them as random variables 
 the opinion-based priors, mainly elicited from widely-regarded experts, are 
subjective in nature  
 on the other hand, priors based on published evidence or recorded information are 
essentially objective 
 both sets of priors effectively measure how plausible the EBM practitioner 
considers the unknown values should be before observing/analysing the objective 
evidence 
 the EBM practitioner revises his beliefs, opinions, pre-understanding, prior 
knowledge after getting the evidences through the Bayesian models and this gives 
rise to a posterior distribution 
 the posterior forms the basis for evidentiary analysis and probability encoding for 
decision making 
 
Allowing the unknown parameters to be random quantities, one makes probabilistic 
statements about them conditional on the sample and prior evidence.  This is a very 
unique and attractive feature of Bayesian analysis, where decision making utilises 
probability statements as the basis for inference.  In fact, all probability statements about 
5. Discussion & Conclusion 
 214 
the unknown quantities should be more appropriately interpreted as “degree of belief”.  
This contrasts significantly with the conventional approach in data analysis where 
inference probabilities are solely generated from observed data that believed to have 
occurred for the fixed parameters.   
The Bayesian framework coheres with the current notion of medical care, with 
provision of sound clinical decisions useful for patient healing as the primary concern.  
Medicine may be a body of scientific knowledge, but healing is a personal skill.  The 
term “healer” has implied many different meanings to cultures across the world 
throughout history.  In modern day, clinicians of different disciplines are responsible for 
the physical care of the ill or diseased.  Although their precise roles vary in part due to 
their type of training, they are responsible for the physical and spiritual care of the 
patients.  As such, healing is more an art than a science.  A good healer should 
demonstrate knowledge and competency about the sufferers’ conditions.  All decisions 
concerning healing require personal skills and the quality of decisions depend largely on 
the immense experience possessed by the clinicians. 
One philosophical question that puzzles EBM practitioners remains.  It is whether 
one can attain knowledge through the proposed Bayesian framework and whether it 
corresponds to scientific truth.  This dissertation demonstrates that knowledge production 
becomes possible only when evidence is interpreted by the subject.  It remains non-
informative if it is not interpreted.  The Bayesian framework also suggests that it is 
“legitimate” for the EBM practitioner to possess a pre-understanding horizon and allows 
the prior evidence be fused with objective data.  The differences in opinion among 
clinicians may be attributed to the inadequacy in current biomedical knowledge and 
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patients’ peculiar conditions, or simply due to their personal preferences and opinions 
that govern their judgement.  However, the end product (posterior) should be a richer and 
deeper understanding of the problem investigated, with meanings of the evidence 
adequately elucidated. This in turn helps the subject to become a knower. 
Following the above argument, scientific medicine is a conjectural discipline. 
Such acknowledgement has a profound influence on how decisions should be made in 
clinical practice.  First, recorded data is never the sole basis of medical decision-making.  
Second, clinicians should not view diseases merely as biological dysfunction and 
patients’ personal preconceptions must be incorporated in the decision-making process.  
Third, to generalise the above assertions, there is no pure objective evidence in practice.  
While many clinicians proudly claim that their decisions are based on scientific merits, 
the much-publicised variations in medical practice may nullify their claim. Realistically, 
all individuals experience different knowledge acquisition processes and their 
preconceptions would, to a large extent, influence how they interpret observable evidence.  
Depending on personal background and training, a clinician may rely on experience, 
intuition and subjective judgement alone, or may enhance these peculiar attributes with 
objective measures for identifying the decision(s) that would lead to the most desired 
results for his patients.  
 While the Bayesian framework acknowledges that knowledge may be developed 
from subjective means (priors involving expert opinions), there are categorical 
differences between knowledge and opinions, which merely indicates an attitude or belief 
towards a phenomenon. Knowledge implies having evidential justification.  It is through 
the revision process, as succinctly described by the Bayesian framework, that knowledge 
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evolves from opinions.  Moreover, knowledge possesses a certain property which opinion 
lacks; that is, the property of generalisability.  However, the attainment of knowledge 
helps to reshape or strengthen one’s expert opinions, which in turn gives rise to warranted 
knowledge.  In the event where published evidence is used as a prior, the Bayesian 
framework reflects that the advance of knowledge (posterior) consists in the modification 
of earlier knowledge (prior).  In a nutshell, the proposed Bayesian framework coheres 
with the way we learn. 
So what are the implications if the Bayesian framework is correct? How does it 
challenge the traditional views of scientific theories?  Traditionally, there are two major 
schools of thought with differing views concerning the nature of truth.  First, the realists 
maintain that truth is an agreement between theory and evidence.  The role of science is 
to identify and discover the entities that surround us and establish their relationships to 
one another.   A theory is deemed “true” when the entities it refers to and the relationship 
it describes correspond to real entities that exist in the world and their real relationships.  
The instrumentalists, on the other hand, believe that a theory is just an abstraction and 
representation of truth and it is meaningless to ask whether it corresponds to reality.  
What really matters is how much its predictions agree with observations.   
Like instrumentalism and realism, the Bayesian framework maintains that truth is 
important to us when we interpret evidence.  However, it argues that the realists and 
instrumentalists are fundamentally wrong in holding the belief that one can somehow 
observe the real world independently of their beliefs and theories.  In reality, our beliefs 
and pre-understanding often shape the way we interpret and gather evidence.  This 
implies that observations are value-laden and there is no absolute truth.  Different people 
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may interpret evidence differently.  More importantly, truth is relative and ever-changing 
and is open to more than one interpretation.  That does not mean there is no truth.  Rather, 
it does not exist independently of the perception of the researchers who try to understand 
it through evidentiary analysis.   
This dissertation asserts that “true interpretation” is value-laden, relative, transient 
and ever-changing, as it does not exist independently of the perception of the EBM 
practitioner.  Under the Bayesian framework, the true interpretation is the one that best 
coheres with both the prior evidence and objective evidence.  Truth may come to light 
from the union of these horizons, albeit an uncertain or a transitional one.  
Lastly, this dissertation does not intend to suggest that all problems concerning 
medical decision analysis are solved with the acceptance of the Bayesian framework.  To 
provide sound solutions to medical decision problems, clinicians must have solid 
information about the consequences of different choices and must be able to process that 
information accurately [282].  Unfortunately, many clinicians are unable to make 
consistent decisions with the use of medical evidence.  Previous research has also found 
that clinicians asked to consider an individual patient generally make different decisions 
than those asked to consider a group of comparable patients [283].  In fact, a recent 
article even suggests that trained statisticians may make fallacious judgements about 
evidence [284].    
However, one should not be over-pessimistic about the future of EBM.  EBM 
practitioners should take up the challenge to look for better evidence in support of their 
practice and communicate their ideas with their fellow clinicians to upgrade the current 
medical practice.  
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5.3 The Future Development of EBM  
A competent EBM practitioner should be an informed knower, an effective 
communicator with his patients and fellow clinicians, a devoted and passionate healer, a 
diligent evidence-seeker, an avid and adroit user of evidence, an alert critique and analyst, 
an insightful and rational decision-maker, a brave explorer, an imaginative methodologist, 
and a keen learner ready to embrace state-of-the-art quantitative techniques in his practice.  
An immediate implication of adopting the Bayesian framework to EBM practice is that 
practitioners need to upgrade themselves constantly.  An EBM practitioner must not only 
be competent in his field of specialisation and applications, but also able to guide his 
chosen experts to reveal their opinions useful for decision making.  With such valuable 
attributes, EBM investigators will be able to apply the “best” evidence available and 
practice in a setting where the conventional framework does not permit.  Recognising the 
importance and usefulness of incorporating priors in decision analysis, Bayesian EBM 
encourages practitioners to be more proactive in seeking evidential support from fellow 
clinicians.  Through more collaboration, EBM practitioners with different skills and 
expertise will be available for co-operation and discussion. 
 
5.3.1 Broaden Sources of Evidence 
In future, EBM will rely on an increasingly complex surveillance of evidence.  It 
will integrate elements from a much broader perspective.  The pragmatic benefits of 
integrating results from other health-related fields and complimentary and alternative 
medicine (nutrition, medical herbalism, Chinese traditional medicine, chiropractic 
therapy, homeopathy, osteopathy with naturopathy, etc.) is readily seen.  Acupuncture 
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has now been recognised by scientific medicine as a safer alternative to treat acute back 
sprain and conventional anaesthesia for frail patients to undergo the trauma of minor 
surgery.  A large number of studies involving human subjects and animals have also 
demonstrated that green tea polyphenols possess cardioprotective, neuroprotective and 
antimicrobial properties [285-290], provide protection against untraviolet light-induced 
DNA damage, ageing, obesity and dental caries [291-293], and may even help to improve 
the effectiveness of chemotherapy in treating cancers as a synergistic agent.  In order to 
identify the “best” evidence, EBM practitioners need to consider more sources of 
evidence. 
Following a similar line of argument, clinical case reports will play a more 
important role in the future of Bayesian EBM.  Clinical experience—the first and 
foremost source of medical expert opinions—depends heavily on the observation of 
clinical case reports.  Long been recognised as the “special cases that advance the 
knowledge, research and practice of medicine” [294], case reports have been familiar 
elements of medical journals.  Unlike extensive research such as randomised controlled 
trial, cohort study and case-control study, case reports published in medical journals, in 
one form or another, usually comprise much fewer subjects.  Although the results are not 
generalisable, they are the only source of evidence about rare diseases.  Where else can a 
clinician turn to for guidance and inspiration while treating such unusual and unfamiliar 
diseases?  There are no existing guidelines which the clinicians may follow.  Case reports, 
however limited, may also help EBM practitioners to develop hypotheses for further 
studies.  This also means that case reports may serve to formulate the objective priors for 
Bayesian analyses.  Therefore, case reports should form an integral part of a 
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comprehensive database together with evidences generated from full-scale research 
studies. 
Being able to draw on more than one system of knowledge means that EBM 
practitioners are exposed to more useful and relevant evidence for identifying alternatives 
for medical decision making.  In addition, it also enriches the knowledge base of EBM 
practitioners.  Undoubtedly, this offers more alternative treating plans for patients in the 
future. 
In fact, patients will become a more integrated part of decision making.  
Disadvantaged patients, like the rest of the healthy citizens and as equals in their 
humanity, have their claim to engage in their care.  EBM will be viewed as “medicine 
with a human face”, making a place for itself somewhere between bedside clinical work 
with the patient and decision making [295].  Favoured by health policy-makers [296], 
EBM decisions will be increasingly accountable in courts of law [297-298].  
 
5.3.2 Power Priors 
Being evidence-based, EBM’s success will be evaluable and critically evaluated.   
This in turn propels continual methodological advancement.  To excel in his endeavours, 
a methodologist must continue to sharpen and upgrade his analytical tools.  One expects 
to witness more exciting and ground-breaking activities to take place in the applications 
and development of Bayesian methodology in the near future.   
Recognising that prior elicitation plays a crucial role in Bayesian analysis, the 
power prior model [299-300] enables analysts to construct informative prior based on 
historical data.  It takes the following general form: 
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g(α | evidence, a0) ∝ h(α) × 0
a




where h(α) is the initial prior for α before observing historical evidences.  The parameter 
a0, usually ranges from 0 to 1, serves to weight the historical evidences and therefore 
controls the heaviness of the tail of the prior for α.  By setting a0=1, one suggests that the 
historical evidences are crucial in determining the current evidences and the model (5.1) 
corresponds to the posterior distribution of α from previous studies.  If a0=0, then (5.1) 
does not depend on historical evidences.   The model may be completed by specifying a 
prior for a0, which usually assumes a beta distribution or a truncated normal or gamma 
distribution.  Since its development, several attempts were made to facilitate relational 
analysis based on historical evidences.  These include the applications in generalised 
linear mixed model, logistic regression and survival analysis [101].   
 
5.3.3 Beta Regression 
A more recent methodological development which offers good opportunity for 
path-breaking discoveries lies with the application of beta distribution as the likelihood 
for observed evidences.  Beta distribution, well-known for its versatility as it can model 
data of all shapes, has a rather unjustifiable limited use in contemporary conventional and 
Bayesian analyses.  As described in Chapter 3, most of the Bayesian models make use of 
beta distribution as a default conjugate pdf.  As a bounded distribution, however, it has 
many potential applications in medical decision analysis. Many medical outcomes are 
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bounded in nature (proportions, percentages, etc.), so it may be inappropriate to consider 
unbounded distributions as a close approximation.  In fact, even time to event data are 
bounded as a life cannot go on indefinitely.     
Sadly, beta distribution is only beginning to gain popularity among conventional 
statisticians in recent years.  At its infant stage, most statisticians focus on the application 
of standard beta distributions (0≤y≤1; a, b>0) [301-302].  However, this dissertation 
advocates the use of the more general 4-parameter beta distribution for handling bounded 
outcome (y) via a relational model [303]: 
 















where a and b are shape parameters, c and d the bounds of y (location parameters), and 
B(a, b) the beta function.  The mean and variance of the distribution are E[Y] = 
c+(d−c)a/(a+b) and V[Y] = (d−c)2ab/[(a+b)2(a+b+1)] = (E[Y]−c)(d−E[Y])/(a+b+1), 
respectively.  Note that the variance is a function of the mean and a dispersion parameter 
(a+b).  With the standard form (i.e., c=0, d=1) as its special case, the proposed 
distribution is extremely flexible as it allows y be bounded on any interval.  It is 
applicable for modelling all bounded outcomes, with proportion as its special case.   
To estimate the effects of predictors on y, one specifies the following link 
function:   
 
 







     
(5.3) 
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where β is a vector of unknown parameters and x the observations of the predictors.  The 
dispersion is φ = α'ze  and x and z, may be distinct.  The formulation offers a direct 
interpretation of the predictors’ effects upon E[Y] and dispersion.  As readily seen, one 
advantage with the proposed model is that it handles dispersion explicitly. Following the 
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For a fixed E[Y], a large dispersion results in a small V[Y]. After some algebraic 





































































where Γ(•) is gamma function. Following conventional wisdom, analysts would estimate 
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analysts must identify the appropriate priors for the parameters in analysis.  Though 
daunting, this promises to be an exciting field for exploration in methodological research.  
Other bounded distributions [304] may also be considered.    
 
5.3.4 Generalised Linear Latent and Mixed Model 
Another potential area of research in probability encoding with advanced 
statistical techniques lies with the enhancement of the hugely popular generalised linear 
latent and mixed model (GLLAMM) [305-309].  As a class of multilevel latent variable 
models for outcomes of mixed type, GLLAMM (www.gllamm.org) seeks to unify all 
multivariate statistical models, which include GLM [91], survival analysis [97], 
hierarchical models [107], latent class analysis [310] and structural equation models 
[311], etc.   
The GLLAMM is specified with: 
 
 the conditional expectation(s) of the outcome given the latent and observed 
covariates 
 structural equations for the latent variables on covariates 
 the distribution of the latent variables  
 
As in the Bayesian models for synthesising evidences from various sources, GLLAMM 
includes latent or unobserved variables that are interpreted as random effects.  Moreover, 
the latent variables can very at different levels.  The current version of GLLAMM is run 
with Stata’s maximum likelihood commands, augmented with the adaptive quadrature. 
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One may view the bounded regression model with beta distribution (5.6), 
discussed within the context of GLM, as a special case of GLLAMM.  It will also be a 
great achievement if a Bayesian version of GLLAMM is developed. 
 
5.3.5 Bayesian Belief Network 
The idea of applying networks to represent probabilistic information was 
conceived in the 1960s [312] and evolved rapidly in 1980s, thanks largely to the 
advances derived from the seminal works of Pearl (1986, 1988, 1995) [313-315].  The 
Bayesian belief networks (BBN) have developed at the interface between statistics, 
artificial intelligence and expert systems.   
A BNN consists of a network of nodes connected by direct links, with a 
probability function attached to each node [20, 316], which represents a variable.  Each 
node is in turn made up of states, or a set of probable values for each variable.  Beliefs 
are the probability that a variable will be in a certain state based on the addition of 
evidence in a current situation.  Supported by the Bayes’ rule, every node also has a 
conditional probability table associated with it.  The nodes are connected to show 
causality with an arrow indicating the direction of influence.  As such, BNNs are 
graphical models that encode probabilistic relationships among variables of interest 
[317].   
The BNNs are extremely useful when the information is vague, incomplete, 
conflicting and uncertain.  For example, the consulting experts for a particular medical 
decision problem may be uncertain about his knowledge.  By providing a structured 
combination of diverse lines of evidences, BNNs are able to address many real-life 
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medical decision problems and serve as decision-support tools helpful for combining 
expert knowledge with available empirical data [318].  It is now possible for both the 
structure and parameters of a BNN be learnt directly from a data set, and for this reason 
BNNs are being increasingly applied in a wide variety of medical domains where 
automated reasoning is required.  The most popular expert system using BNN in 
pathology is PATHFINDER [319].  A good introduction to BNN and a brief history of its 
development is found in reference [320].   
From the statistical point of view, BNNs are indispensable tools for dealing with 
high dimensional data problems as they allow a reduction in the complexity of the 
phenomenon under study by representing joint relationships between a set of variables 
through conditional relationships.  Besides applying for making decisions, statisticians 
have also found another area of application in BNN [321-322], thanks to its unique 
hierarchical ordering structure.  It is now possible to develop an automated data 
imputation method whose main goal is to preserve as much as possible the joint 
distribution specified in the BNN.  This may provide great help to the data missing 
problems which pervade most EBM analyses.   Most data imputation techniques are 
satisfactory only in the univariate scenario, but BNNs are able to preserve multivariate 
statistical relationships and logical constraints in the data (logical consistency) 





5. Discussion & Conclusion 
 227 
5.3.6 Data Mining 
More recently, an alternative approach to statistics in constructing predictive 
models useful for probability encoding have been rapidly developed.  The emerging field 
of data mining is a blend of statistics, artificial intelligence and database research [323].  
To be specific, data mining is a technology that blends conventional data analysis 
methods with sophisticated algorithms for processing large volumes of data.  It has also 
opened up new and exciting opportunities for data exploration and analysing old data in 
new ways.  In fact, BNNs are recognized as a data mining tool by the relevant community. 
The two disciplines of statistics and data mining have common aims in that both 
are concerned with discovering structure in data [324].  Most statisticians, however, are 
concerned with primary data analysis, that is, the data are collected with a particular 
question or a set of questions in mind [325].  On the other hand, data mining is entirely 
concerned with secondary data analysis, which aimed at finding unsuspected 
relationships that are of interest or value to the database owners [325].  Data mining 
techniques are able to cope with large data bases, which may contain contaminated 
information.  Moreover, superabundance of data might render all statistical tests 
meaningless as they will lead to a significant result even with a minute effect.  Very large 
data sets are unlikely to conform to the i.i.d assumption which underlies most statistical 
models.  It is much more likely that some regions of the data space will be sampled more 
heavily than others at different times.  Last but not least, very large data sets are likely to 
have been subjected to selection bias of various kinds [325] and may not conform to the 
statisticians’ idealised modelling assumptions.  The goal of applying data mining 
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techniques in biomedical research is to promote the optimum use of diverse data sets by 
enabling EBM researchers to make sound decisions.  
As a growing area of research interest, the intersection and interaction between 
data mining and statistics is inevitable.  Many useful data mining techniques are now 
available for dealing with the prediction problems [326-329], which are of paramount 
interest to medical decision analysts.  Practical guides on solving data analytic problems 
with both disciplines can be found in references [329-332].  The applications of data 
mining will help to enrich the field of statistics.   
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5.4 A Final Word 
The field of medicine has been significantly refined and restructured in recent years.  
Most of the new challenges are related to its direction and methodology.  With emphasis 
on evidential utilisation, EBM opens the gate to further refined and more complete 
medical research.  Accumulated from one generation to the next, the wealth of medical 
evidence contained in published journals will continue to grow with time.  The immediate 
task is then to make good use of the existing evidences and apply them in decision 
making, while setting sight on validating these evidences under more stringent conditions 
and seeking new ones in unexplored fields.  This sets the overall future direction for 
EBM practitioners. 
The next challenge is to break new grounds in methodology relevant to EBM 
practice.  As discussed earlier, methodology is required to establish how new knowledge 
may be gained.  A methodology is a system of principles and general ways of organising 
and structuring theoretical and practical activities.  Scientific progress is not limited to the 
accumulation of knowledge.  It is also a process of evolving new means of seeking and 
acquiring knowledge.  The Bayesian methodology, which captures the essence of 
knowledge acquisition [333], should therefore be seen as an invaluable asset to EBM.   
The objectivity of the conventional scientific approach has been obtained by 
disregarding any prior knowledge about the phenomenon under investigation.  However, 
some form of expert opinion can be quantified and applied in research.  It may also 
provide an angle in which one may adopt for interpreting the collected evidence.  While a 
clinician may remain as objective as possible, he is entitled to have a personal stance.  In 
fact, clinical instincts and independent thinking—developed through experience and 
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coloured by personal values—should be valued as the prized attributes of a capable 
clinical decision-maker.  It is also a waste of information if such expert opinions are 
ignored in analysis.  Therefore, a competent methodologist should recognise the 
importance of such opinions and utilise them to the fullest in analysis.  The current 
framework of EBM—devoted to downsize the malpractice of authoritarianism and 
consequently gives an utmost respect for evidence—places an extremely low value on 
expert opinion.  Moreover, Bayesian analyses may be “objectified” with the use of non-
informative priors.  The Bayesian framework is thus strongly advocated for EBM 
practice as a unified framework for actions in the face of uncertainty. 
Since its inception EBM seeks to revolutionise the organisation and structure to 
medical decisions.  While EBM does not replace clinical skills and experience, it 
organises, expands and completes them. It also sets the path for future medical practice 
and calls for a systematic and integrated approach in searching for the relevant medical 
evidence for improving our current diagnosis and treatment.  EBM reflects a probabilistic 
shift in today’s paradigm of medicine dealing with a myriad of uncertainties.  While 
some clinicians may consider EBM as evolutionary rather than revolutionary, no one can 
dispute the fact that it has brought about a new thinking in medicine.   
The Bayesian framework promises to provide a new dimension to this revolution.  
The new millennium has already witnessed a burst of research activities in applying 
Bayesian methods to solve medical problems [14, 102-103, 113, 334-338]. Illuminating 
the present and pointing to the future, Bayesian models will continue to excite EBM 
researchers in all areas of research and decision making. 
  231 
BIBLIOGRAPHY 
1. Howard, R.A. (1988).  Decision analysis: practice and promise.  Management Science, 
34, 679-695. 
 
2. Von Neumann, J., & Morgenstern, O. (1944). Theory of games and economic 
behaviour.  Princeton: Princeton University Press. 
 
3. Stirling, W.C. (2003). Satisficing games and decision making: with applications to 
engineering and computer science.  Cambridge: Cambridge University Press. 
 
4. LaValle I.H. (1978). Fundamentals of decision analysis. New York: Holt, Rinehart 
and Winston.  
 
5. Shachter, R.  (1986). Evaluating influence diagrams.  Operations Research, 34, 871-
882.  
 
6. Clement, R.T., & Reilly, T. (2001). Making hard decisions with DecisionTools.  
Australia: Duxbury.   
 
7. Sox, H.C., Blatt, M.A., Higgins, M.C., & Marton, K.I. (1990). Medical decision 
making.  Singapore: PG Publishing Pte Ltd. 
 
8. Tversky, A., & Kahneman, D. (1974).  Judgement under uncertainties: heuristics and 
biases.  Science, 185(4157), 1124-1131. 
 
9. Kahneman, D., & Tversky, A. (1979).  Prospect theory: an analysis of decision under 
risk. Econometrica, 47, 263-291. 
 
10. Tversky, A., & Kahneman, D. (1981).  The framing of decisions and the psychology 
of choice.  Science, 211(4481), 453-458. 
 
11. Von Winterfeldt, D., & Edwards, W. (1986).  Decision analysis and behavioural 
research.  Cambridge: Cambridge University Press. 
 
12. Hogarth, R. (1987).  Judgement and choice. New York: Wiley. 
 
13. Sackett, D.L., Rosenberg, W.M.C., Gray, J.A.M., Haynes, R.B., & Richardson, W.S. 
(1996).  Evidence based medicine: what is and what it isn’t.  British Medical Journal, 
312(7023), 71-72. 
 
14. Prevost, T.C., Abrams, K.R., & Jones, D.R. (2000). Hierarchical models in 
generalised synthesis of evidence: an example based on studies on breast cancer 
screening.  Statistics in Medicine, 19, 3359-3376. 
 
  232 
15. Paffenbarger, R.S., Hyde, R.T., Wing, A-L., & Hsieh, C-C. (1986).  Physical activity, 
all cause mortality, and longevity of college alumni.  New England Journal of 
Medicine, 314(10), 605-613. 
 
16. Lissner, L., Bengtsson, C., Björkelund, C., & Wedel, H. (1996). Physical activity 
levels and change in relation to longevity: a prospective study of Swedish women. 
American Journal of Epidemiology, 143(1), 54-62. 
 
17. Van Saase, J.L.C.M., Noteboom, W.M.P., & Vandenbroucke, J.P. (1990). Longevity 
of men capable of prolonged vigorous physical exercise: a 32 year follow up of 2259 
participants in the Dutch eleven cities ice skating tour.  British Medical Journal, 
301(6790), 1409-1411. 
 
18. Lifson, M.W. (1972). Decision and risk analysis for practicing engineers. Boston: 
Cahners Books. 
 
19. Silverman, M.E., Murray, T.J., & Bryan, C.S. (2002). The quotable Osler. 
Philadelphia: American College of Physicians. 
 
20. Pearl, J. (2000). Causality: models, reasoning, and inference.  Cambridge: Cambridge 
University Press. 
 
21. Neyman, J. (1950). First course in probability and statistics. New York: Henry Holt. 
 
22. Breiman, L. (1992).  Probability. Philadelphia: Society for Industrial and Applied 
Mathematics. 
 
23. Billingsley, P. (1995). Probability and measure. New York: Wiley. 
 
24. Rosenthal, J.S. (2003).  A first look at rigorous probability theory.  Singapore: World 
Scientific. 
 
25. McQueen, D.  (2003). Strengthening the evidence base for health promotion.  Health 
Promotion International, 16(3), 261-268.  
 
26. Bayes, T.  (2002). An essay towards solving a problem in the doctrine of chance.  In: 
Swinburne, R., editor.  Bayes’s Theorem.  Oxford: Oxford University Press. 
 
27. Miller, D.W., & Miller, C.G. (2005). On evidence, medical and legal. Journal of the 
American Physicians and Surgeons, 10(3), 70-75. 
 
28. Straus, S.E., & McAlister, F.A.  (2000). Evidence-based medicine: a commentary on 
common criticisms. Canadian Medical Association Journal, 153(7), 837-841. 
 
29. Tiwari, L., & Puliyel, J.M.  (2004). Truth and evidence based medicine: spin is 
everything.  British Medical Journal, 329(7473), 1043. 
  233 
 
30. Silverman, W.A. (1999). Where’s the evidence—debates in modern medicine.  
Oxford: Oxford University Press. 
 
31. Cramér, H. (1963). Mathematical methods of statistics.  Princeton: Princeton 
University Press. 
 
32. Rao, C.R. (1973). Linear statistical inference and its applications. New York: Wiley. 
 
33. Lehmann, E. (1986). Testing statistical hypothesis. New York: Wiley. 
 
34. Neter, J., Kutner, M.H., Nachtsheim, C.J., & Wasserman, W. (1996).  Applied linear 
statistical models.  Boston: McGraw-Hill. 
 
35. Gadamer, H.G. (2006).  Truth and methods.  London: Continuum. 
 
36. Bontekoe, R. (1996). Dimensions of the hermeneutic circle.  New Jersey: Humanities 
Press International. 
 
37. Norton, J.D. (2007).  Probability disassembled.  The British Journal of the Philosophy 
of Science, 58(2), 141-171. 
 
38. Nau, R.F. (2001). De Finetti was right: probability does not exist.  Theory and 
Decision, 51(2-4), 89-124. 
 
39. De Finetti, B. (1974). Theory of probability.  New York: Wiley. 
 
40. Ramsey, F. (1950). Foundations: essays in philosophy, logic, mathematics and 
economics.  London: Routledge.  
 
41. Savage, L.J. (1954).  The foundation of statistics.  New York: Wiley. 
 
42. Anscombe, F.J., & Aumann, R.J. (1963). A definition of subjective probability.  
Annals of Mathematical Statistics, 34, 199-205. 
 
43. Kadane, J.B., & Winkler, R.L. (1988).  Separating probability elicitation from utilities.  
Journal of the American Statistical Association, 83, 357-363.  
 
44. Chaloner, K.  (1996). Elicitation of prior distributions.  In: Berry, D.A., & Stangl, 
D.K., editors.  Bayesian Biostatistics, 141-156. New York: Marcel Dekker. 
 
45. Kadane, J.B., & Wolfson, L.J.  (1996). Priors for the design and analysis of clinical 
trials.  In: Berry, D.A., & Stangl, D.K., editors.  Bayesian Biostatistics, 157-184.  
New York: Marcel Dekker. 
 
 
  234 
46. Kadane, J.B., & Wolfson, L.J. (1998). Experiences in elicitation.  The Statistician, 
47(1), 3-19. 
 
47. Karni, E., & Safra, Z. (1995). The impossibility of experimental elicitation of 
subjective probabilities.  Theory and Decision, 38(3), 313-320. 
 
48. O’Hagan, A. (1998). Eliciting expert beliefs in substantial practical applications.  The 
Statistician, 47(1), 21-35. 
 
49. Huber, F. (2005). Subjective probabilities as basis for scientific reasoning?   Theory 
and Decision, 56(1), 101-116. 
 
50. Dongen, S.V. (2006).  Prior specification in Bayesian statistics: three cautionary tales.  
Journal of Theoretical Biology, 242(1), 90-100. 
 
51. Chan, S-P., & Poh, K-L. (2005).  Application of Bayesian linear regression in 
biomedical research.  Singapore General Hospital Proceedings, 13(3), 154-161. 
 
52. Laplace, P. (1812). Théorie analytique des probabilitiés. Courcier, 387. 
 
53. Williamson, J. (2007).  Inductive influence.   Theory and Decision, 58(4), 689-708. 
 
54. Berger, J. (2006). The case for objective Bayesian analysis.  Bayesian Analysis, 1(3), 
385-402 
 
55. Bayarri, M.J., & Berger, J. (2004). The interplay between Bayesian and frequentist 
analysis.  Statistical Science, 19, 58-80. 
 
56. Jeffreys, H. (1961).  Theory of probability.  London: Oxford University Press. 
 
57. Jaynes, E.T. (2003). Probability theory: the logic of science.  Cambridge: Cambridge 
University Press.   
 
58. Fienberg, S.E. (2006). When did Bayesian inference becomes “Bayesian”? Bayesian 
Analysis, 1(1), 1-40. 
 
59. Goldstein, M. (2006). Subjective Bayesian analysis: principles and practice.  
Bayesian Analysis, 1(3), 403-420. 
 
60. Christen, J.A. (2006). Stop using “subjective” to refer to Bayesian analysis. Bayesian 
Analysis, 1(3), 421-422. 
 
61. Draper, D. (2006). Coherence and calibration: comments on subjectivity and 
“objectivity”. Bayesian Analysis, 1(3), 423-428. 
 
  235 
62. Feinberg, S.E. (2006). Does it make sense to be an “objective Bayesian”?  Bayesian 
Analysis, 1(3), 429-432. 
 
63. Kadane, J.B. (2006). Is “objective Bayesian analysis” objective, Bayesian, or wise? 
Bayesian Analysis, 1(3), 433-436. 
 
64. Kass, R.E. (2006). Kinds of  Bayesians. Bayesian Analysis, 1(3), 437-440. 
 
65. Lad, F. (2006). Objective Bayesian statistics…Do you buy it? Should we sell it?  
Bayesian Analysis, 1(3), 441-444. 
 
66. O’Hagan, A. (2006). Science, subjectivity and software. Bayesian Analysis, 1(3), 
445-450. 
 
67. Wasserman, L. (2006). Frequentist Bayes is objective. Bayesian Analysis, 1(3), 451-
456. 
 
68. Tibshirani, R. (1989).  Noninformative priors for one parameter of many. Biometrika, 
74, 604-608. 
 
69. O’Hagan, A. (1994). Kendall’s advanced theory of statistics, Vol. 2B. Bayesian 
inference. London: Arnold. 
 
70. Hampel, C.G. (1945). Studies in the logic of confirmation.  Mind, 54, 1-26. 
 
71. Good, I.J. (1960). The paradox of confirmation.  The British Journal of the 
Philosophy of Science, 11, 145-149. 
 
72. Vranas, P.B.M. (2004). Hempel’s raven paradox: a lacuna in the standard Bayesian 
solution.  The British Journal of the Philosophy of Science, 55, 545-560. 
 
73. Dowe, D.L., Gardner, S., & Oppy, G. (2007). Bayes not bust! Why simplicity is no 
problem for bayesians.  The British Journal of the Philosophy of Science, 58(4), 709-
754. 
 
74. Bernado, J.M. (1997). Statistical inference as a decision problem: the choice of 
sample size.  The Statistician, 46(2), 151-154. 
 
75. Weiss, R. (1997). Bayesian sample size calculations for hypothesis testing.  The 
Statistician, 46(2), 185-192. 
 
76. Joseph, L., & Bélisle, P. (1997). Bayesian sample size determination for normal 
means and difference between normal means.  The Statistician, 46(2), 209-226. 
 
  236 
77. Rahme, E., Jospeh, L., & Gyorkos, T.W. (2000). Bayesian sample size determination 
for estimating binomial parameters from data subject to misclassification.  Journal of 
the Royal Statistical Society Series C (Applied Statistics), 49(1), 119-128.  
 
78. Wiper, M.P., & Pettit, L.I. (1994). Bayesian estimation of the binomial parameter n.  
Applied Statistics, 43(1), 233-236. 
 
79. Jeevanand, E.S. (1997). Bayes estimation of P(X2<X1) for a bivariate Pareto 
distribution.  The Statistician, 46(1), 93-99. 
 
80. Bolstad, W.M. (2004). Introduction to Bayesian statistics. New Jersey: Wiley. 
 
81. Box, G., & Tiao, G. (1992). Bayesian Inference in statistical analysis. New York: 
Wiley. 
 
82. Basu, S., Banerjee, M., & Sen, A. (2000). Bayesian inference for Kappa from single 
and multiple studies.  Biometrics, 56(2), 577-582. 
 
83. Bernado, J.M., & Perez, S. (2007). Comparing normal means: new methods for an old 
problem.  Bayesian Analysis, 2(1), 45-58. 
 
84. Bernardo, J.M., & Smith, A.F.M.  (1994). Bayesian theory.  Chichester: Wiley. 
 
85. Kadane, J.B. (1996). Bayesian methods and ethics in a clinical trial design. New 
York: Wiley. 
 
86. Johnson, V.E. (2007). Bayesian model assessment using pivotal quantities. Bayesian 
Analysis, 2(4), 719-734. 
 
87. Bertolino, F., Racugno, W., & Moreno, E. (2000). Bayesian model selection approach 
analysis of variance under heteroscedasticity.  Journal of the Royal Statistical Society 
Series D (The Statistician), 49(4), 503-517. 
 
88. Maddala, G.S. (1977).  Econometrics. Singapore: McGraw-Hill. 
 
89. Koop, G. (2003). Bayesian econometrics. Chichester: Wiley… 
 
90. Press, S.J. (1989). Bayesian statistics: principles, models, and applications.  New 
York: Wiley. 
 
91. McCulloch, P., & Nelder, J.A.  (1989). Generalized linear models.  London: 




92. Dipak, D.K., Ghosh, S.K., & Mallick, B.K. (2000).  Generalized linear models: a 
Bayesian perspective.  New York: Marcel Dekker, Inc. 
 
  237 
93. Dey, D.K., & Rao, C.R. (2005).  Bayesian thinking: modelling and computation.  The 
Netherlands: Elsevier. 
 
94. Congdon, P. (2001).  Bayesian statistical modelling.  Chichester: Wiley. 
 
95. Berry D.A., & Stangl, D.K. (1996).  Bayesian biostatistics.  New York: Marcel 
Dekker. 
 
96. Gill, J. (2002). Bayesian methods: a social and behavioural sciences approach.  Boca 
Raton: Chapman & Hall. 
 
97. Hosmer, D.W., & Lemeshow, S.  (1999). Applied survival analysis: regression 
modelling of time to event data.  New York: Wiley. 
 
98. Collette, D. (2003). Modelling survival data in medical research.  London: Chapman 
& Hall. 
 
99. Cleves, M.A., Gold, W.W., & Gutierrez, R.G. (2002). An introduction to survival 
analysis using Stata.  Texas: Stata Press. 
 
100.  Cox, D. (1972). Regression models and life tables. Journal of the Royal Statistical   
Society Series B, 34, 187-220. 
 
101. Ibrahim, J.G.  Chen, M-H., & Sinha, D. (2001). Bayesian survival analysis. New 
York: Springer Verlag. 
 
102. Volinsky, C.T., Madigan, D., Raftery, A.E., & Kronmal, R.A. (1997). Bayesian 
model averaging in proportional hazard models: assessing the risk of a stroke.  
Applied Statistics, 46(4), 433-448. 
 
103. Soliman, A.A. (2000). Bayes prediction in a Pareto lifetime model with random 
sample size.  Journal of the Royal Statistical Society Series D (The Statistician), 
49(1), 51-62 
 
104. Sinha, D., & Dey, D.K. (1997).  Semiparametric Bayesian analysis of survival data. 
Journal of the American Statistical Association, 92, 1195-1212. 
 
105. Lindsay, J.K. (1993). Models for repeated measurements.  Oxford: Oxford 
University Press.   
 
106. Hardin, J.W., & Hilbe, J.M. (2001). Generalized linear models and extensions. 
Texas: Stata Press.  
 
107. McCulloch, C.E., & Searle, R.S. (2001). Generalized, linear and mixed models. 
New York: Wiley. 
 
  238 
108. Hardin, J.W., & Hilbe, J.M. (2003).  Generalized estimating equations.  Boca 
Raton: Chapman & Hall/CRC Press. 
 
109. Gelman, A., & Hill, J. (2006). Data analysis using regression and 
multilevel/hierarchical models. Cambridge: Cambridge University Press.  
 
110. Rossi, P.E., Allenby, G.M., & McCulloch, R. (2005). Bayesian statistics and 
marketing.  Chichester: Wiley. 
 
111. Hobert, J., & Casella, G. (1996). The effect of improper priors on Gibb sampling in 
hierarchical models. Journal of the American Statistical Association, 91, 1461-
1473. 
 
112. Lenk, P., & DeSarbo, W. (2000). Bayesian inference for finite mixtures of 
generalised linear models with random effects. Psychometrika, 65, 93-119. 
 
113. Dukić, V., & Dignam, J. (2007). Bayesian hierarchical multiresolution hazard 
model for the study of time-dependent failure patterns in early stage breast cancer.  
Bayesian Analysis, 2(3), 591-610. 
 
114. Sutton, A.J., Jones, D.R., Abrams, K.R., Sheldon, T.A., & Song, F. (2000). 
Methods for Meta-analysis in medical research. London: Wiley. 
 
115. DerSimonian, R., & Laird, N. (1986). Meta analysis in clinical trials. Controlled 
Clinical Trials, 7, 177-188. 
 
116. Thompson, S. (1994). Why sources of heterogeneity in meta-analysis should be 
investigated. British Medical Journal, 309(6965), 1351-1355.  
 
117. Smith, G., Egger, M., & Phillips, A. (1997). Meta-analysis: beyond the grand mean?  
British Medical Journal, 315(7122), 1610-1614. 
 
118. Stern, J.M., & Simes, R.J. (1997). Publication bias: evidence of delayed publication 
in a cohort study of clinical research projects. British Medical Journal, 315(7109), 
640-645. 
 
119. Hedges, L.V., & Olkin, I. (1985).  Statistical methods for meta-analysis.  London: 
Academic Press. 
 
120. Thompson, S., & Higgins, R. (2002). How should meta-regression analyses be 
undertaken and interpreted?  Statistics in Medicine, 21, 1559-1574. 
 
121. Goldstein, H., Yang, M., Omar, R., Turner, R., & Thompson, S. (2000). Meta-
analysis using multi-level models with an application to the study of class size.  
Journal of the Royal Statistical Society Series C (Applied Statistics), 49(3), 399-412. 
 
  239 
122. Hastings, W.K. (1970). Monte Carlo sampling methods using Markov chains and 
their applications.  Biometrika, 57, 97-109. 
 
123. Casella, G., & George, E.I. (1992).  Explaining the Gibbs sampler.  The American 
Statistician, 46(3), 167-174. 
 
124. Tierney, L. (1994).  Markov chains for exploring posterior distributions.  The 
Annals of Statistics, 22, 1701-1762. 
 
125. Bremaud, P. (1999).  Markov chain: Gibbs fields, monte carlo simulation, and 
queues. New York: Springer Verlag. 
 
126. Chen, M-H., Shao, Q-M., & Ibrahim, J.G. (2000).  Monte Carlo methods in 
Bayesian computation. New York: Springer Verlag. 
 
127. Liu, J. (2001).  Monte Carlo strategies in scientific computing.  New York: Verlag 
Springer. 
 
128. Brooks, S.P. (1998). Markov chain Monte Carlo method and its application.  The 
Statistician, 47(1), 69-100. 
 
129. Diaconis, P., & Ylvisaker, D. (1979).  Conjugate priors for exponential families.  
The Annals of Statistics, 17, 269-281. 
 
130. R.A. Fisher (1921). On the probably error of a coefficient of correlation deduced 
from a small sample.  Metron, 1, 3-32. 
 
131. R.A. Fisher (1922). On the mathematical foundation of theoretical statistics. 
Philosophical Transactions of the Royal Society, 222, 309-368. 
 
132. Albert, J., & Chib, S. (1993).  Bayesian regression analysis of binary and 
polychotomous response data. Journal of the American Statistical Association, 88, 
657-667. 
 
133. Hosmer, D.W., & Lemeshow, S. (2000). Applied logistic regression.  New York: 
Wiley. 
 
134. Von Mises, R. (1947).  On the asymptotic distribution of differentiable statistical 
function. Annals of Mathematical Statistics, 18, 309-348.  
 
135. Papathanasiou, V. (1993). Some characteristic properties of the Fisher information 
matrix type inequalities.  Journal of Multivariate Analysis, 14, 256-265. 
 
136. Rao, B.L.S.P. (1978). Rate of convergence of Berstein-von Mises approximation 
process.  Serdica, 4, 36-42. 
 
  240 
137. Das, S., & Dey, D.K. (2006). On Bayesian analysis of generalised linear models 
using the Jacobian technique.  The American Statistician, 60(3), 36-42. 
 
138. Cameron, A.C., & Trivedi, P.K. (1998). Regression analysis of count data. New 
York:  Cambridge University Press. 
 
139. Hilbe, J.M. (2007). Negative binomial regression. Cambridge:  Cambridge 
University Press. 
 
140. Geyer, C.J. (1992).  Practical Markov chain Monte Carlo.  Statistical Science, 7(4), 
473-511. 
 
141. Kass, R.E., Carlin, B.P., Gelman, A., & Neal, R.M.  (1998). Markov chain Monte 
Carlo in practice: a roundtable discussion.  The American Statistician, 52(2), 93-
100. 
 
142. Zellner, A., & Min, C-K. (1995). Gibbs sampler: convergence criteria.  Journal of 
the American Statistical Association, 90, 921-927. 
 
143. Serfling, R.J. (1980).  Approximation theorems of mathematical statistics.  143-149. 
Singapore: Wiley. 
 
144. Carlin, B.P., & Louis, T.A. (2000). Bayes and empirical Bayes methods for data 
analysis. New York: Chapman & Hall. 
 
145. Huber, P.J. (1981). Robust statistics. New York: Wiley. 
 
146. Freund, Y.  (1995). Boosting a weak learning algorithm by majority.  Information & 
Computation, 121, 256-285. 
 
147. Metz, C.E. (1978).  Basic principles of ROC analysis.  Seminars in Nuclear 
Medicine, 8(4), 283-98. 
 
148. Hanley, J.A., & McNeil, B.J. (1982).  The meaning and use of the area under a 
receiver operating characteristic (ROC) curve.  Radiology, 143(1), 29-36. 
 
149. Hanley, J.A., & McNeil, B.J. (1983).  A method of comparing the areas under 
receiver operating characteristic curves derived from the same cases.  Radiology, 
148(3), 839-43. 
 
150. Sampson, S.M. (2001). Treating depression with selective serotonin reuptake 
inhibitors: a practical approach.  Mayo Clinic Proceedings, 76, 739-744. 
 
151. Barbey, J.T., & Roose, S.P. (1998). SSRI safety in overdose.  Journal of Clinical 
Psychiatry, 59(Supplement 15), 42-48. 
 
  241 
152. Cheeta, S., Schifano, F., Oyefeso, A., Webb, L., & Ghodse, A.H. (2004).  
Antidepressant-related deaths and antidepressant prescriptions in England and 
Wales, 1998-2000. British Journal of Psychiatry, 184, 41-47. 
 
153. Goldstein, B.J., & Goodnick, P.J. (1998). Selective serotonin reuptake inhibitors in 
the treatment of affective disorders-III. Tolerability, safety and pharmacoeconomics.  
Journal of Psychopharmacology, 12 (3 Supplement B), S55-87. 
 
154. Pacher, P., Ungvari, Z., Nanasi, P.P., Furst, S., & Kecskemeti, V. (1999).  
Speculations on difference between tricyclic and selective serotonin reuptake 
inhibitor antidepressants on their cardiac effects.  Is there any?  Current Medical 
Chemistry, 6(6), 469-480. 
 
155. Stokes, P.E. (1993). Fluoxetine: a five-year review.  Clinical Therapy, 15(2), 216-
243. 
 
156. Zohar, J., & Westenberg, H.G. (2000). Anxiety disorders: a review of tricyclic 
antidepressants and selective serotonin reuptake inhibitors.  Acta Psychiatrica 
Scandinavica Supplement, 403, 39-49. 
 
157. Katona, C. (2000).  Managing depression and anxiety in the elderly patient.  
European Neuropsychopharmacology, 10(Supplement 4), S427-432. 
 
158. Baldwin, D.S. (2001). Unmet needs in the pharmacological management of 
depression.  Human Psychopharmacology, 16(Supplement 2), S93-99.  
 
159. Wagstaff, A.J., Cheer, S.M., Matheson, A.J., Ormrod, D., & Goa, K.L.  (2002). 
Paroxetine: an update of its use in psychiatric disorders in adults.  Drugs, 62(4), 
655-703. 
 
160. Vaswani, M., Linda, F.K., & Ramesh, S. (2003).  Role of selective serotonin 
reuptake inhibitors in psychiatric disorders: a comprehensive review.  Progress in 
Neuropsychopharmacology & Biological Psychiatry, 27(1), 85-102. 
 
161. Lader, M.H. (1996). Tolerability and safety: essentials in antidepressant 
pharmacotheraphy.  Journal of Clinical Psychiatry, 57(Supplement 2), 39-44. 
 
162. Steffans, D.C., Krishnan, K.R., & Helms, M.J. (1997). Are SSRIs better than TCAs?  
Comparison of SSRIs and TCAs: a meta-analysis.  Depression & Anxiety, 6(1), 10-
18. 
 
163. Thompson, C., & Thompson, C.M.  (1989). The prescribing of antidepressants in 
general practice II: a placebo-controlled trial of low-dose dothiepin. Human 
Psychopharmacology, 4, 191-204.  
 
  242 
164. Kernick, D.P.  (1997). Which antidepressant?  A commentary from general practice 
on evidence-based medicine and health economics.  British Journal of General 
Practice, 47(415), 95-98. 
 
165. Kyle, C.J., Petersen, H.E., & Overo, K.F. (1998). Comparison of the tolerability 
and efficacy of citalopram and amitriptyline in elderly depressed patients treated in 
general practice.  Depression & Anxiety, 8(4), 147-153. 
 
166. Mahendru, R.K., & Mahendru, S. (2001).  Selection of antidepressant drugs in 
general practice.  Journal of Indian Medical Association, 99(1), 54-55. 
 
167. Montgomery, S.A., Henry, J., McDonald, G., Dinan, T., Lader, M., Hindmarch, I., 
Clare, A., & Nutt, D. (1994). Selective serontonin reuptake inhibitors: meta-
analysis of discontinuation rates. International Clinical Psychopharmacology, 9(1), 
47-53. 
 
168. Montgomery, S.A., & Kasper, S. (1995). Comparison of compliance between 
serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis.  
International Clinical Psychopharmacology, 9(Supplement 4), 33-40. 
 
169. Anderson, I.M. (2000). Selective serotonin reuptake inhibitors versus tricyclic 
antidepressants: a meta-analysis of efficacy and tolerability.  Journal of Affecive 
Disorders, 58(1), 19-36. 
 
170. MacGillivray, S., Arroll, B., Hatcher, S., Ogston, S., Reid, I., Sullivan, F., William, 
B., & Crombie, I. (2003).  Efficacy and tolerability of selective serotonin reuptake 
inhibitors compared with tricyclic antidepressants in depression treated in primary 
care: a systematic review and meta-analysis.  British Medical Journal, 326(7397), 
1014. 
 
171. Yildiz, A., Pauler, D.K., & Sachs, G.S. (2004). Rates of study completion with 
single versus split daily dosing of antidepressants: a meta-analysis. Journal of 
Affective Disorders, 78(2), 157-162. 
 
172. Barbui, C., Hotopf, M., Freemantle, N., Boynton, J., Churchill, R., & Eccles, M.P. 
(2004). Treatment discontinuation with selective serotonin reuptake inhibitors 
(SSRIs) versus tricyclic antidepressants (TCAs).  Cochrane Database of Systematic 
Reviews, 2. 
 
173. Yusuf, S., Peto, R., Lewis, J., Collins, R., & Slieght, P.  (1985). Beta blockage 
during and after myocardial infarction: an overview of the randomised trials.  
Progress in Cardiovascular Diseases, 27(5), 335-371. 
 
174. Corne, S.J., & Hall, J.R.  (1989). A double-blind comparative study of fluoxetine 
and dothiepin in the treatment of depression in general practice.  International 
Clinical Psychopharmacology, 4(3), 245-254. 
  243 
 
175. Stott, P.C., Blagden, M.D., & Aitken, C.A. (1993). Depression and associated 
anxiety in primary care: a double-blind comparison of paroxetine and amitriptyline.  
European Neuropsychopharmacology, 3, 324-325. 
 
176. Rosenberg, C., Damsbo, N., Fuglum, E., Jacobsen, L.V., & Horsgard, S. (1994).   
Citalopram and imipramine in the treatment of depressive patients in general 
practice. A Nordic multicentre clinical study.  International Clinical 
Psychopharmacology, 9(Supplement 1), 41-48. 
 
177. Doogan, D.P., & Langdon, C.J.  (1994). A double-blind, placebo-controlled 
comparison of sertraline and dothiepin in the treatment of major depression in 
general practice.  International Clinical Psychopharmacology; 9(2): 95-100. 
 
178. Moon, C.A.L., & Vince, M.  (1996). Treatment of major depression in general 
practice: a double-blind comparison of paroxetine and lofepramine.  British Journal 
of Clinical Practice, 50(5), 240-244. 
 
179. Christiansen, P.E., Behnke, K., Black, C.H., Ohrstrom, J.K., Bork-Rasmussen, H., 
& Nilsson, J. (1996). Paroxetine and amitriptyline in the treatment of depression in 
general practice.  Acta Psychiatrica Scandinavica, 93(3), 158-163. 
 
180. Ravindran, A.V., Judge, R., Hunter, B.N., Bray, J., & Morton, N.H. (1997). A 
double-blind, multicentre study in primary care comparing paroxetine and 
clomipramine in patients with depression and associated anxiety. Paroxetine study 
group.   Journal of Clinical Psychiatry, 58(3), 112-118. 
 
181. Thompson, C. (1991). Sertraline in a primary care setting.  In: Racagni NB, Fukuda 
T, editors.  Biological Psychiatry.  Amsterdam: Elservier, 863-865. 
 
182. Hutchinson, D.R., Tong, S., Moon, C.A.L., Vince, M., & Clarke, A.   (1992). 
Paroxetine in the treatment of elderly depressed patients in general practice: a 
double-blind comparison with amitriptyline. International Clinical 
Psychopharmacology, 6(4 Supplement), 43-51.  
 
183. Rosner, B. (2000).  Fundamentals of biostatistics.  Pacific Grove: Brooks/Cole. 
 
184. Swinkels, J.A., De Jonghe, F. (1995). Safety of antidepressants.  International 
Clinical Psychopharmacology, 9(Supplement 4), 19-25. 
 
185. Kasper, S., Hoflich, G., Scholl, H.P., & Moller, H.J.  (1994). Safety and 
antidepressant efficacy of selective serotonin re-uptake inhibitors.  Human 
Psychopharmacology, 9, 1-12. 
 
186. Glass, G.V. (1976). Primary, secondary and meta-analysis of research.  
Educational Research, 5, 3-8. 
  244 
 
187. Egger, M.G., (1997). Bias in meta-analysis detected by a simple, graphical test.  
British Medical Journal, 314(7109), 629-634. 
 
188. Fleiss, J.L. (1993). The statistical basis of meta-analysis.  Statistical Methods in 
Medical Research, 2, 121-145. 
 
189. Wong, M-K., Arjandas, Ching, L-K., Lim, S-L., & Lo, N-N. (2002). Osteoporotic 
hip fractures in Singapore: costs and patient’s outcome. Annals of Academy of 
Medicine Singapore, 31(1), 3-7.  
 
190. Cooper, C., Campian, G., & Melton, L.J. (1992). Hip fracture in the elderly: a 
worldwide projection. Osteoporosis International, 2, 285-289. 
 
191. Koh, L.K-H., Saw, S-M., Lee, J.J-M., Leong, K-H., & Lee, J. (2001). Hip fracture 
incidence rates in Singapore 1991-1998. Osteoporosis International, 12(4), 311-
318. 
 
192. Scientific Advisory Board, Osteoporosis Society of Canada. (1996). Clinical 
practice guidelines for the diagnosis and management of osteoporosis. Canadian 
Medical Association Journal, 155, 1113-1133. 
 
193. Council of the National Osteoporosis Foundation. (1996). Guidelines for the early 
detection of osteoporosis and prediction of fracture risk. South African Medical 
Journal, 86(9), 1113-1116. 
 
194. Lydick, E., Cook, K., Turpin, J., Melton, M., Stine, R., & Byrnes, C. (1998).  
Development and validation of a simple questionnaire to facilitate identification of 
women likely to have low bone density.  American Journal of Managed Care, 4(1), 
37-48. 
 
195. Cadarette, S.M., Jaglal, S.B., Kreiger, N., McIssac ,W.J., Darlington, G.A., & Tu, 
J.V. (2000).  Development and validation of the osteoporosis risk assessment 
instrument to facilitate selection of women for bone densitometry.  Canadian 
Medical Association Journal, 162(9), 1289-1294.   
 
196. Weinstein, L., & Ullery, B. (2000).  Identification of at-risk women for 
osteoporosis screening.  American Journal of Obstetrics Gynecology, 183(3), 547-
549. 
 
197. Michaelsson, K., Bergstrom, R., Mallmin, H., Holmberg, L., Wolk, A., & 
Ljunghall, S. (1996). Screening for osteoporosis: selection by body composition.  
Osteoporosis International, 6(2), 120-126.  
 
198. Koh, L.K-H., Sedrine, W.B., Torralba, T.P., Kung, A., Fujiwara, S., Chan, S-P., 
Huang, Q.R., Rajatanavin, R., Tsai, K-S., Park, H-M., & Reginster, J.Y. (2001).  A 
  245 
simple tool to identify Asian women at increased risk of osteoporosis.  
Osteoporosis International, 12(8), 699-705. 
 
199. Marshall, D., Johnell, O., & Wedel, H. (1996).  Meta-analysis of how well measure 
of bone mineral density predicts occurrence of osteoporortic fractures.  British 
Medical Journal, 312(7041), 1254-1259. 
 
200. Scheaffer, R.L., Mendenhall, W., & Ott, L. (1990).  Elementary Survey Sampling.  
118-119. Belmont: Duxbury. 
 
201. Ministry of Health (2000). National Health Survey 1998. Ministry of Health, 
Singapore.  
 
202. Food and Nutrition Department (1994). Food Consumption Study 1993. Ministry of 
Health, Singapore. 
 
203. Park, H-M., Sedrine, W.B., Reginster, J.Y., Ross, P.D., & OSTA (2003). Korean 
experience with the OSTA risk index for osteoporosis: a validation study. Journal 
of Clinical Densitometry, 6(3), 247-250. 
 
204. Kung, A-W., Ho, A-Y., Sedrine, W.B., Reginster, J.Y., & Ross, P.D. (2003). 
Comparison of a simple clinical risk index and quantitative bone ultrasound for 
identifying women at increased risk of osteoporosis. Osteoporosis International, 
14(9), 716-721. 
 
205. Ministry of Health, National Medical Research Council, Osteoporosis Society of 
Singapore (2002).  Clinical Practice Guideline: Osteoporosis.  Ministry of Health, 
Singapore. 
 
206. Altman, D.G. (1999).  Practical statistics for medical research. 417-418. Boca 
Raton: Chapman & Hall. 
 
207. Giardiello, F.M., Hamilton, S.R., Krush, A.J., Piantadosi, S., Hylind, L.M.,  Celano, 
P., Booker, S.V., Robinson, CR, & Offerhaus, G.J. (1993).  Treatment of colonic 
and rectal adenomas with sulindac in familial adenomatous polyposis.  New 
England Journal of Medicine, 328(18), 1313-1316. 
 
208. Giardiello, F.M., Yang, V.W., Hylind, L.M., Krush, A.J., Petersen, G.M., Trimbath, 
J.D., Piantadosi, S., Garrett, E., Geiman, D.E., Hubbard, W., Offerhaus, G.J., &. 
Hamilton, S.R. (2002).  Primary chemoprevention of familial adenomatous 
polyposis with sulindac.  New England Journal of Medicine, 346(14), 1054-1059. 
 
209. Pasricha, P.J., Bedi, A., O’Connor, K., Rashid, A., Akhtar, A.J., Zahurak, M.L., 
Piantadosi, S., Hamilton, S.R., & Giardiello, F.M.  (1995). The effects of sulindac 
on colorectal proliferation and apoptosis in familial adenomatous polyposis.  
Gastroenterology, 109(3), 994-998. 
  246 
 
210. Piantadosi, S.  (1997). Clinical trials: a methodological perspective.  479-481. New 
York: Wiley, 479-481. 
 
211. Ladenheim, J., Garcia, G., Titzer, D., Herzenburg, H., Lavori, P., Edson, P., & 
Omary, M.B. (1995).  Effect of sulindac on sporadic colonic polyps.  
Gastroenterology, 108(4), 1083-1087. 
 
212. Giardiello, F.M., Offerhaus, J.A., Tersmette, A.C., Hylind, L.M., Krush, A.J., 
Brensinger, J.D., Booker, S.V., & Hamilton, S.R. (1996).  Sulindac induced 
regression of colorectal adenomas in familial adenomatous polyposis: evaluation of 
predictive factors.  Gut, 38(4), 578-581. 
 
213. Halstead, S.B. (2002). Dengue. Current Opinion of Infectious Disease, 15(5), 471-
476. 
 
214. Gibbons, R.V., & Vaughn, D.W. (2000). Dengue: an escalating problem. British 
Medical Journal, 324(7353), 1563-1566. 
 
215. Chow, A., Ye, T., & Ang, L-W. (2005). Dengue epidemiological update. Ministry 
of Health Information Paper 2005.  
 
216. Chia, A., Luu, C-D., Mathur, R., Cheng, B., & Chee, S-P. (2006). 
Electrophysiological findings in patients with dengue-related maculopathy.  
Archives of Ophthalmology, 124(10), 1421-1426. 
 
217. Chan, D.P., Teoh, S.C., Tan, C.S., & The Eye Institute Dengue-Related Ophthalmic 
Complications Workgroup (2006). Ophthalmic complications of dengue. Emerging 
Infectious Diseases, 12(2), 285-289.  
 
218. Chlebicki, M.P., Ang, B., Barkham, T., & Laude, A. (2005). Retinal hemorrhages 
in 4 patients with dengue fever. Emerging Infectious Diseases, 11(5), 770-772. 
 
219. Madsen, P.L., & Thybo, S. (2005). Ocular complications of dengue fever. Ugeskr 
Laeger, 167(43), 4083-4084. 
 
220. Nainiwal, S., Garg, S.P., Prakash, G., & Nainiwal, N. (2005). Bilateral vitreous 
haemorrhage associated with dengue fever.  Eye, 19(9), 1012-1013. 
 
221. Siqueira, R.C., Vitral, N.P., Campos, W.R., Orefice, F., & De Moraes Figueiredo, 
L.T. (2004). Ocular manifestations in dengue fever. Ocul Immunoogy & 
Inflammation, 12(4), 323-327. 
 
222. Lim, W-K., Mathur, R., Koh, A., Yeo, R., & Chee, S-P. (2004). Ocular 
manifestations of dengue fever. Ophthalmology, 111(11), 2057-2064. 
 
  247 
223. Cruz-Villegas, V., Berrocal, A.M., Davis, J.L. (2003). Bilateral choroidal effusions 
associated with dengue fever. Retina, 23(4), 576-578. 
 
224. Haritoglou, C., Dotse, S.D., Rudolph, G., Stephan, C.M., Thurau, S.R., & Klauss, 
V. (2002). A tourist with dengue fever and visual loss.  The Lancet, 360(9339), 
1070. 
 
225. Haritoglou, C., Scholz, F., Bialasiewicz, A., & Lauss, V. (2000). Ocular 
manifestation in dengue fever. Ophthalmologe, 97(6), 433-436. 
 
226. Wen, K-H., Sheu, M-M., Chung, C-B., Wang, H-Z., & Chen, C-W. (1989). The 
ocular fundus findings in dengue fever. Gaoxiong Yi Xue Ke Xue Za Zhi (高雄医科
杂志), 5(1), 24-30. 
 
227. Spitznas, M. (1978). Macular hemorrhage in dengue fever. Klinische Monatsblatter 
fur Augenheilkunde, 172, 105-107. 
 
228. Deutman, A.F., & Bos, P.J. (1979). Macular bleeding in dengue fever. Klinische 
Monatsblatter fur Augenheilkunde, 175(3), 429. 
 
229. Singapore Ministry of Health (2004). A guide on infectious diseases of public 
health importance in Singapore. 6
th
 ed.  
 
230. Kurane, I, Innis, B.L., Nimmannitya, S., Nisalak, A., Meager, A., Janus, J., & Ennis, 
F.A. (1991). Activation of T lymphocytes in dengue virus infections. High levels of 
soluble interleukin 2 receptor, soluble CD4, soluble CD8, interleukin2 and 
interferon-γ in sera of children with dengue. Journal of Clinical Investigation, 
88(5), 1473-1480. 
 
231. Kurane, I., & Ennis, F.A. (1992). Immunity and immunopathology in dengue virus 
infections. Seminars in Immunology, 4(2), 121-127. 
 
232. Venketasubramanian, N. (1999).  Stroke in Singapore—an overview.  Singapore 
Medical Journal, 40(1), 1-7. 
 
233. Ariesen, M.J., Algra, A., Van der Worp, H.B., & Rinkel, G.J.E.  (2005).  
Applicability and relevance of models that predict short term outcome after 
intracerebral haemorrhage. Journal of Neurology, Neurosurgery &  Psychiatry, 
76(6), 839-844. 
 
234. Nilsson, O.G., Lindgren, A., Brandt, L., & Saveland, H. (2002). Prediction of death 
in patients with primary intracerebral haemorrhage: a prospective study of a 
defined population.  Journal of Neurosurgery, 97(3), 531-536. 
 
235. Wood, S.N. (2006). Generalized additive model: an introduction with R. Boca 
Raton: CRC Press. 
  248 
 
236. Breiman, L., Friedman, J.H., Olshen, R.A., & Stone, C.J. (1998). Classification and 
regression trees.  Boca Raton: Chapman & Hall. 
 
237. Chan, K-Y., & Low, W-Y. (2004). LOTUS: an algorithm for building accurate and 
comprehensive logistic regression trees.  Journal of Computer Graphical Statistics, 
13, 826-852. 
 
238. Siegel, S., & Castellan, N.J. (2000). Nonparametric statistics for the behavioural 
science.  Singapore: McGraw-Hill. 
 
239. Teasdale, G., & Jennett, B.  (1974). Assessment of coma and impaired 
consciousness: a practical scale.  The Lancet, 2(7872), 81-84. 
 
240. Lemeshow, S., & Hosmer, D.W. (1982). A review of goodness-of-fit statistics for 
use in the development of logistic regression model.  American Journal of 
Epidemiology, 115(1), 92-106. 
 
241. Flegal, K.M., Graubard, B.I., Williamson, D.F., & Gail, M.H. (2005).  Excess deaths 
associated with underweight, overweight and obesity.  Journal of American Medical 
Association, 293(15), 1861-1867.    
 
242. Thom, E. (2000). A randomised, double-blind, placebo-controlled trial of a new 
weight-reducing agent of natural origin.  The Journal of Medical Research, 28, 229-
233. 
 
243. Pedersen, J.O., Zimmermann, E., Stallknecht, B.M., Brunn, J.M., Kroustrup, J.P., 
Larsen, J.F., & Helge, J.W.  (2006). Lifestyle intervention in the treatment of severe 
obesity.  Ugeskr Laeger, 168(2), 167-172.  
 
244. Wadden, T.A., & Foster, G.D. (2000).  Behavioural treatment of obesity.  Medical 
Clinics of North America, 84, 441-462. 
 
245. Kramer, F.M., Jeffrey, R.W., Forster, J.L., & Snell, M. K. (1989). Long term follow-
up of behavioural treatment for obesity: patterns of weight regain in men and women.  
International Journal of Obesity, 13(2), 123-136. 
 
246. Phelan, S., & Wadden, T.A.  (2002). Combining behavioural and pharmacological 
treatments for obesity.  Obesity Research, 10(6), 560-574. 
 
247. Hensrud, D.D., Weinsier, B.E., Darnell, B.E., & Hunter, G.R. (1995). Relationship of 
co-morbidities of obesity to weight loss and four-year weight maintenance/rebound.  
Obesity research, 3(Supplements 2), s217-s222. 
 
248. Fox, K.M., & EURopean trial ON reduction of cardiovascular events with Perindopril 
in stable coronary Artery disease Investigators. (2003). Efficacy of perindopril in 
  249 
reduction of cardiovascular events among patients with stable coronary artery disease: 
randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).  
The Lancet, 362(9386), 782-788. 
 
249. Domanski, M., Krause-Steinrauf, H., Deedwania, P., Follmann, D., Ghali, J.K., 
Gilbert, E., Haffner, S., Katz, R., Lindenfeld, J., Lowes, B.D., Martin, W., McGrew, 
F., Bristow, M.R., & BEST investigators. (2003). The effect of diabetes on outcomes 
of patients with advanced heart failure in the BEST trial.  Journal of American 
College of Cardiology, 42(5), 914-922. 
 
250. De Groote, P., Lamblin, N., Mouquet, F., Plichon, D., McFadden, E., Van Belle, E., & 
Bauters, C. (2004). Impact of diabetes mellitus on long-term survival in patients 
with congestive heart failure. European Heart Journal, 25(8), 656-662. 
 
251. Gustafsson, I., Brendorp, B., Seibaek, M., Burchardt, H., Hildebrandt, P., Kober, L., 
& Torp-Pedersen, C. (2004).  Influence of diabetes and diabetes-gender interaction 
on the risk of death in patients hospitalized with congestive heart failure.  Journal of 
American College of Cardiology, 43(5), 771-777. 
 
252. Hjalmarson, A, Goldstein, S., & Fagerberg, B. (2000). Effects of controlled-release 
metoprolol on total mortality, hospitalisation, and well-being in patients with heart 
failure: the Metoprolol CR/XL randomised intervention trial in congestive heart 
failure (MERIT-HF).  Journal of the American Medical Association, 283(10), 1295-
1302. 
 
253. Brophy, J.M., Joseph, L., & Rouleau, J.L. (2001).  β–blockers in congestive heart 
failure.  Annals of Internal Medicine, 134, 550-560. 
 
254. McAlister, F.A., Ezekowitz, J., Tonelli, M., & Armstrong, P.W. (2004). Renal 
insufficiency and heart failure: prognostic and therapeutic implications from a 
prospective cohort study.  Journal of the American Heart Association, 109, 1004-
1009. 
 
255. Mak, K-H., Chia, K-S., Kark, J-D., Chua, T., Tan, C., Foong, B-H., Lim, Y-L., & 
Chew, S-K.  (2003). Ethnic differences in acute myocardial infarction in Singapore.  
European Heart Journal, 24(2), 151-160. 
 
256. Kamalesh, M., Subramanian, U., Saweda, S., Eckert, G., Temkit, M’H., & Tierney, 
W. (2006). Decreased survival in diabetic patients with heart failure due to systolic 
dysfunction.  The European Journal of Heart Failure, 8(4), 404-408. 
 
257. Varela-Roman, A., Shamagian, L.G., Caballero, E.B., Ramos, P.M., Veloso, P.R., 
& Gonzalez-Juanatey, J.R. (2005). Influence of diabetes on the survival of patients 
hospitalised with heart failure: a 12-year study.  The European Journal of Heart 
Failure, 7(5), 859-864. 
 
  250 
258. Das, S.R., Drazner, M.H., Yancy, C.W., Stevenson, L.W., Gersh, B.J., & Dries, 
D.L. (2004). Effects of diabetes mellitus and ischemic heart disease on the 
progression from asymptomatic left ventricular dysfunction to symptomatic heart 
failure: a retrospective analysis from the Studies of Left Ventricular Dysfunction 
(SOLVD) Prevention trial. American Heart Journal, 148(5), 883-888. 
 
259. Burger, A., Tsao, L., & Aronson, D. (2005). Prognostic impact of diabetes mellitus 
in patients with acute decompensated heart failure. The American Journal of 
Cardiology, 95(9), 1117-1119.  
 
260. Eshaghian, S., Horwich, T.B., & Fonarow, G.C. (2006). An unexpected inverse 
relationship between HbA1c levels and mortality in patients with diabetes and 
advanced systolic heart failure.  American Heart Journal, 151(1), 91.e1-91.e6. 
 
261. McDonald, S.P., Russ, G.R., Kerr, P.G., Collins, J.F., & Australia and New 
Zealand Dialysis and Transplant Registry.  (2002). ESRD in Australia and new 
Zealand at the end of millennium: a report from the ANZDATA registry.  
American Journal of Kidney Diseases, 40(6), 1122-1131. 
 
262. Foley, R.N., Parfrey, P.S., Harnett, J.D., Kent, G.M., O’Dea, R., Murray, D.C., & 
Barre, P.E. (1998).  Mode of dialysis therapy and mortality in end-stage renal 
disease.  Journal of American Society of Nephrology, 9(2), 267-276. 
 
263. Disney, A.P. (1995). Demography and survival of patients receiving treatment for 
chronic renal failure in Australia and New Zealand: report on dialysis and renal 
transplantation treatment from the Australia and New Zealand Dialysis and 
Transplant Registry.  American Journal of Kidney Diseases, 25, 165-175. 
 
264. Marcelli, D., Spotti, D., Conte, F., Tagliaferro, A., Limido, A., Lonati, F., Malberti, F., 
& Locatelli, F. (1996).  Survival of diabetic patients on peritoneal dialysis or 
haemodialysis.  Peritoneal Dialysis International, 16(Supplement 1), S283-S287. 
 
265. Vonesh, E.F., & Moran, J. (1999).  Mortality in end-stage renal disease: a 
reassessment of differences between patients treated with haemodialysis and 
peritoneal dialysis.  Journal of the American Society of Nephrology, 10(2), 354-365. 
 
266. Mircescu, G., Garneata, L., Florea, L., Cepoi, V., Capsa, D., Covic, M., Gherman-
Caprioara, M., Gluhovschi, G., Golea, O.S., Barbulescu, C., Rus, E., Santimbrean, 
C., Mardare, M., & Covic A. (2006).  The success story of peritoneal dialysis in 
Romania: analysis of differences in mortality by dialysis modality and influence of 
risk factors in a national report.  Peritoneal Dialysis International, 26(2), 266-275. 
 
267. Held, P.J., Port, F.K., Turenne, M.N., Gaylin, D.S., Hamburger, R.J., & Wolfe, R.A. 
(1994).  Continuous ambulatory peritoneal dialysis and haemodialysis: comparison 
of patient mortality with adjustment for comorbid conditions.  Kidney International, 
45(4), 1163-1169. 
  251 
 
268. Vonesh, E.F., Snyder, J.J., Foley, R.N., & Collins, A.J. (2004).  The differential 
impact of risk factors on mortality in haemodialysis and peritoneal dialysis.  Kidney 
International, 66(6), 2389-2401. 
 
269. Lee, G. (2003).  End-stage renal disease in the Asian-Pacific region.  Seminars in 
Nephrology, 23(1), 107-114. 
 
270. Van Biesen, W., Vanholder, R.C., Veys, N., Dhondt, A., & Lameire, N.H. (2000).  An 
Evaluation of an Integrative Care Approach for End-Stage Renal Disease Patients. 
Journal of the American Society of Nephrology, 11, 116-125. 
 
271. Locatelli, F., Marcelli, D., Conte, F., Limido, A., Lonati, F., Malberti, F., & Spotti, D. 
(1995).  1983 to 1992: report on regular dialysis and transplantation in Lombardy.  
American Journal of Kidney Diseases, 25, 196-205. 
 
272. Choong, H-L. (2005).  Second report of the Singapore renal registry 1998.  Singapore 
Health Promotion Board. 
 
273. O’Brien, S.R., Hein, E.W., & Sly, R.M. (1980). Treatment of acute asthmatic attacks 
in a holding unit of a pediatric emergency room.  Annals of Allergy, 45(3), 159-162. 
 
274. Willert, C., Davis, A.T., Herman, J.J., Holson, B.B., & Zieserl, E. (1985). Short-term 
holding room treatment of asthmatic children.  The Journal of Pediatrics, 106(5), 707-
711. 
 
275. Miescier, M.J., Nelson, D.S.,  Firth, S.D., & Kadish, H.A. (2005).  Children with 
asthma admitted to a pediatric observation unit.  Pediatric Emergency Care, 21(10), 
645-649. 
 
276. Levett, I., Berry, K., & Wacogne, I. (2006). Review of a paediatric emergency 
department observation unit.  Emergency Medicine Journal, 23(8), 612-613. 
 
277. Arendts, G., MacKenzie, J., & Lee, J.K. (2006).  Discharge planning and patient 
satisfaction in an emergency short-stay unit. Emergency Medicine Australasia, 18(1), 
7-14. 
 
278. Abe, O., Abe, R., Enomoto, K., & Kikuchi, K. (1998). Polychemotherapy for early 
breast cancer: an overview of the randomised trials.  The Lancet, 352(9132), 930-942. 
 
279. Cole, B.F., Gelber, R.D., Gelber, S., Coates, A.S., & Goldhirsch, A. (2001).  
Polychemotherapy for early breast cancer: an overview of the randomised clinical 
trails with quality-adjusted survival analysis. The Lancet, 358(9278), 277-286. 
 
280. Clarke, M., Collins, R., Darby, S., Davies, C., Elphinstone, P., Evans, E., Godwin, J., 
Gray, R., Hicks, C., James, S., MacKinnon, E., McGale, P., McHugh, T., Peto, R., 
  252 
Taylor, C., Wang, Y., & Early Breast Cancer Trialists’ Collaborative Group. (2005). 
Effects of radiotherapy and of differences in the extent of surgery for early breast 
cancer on local recurrence and 15-year survival: an overview of the randomised 
trials..  The Lancet, 366(9503), 2087-2106. 
 
281. Jenicek, M. (2003). Foundations of evidence-based medicine. Boca Raton: The 
Parthenon Publishing Group.   
 
282.  Eddy, D.M. (1996).  Clinical decision making: from theory to practice.  Boston: 
Jones and Bartlett Publishers 
 
283. Redelmeier, D.A., & Tversky, A. (1990). A discrepancy between decisions for 
individual patients and for groups.  New England Journal of Medicine, 322, 1162-
1164. 
 
284. Sesardic, N. (2007). Sudden infant death or murder? A royal confusion about 
probabilities.  The British Journal for the Philosophy of Science, 58(2), 299-329. 
 
285. Imai, K., Suga, K., & Nakachi, K. (1997).  Cancer preventive effects of drinking 
green tea among a Japanese population.  Preventive Medicine, 26(6), 769-775. 
 
286. Doss, M.X., Potta, S.P., Hescheler, J., & Sachinidis, A.  (2005). Trapping of growth 
factors by catechins: a possible therapeutic target for prevention of proliferative 
diseases. Journal of Nutritional Biochemistry, 16(5), 259-266. 
 
287. Nagano, J., Kono, S., Preston, D.L., & Mabuchi, K.  (2001). A prospective study of 
green tea consumption and cancer incidence, Hiroshima and Nagasaki (Japan).  
Cancer Causes Control, 12(6), 501-508. 
 
288. Zhong, L., Goldberg, M.S., Gao, Y-T, Hanley, J.A., Parent, M.E., & Jin, F.  (2001). 
A population-based case-control study of lung cancer and green tea consumption 
among women living in Shanghai, China.  Epidemiology, 12(6), 695-700. 
 
289. Wu, A-H., Yu, M-C., Tseng, C-C., Hankin J., & Pike, M.C.  (2003). Green tea and 
risk of breast cancer in Asian Americans.  International Journal of Cancer, 106(4), 
574-579. 
 
290. Jian, L., Xie, L-P., Lee, A-H., & Binns, C.W.  (2004). Protective effect of green tea 
against prostate cancer: a case-control study in southeast China.  International 
Journal of Cancer, 108(1), 130-135. 
 
291. Ji, B-T, Chow, W-H, Yang, G., McLaughlin, J.K., Gao, R-N, Zheng, W,  Shu, X-O, 
Jin, F., Fraumenti, J.F., & Gao, Y-T. (1996). The influence of cigarette smoking, 
alcohol and green tea consumption on the risk of carcinoma of the cardia and distal 
stomach in Shanghai, China.  Cancer, 77(12), 2449-2457. 
 
  253 
292. Katiyar, S.K., Perez, A., & Mukhtar, H.  (2000). Green tea polyphenols treatment 
to human skin prevents formation of ultraviolet light B-induced pyrimidine 
dimmers in DNA.  Clinical Cancer Research, 6(10), 3864-3869. 
 
293. Kovacs, E.M., Lejeune, M.P., Nijs, I., Westerterp-Plantenga, M.S.  (2004). Effects 
of green tea on weight maintenance after body-weight loss.  British Journal of 
Nutrition, 91(3), 431-7. 
 
294. Jenicek, M. (2001). Clinical case reporting in evidence-based medicine.  London: 
Arnold. 
 
295. Lohr, K.N., Eleazer, K., & Mauskopf, J. (1998).  Health policy issues and 
applications for evidence-based medicine and clinical practice guidelines.  Health 
Policy, 46(1), 1-19. 
 
296. Straus, S.E., & McAlister, M.D. (1999).  Evidence-based medicine: past, present, 
and future.  Annals of the Royal College of Physicians and Surgeons of Canada, 32, 
260-263. 
 
297. Hurwitz, B. (1995).  Clinical guidelines and the law: advice, guidance or regulation? 
Journal of Evaluation in Clinical Practice, 1(1), 49-60. 
 
298. Pelly, J.E., Newby, L., Tito, F., Redman, S., & Adrian, A.M. (1998).  Clinical 
practice guidelines before the law: sword or shield? Medical Journal of Australia, 
169, 330-333. 
 
299. Ibrahim, J.G., & Chen, M-H. (1998). Power prior distributions and Bayesian 
computation for proportional hazards model.  Sankhya Series B, 60, 48-64. 
 
300. Ibrahim, J.G., & Chen, M-H. (2002). Power prior distributions for regression 
models.  Statistical Science, 15(1), 46-60. 
 
301. Paolino, P.  (2001). Maximum likelihood estimation of models with beta-
distributed dependent variables.  Political Analysis, 9(4), 325-346. 
 
302. Ferrari, S.L., & Cribari-Neto, F. (2004).  Beta regression for modelling rates and 
proportions.  Journal of Applied Statistics, 31(7), 799-815. 
 
303. Chan, S-P. (2006).  Beta regression analysis of Singapore general election results.   
In Proceedings: 2
nd
 IMT-GT 2006 Regional Conference on Mathematics, Statistics 
and Applications, June 2006, Penang, Malaysia, 201-204.   
 
304. Kumaraswamy, P. (1980). A generalized probability density function for double-
bounded ransom processes.  Journal of Hydrology, 46, 79-88. 
 
  254 
305. Rabe-Hesketh, S., Skrondal, A., & Pickles, A. (2002).  Reliable estimation of 
generalised linear mixed models using adaptive quadrature. The Stata Journal, 2, 1-
21. 
 
306. Rabe-Hesketh, S., Skrondal, A, & Pickles, A. (2004). Generalized multilevel 
structural equation modelling. Psychometrika, 69(2), 167-190. 
 
307. Rabe-Hesketh, S., & Skrondal, A. (2005). Multilevel and longitudinal modeling 
using Stata.  Texas: Stata Press. 
 
308. Rabe-Hesketh, S., Skrondal, A., & Pickles, A. (2005). Maximum likelihood 
estimation of limited and discrete dependent variable models with nested random 
effects. Journal of Econometrics, 128, 301-323. 
 
309. Skrondal, A, & Rabe-Hesketh, S. (2004). Generalized latent variable modeling: 
multilevel, longitudinal, and structural equation models.  Boca Raton: Chapman & 
Hall/CRC Press. 
 
310. McCutcheon, A. L. (1987).  Latent class analysis.  California: Sage Publications.  
 
311. Kaplan, D. (2000) Structural equation modeling: foundations and extensions. 
California: Sage Publications. 
 
312. Good, I.J. (1961). A causal calculus.  British Journal of the Philosophy of Science, 
11, 305-318. 
 
313. Pearl, J. (1986). Fusion, propagation and structuring in belief networks.  Artificial 
Intelligence, 29, 241-288. 
 
314. Pearl, J. (1988). Probabilistic reasoning in intelligence systems: networks of 
plausible inference.  California: Morgan Kauffmann. 
 
315. Pearl, J. (1995). Causal diagrams for empirical research.  Biometrika, 82(4), 669-
688. 
 
316. Jensen, F.V. (2001). Bayesian networks and decision graphs.  New York: Springer 
Verlag. 
 
317. Bǿttcher, S.G., & Dethlefsen, C. (2003). DEAL: a package for learning Bayesian 
networks (http://www.math.auc.dk/novo/deal). 
 
318. Marcot, B.G., Holthausen, R.S., Raphael, M.G., Rowland, M., & Wisdom, M. 
(2001). Using Bayesian belief networks to evaluate fish and wildlife population 
variability under land management alternatives from an environmental impact 
statement.  Forest Ecology and Management, 153(1-3), 29-42. 
 
  255 
319. Heckerman, D. (1991). Probabilistic similarity networks.  Cambridge: MIT Press. 
 
320. Russell, S.J., & Norvig, P. (2003).  Artificial intelligence.  New Jersey: Pearson 
Education.   
 
321. Thibaudeau, Y., & Winkler, W.E. (2002). Bayesian networks representations, 
generalized imputation, and synthetic micro-data satisfying analytic constraints. 
Technical Report RRS200219, United States Bureau of the Census, Washington DC. 
 
322. Di Zio, M., Scanu, M., Coppola, L., Luzi, O., & Ponti, A. (2004). Bayesian 
networks for imputation.  Journal of the Royal Statistical Society (Statistics in 
Society), 167(2), 309-322. 
 
323. Pregibon, D. (1996). Data mining.  Statistical Computing and Graphics Newsletter, 
7, 8. 
 
324.  Hand, D.J. (1999). Statistics and data mining: intersecting disciplines.  
Proceedings of the 7
th
 Association of Computing Machinery’s (ACM 
SIGKDD) International Conference on Knowledge Discovery and Data 
Mining, 1(1), 16-19. 
 
325. Hand, D.J. (1998). Data mining: statistics and more? The American Statistician, 
52(2), 112-118.  
 
326. Han, J-W., & Kamber, M. (2006). Data mining: concepts and techniques.  
California: Morgan Kauffmann. 
 
327. Giudici, P. (2003). Applied data mining: statistical methods for business and 
industry.  Chichester: Wiley. 
 
328. Cherkassky, V., & Mulier, F. (2007). Learning from data: concepts, theory, and 
methods.  New Jersey: Wiley. 
 
329. Myatt, G.J. (2007). Making sense of data: a practical guide to exploratory data 
analysis and data mining.  New Jersey: Wiley. 
 
330. Fisher, D., & Lenz, H-J. (1996). Learning from data: artificial intelligence and 
statistics Vol. 5. New York: Springer. 
 
331. Nakhaeizadeh, G., & Taylor, C.C. (1997). Machine learning and statistics. New 
York: Wiley. 
 
332. Kay, J.W., & Titterington, D.M. (1999). Statistics and neural network: advances at 
the interface. New York: Oxford University Press. 
 
333. Lindley, D.V. (2006). Understanding Uncertainty. New Jersey: Wiley. 
  256 
 
334. Chen, M-H., Dey, D.K., & Sinha, D. (2002). Bayesian analysis of multivariate 
mortality data with large families.  Journal of the Royal Statistical Society Series C 
(Applied Statistics), 49(1), 135-150. 
 
335. Chen, M-H., Harrington, D.P., & Ibrahim, J.G. (2002). Bayesian cure rate models 
for malignant melanoma: a case-study of Eastern Cooperative Oncology Group 
trial E1690.  Journal of the Royal Statistical Society Series C (Applied Statistics), 
51(2), 135-150. 
 
336. Basu, S., Sen, A. & Benerjee, M. (2003). Bayesian analysis of competing risks with 
partially masked cause of failure.  Journal of the Royal Statistical Society Series C 
(Applied Statistics), 52(1), 77-93. 
 
337. Mezzetti, M., Ibrahim, J.G., Bois, E.Y., Ryan, L.M., Ngo, L., & Smith, T.J.. (2003). 
A Bayesian compartmental model for the evaluation of th1.3-butadiene metabolism.  
Journal of the Royal Statistical Society Series C (Applied Statistics), 52(3), 291-305. 
 
338. Rutter, C.M., & Simon, G. (2004). A Bayesian method for estimating the accuracy 
of recalled depression.  Journal of the Royal Statistical Society Series C (Applied 
Statistics), 53(2), 341-353. 
